

تقييم الحالة التأكسدية لمرضى داء السكري بأستخدام بعض المؤشرات الأنزيمية

أطروحة مقدمة الى
مجلس كلية العلوم - جامعة بابل
وهي جزء من متطلبات نيل درجة الدكتوراه فلسفة علوم
في علوم الكيمياء / الكيمياء الحياتية السريرية

من
فردوس عباس جابر

الخلاصة

يعتبر داء السكري من المشاكل الصحية الشائعة، والذي يتميز بارتفاع مستوى السكر الناجم عن فقدان أو النقص النسبي للأنسولين الذي تفرزه خلايا بيتا في جزر لانكرهانس في البنكرياس.

يعد مرض السكري من العناصر المتلازمة Syndrome لضغط المؤكسدات ذات الصلة بالتوازن بين أنواع الأوكسجين الفعال ونظام الكاسحات Scavengers. تهدف هذه الدراسة إلى إظهار مستوى ضغط المؤكسدات للمصابين بالنوع الأول والنوع الثاني من مرض السكري وكشف أقوى مؤشر للجذور الحرة في حالة هذا المرض. تم إجراء هذه الدراسة في مستشفى الديوانية العام وفي قسم الكيمياء / كلية العلوم / جامعة بابل وفي قسم الكيمياء / كلية الطب / جامعة النهرين، العراق. صممت هذه الدراسة لغرض الكشف عن بعض المتغيرات الكيميائية الحياتية لمصل الدم. خضع ٥٠ مريضاً بالسكري من النوع الأول، و ٥٠ مريضاً بالسكري من النوع الثاني، و ٥٠ شخصاً سويًا لفحوصات هذه الدراسة.

القياسات الرئيسية في هذه الدراسة هي قياس التغيرات البيولوجية النوعية لمتلازمات الحالة التأكسدية (أكسدة الدهون وارتفاع مستوى الهوموستتين) وقياس فعالية بعض مضادات الأكسدة الإنزيمية Enzymatic Antioxidants: إنزيم Superoxide Dismutase وإنزيم Catalase وإنزيم Glutathione S-transferase وإنزيم Creatine Kinase وقياس بعض مضادات الأكسدة غير الإنزيمية Non-enzymatic Antioxidants: الكلوتاثايون Glutathione وفيتامين E وفيتامين C وفيتامين A وقياس العناصر التالية: الحديد والنحاس والزنك والكروم والسيلينيوم.

سجلت نتائج هذه الدراسة ظهور ارتفاع ملحوظ في مستوى المالون داي ألدهايد (النتائج النهائي لأكسدة الدهون) والهوموستتين الكلي في مصول دم المرضى المصابين بالسكري من النوع الأول والثاني عن ذلك المستوى الذي ظهر في المجموعة الضابطة. أظهرت مستويات أكسدة الدهون ارتباط معنوي سالب جدير بالملاحظة مع مستويات فيتامين E ($r = -0.345, P < 0.05$) ولم يظهر أي ارتباط مع فيتامين C و A في مصول المرضى المصابين بالنوع الأول من مرض السكري، بينما في المرضى المصابين بالنوع الثاني من مرض

السكري، فقد أظهرت ارتباطا معنويا سالبا مع مستويات فيتامين C ($r = -0.284, P \leq 0.05$) ولم يظهر أي ارتباط معنوي مع فيتامين E و A.

أشارت هذه الدراسة إلى أن الإنزيمين Superoxide Dismutase و Glutathione S-transferase يرتفع مستواه بشكل ملحوظ في مصل دم المرضى المصابين بالنوع الأول والثاني من مرض السكري عن مستوياتها في المجموعة الضابطة ($P \leq 0.05$). ولكن الدراسة أظهر انخفاضاً ملحوظاً في مستويات إنزيمي Creatine Kinase و Catalase في مرضى كلا نوعي مرض السكري. على الرغم من ذلك فإن مستوى فعالية إنزيم Superoxide Dismutase في كلا نوعي مرض السكري يميل إلى أن يكون متفاوتاً ولكنه لم يظهر ارتباطاً معنوياً مع مستويات النحاس وإنزيم Catalase. بينما أظهر ارتباطاً معنوياً سالباً مع مستوى الزنك ($P \leq 0.05$).

أظهرت الدراسة أيضاً انخفاضاً معنوياً في مستويات الكلوتاتايون وفيتامين E وفيتامين C وفيتامين A في مصل المرضى المصابين بمرض السكري من النوع الأول والثاني بالمقارنة مع المجموعة الضابطة ($P \leq 0.05$). فضلاً عن أن الكلوتاتايون قد أظهر علاقات غير معنوية مختلفة مع مستويات المألون داي ألدهايد و الهوموستتين الكلي وفعالية إنزيم Creatine Kinase في مصل المرضى المصابين بمرض السكري من النوع الأول والثاني. إضافة إلى ذلك، أظهر الكلوتاتايون ارتباطاً معنوياً سالباً مع مستوى فعالية إنزيم Glutathione S-transferase في مصل دم المرضى المصابين بالنوع الثاني من مرض السكري ($r = -0.309, P \leq 0.05$)، في حين كان هذا الارتباط غير معنوي لدى المرضى المصابين بالنوع الأول من مرض السكري.

دللت هذه الدراسة على أن مرض السكري يسبب اضطراب في مستويات العناصر النزرة، لذا كان هناك انخفاض معنوي في مستوى الحديد والزنك والكروم والسيلينيوم في مصل دم المرضى المصابين بالنوع الأول من مرض السكري عن مستواها في المجموعة الضابطة ($P \leq 0.05$). بينما لوحظ انخفاض معنوي لدى مرضى النوع الثاني من مرض السكري عن تلك التي ظهرت في المجموعة الضابطة. كما أن هنالك ارتفاع معنوي في مستويات النحاس في مصل دم المرضى المصابين بمرض السكري من النوع الأول والثاني عن مستوياته في المجموعات الضابطة ($P \leq 0.05$).

في هذه الدراسة، لوحظت زيادة غير معنوية، في مستويات كل من المألون داي ألدهايد، الهوموستتين الكلي، النحاس، الحديد وفعالية إنزيم Glutathione S-transferase في

حين ظهر انخفاض طفيف، ولكن غير معنوي أيضاً، في مستويات كل من الكلوتاثايون، فيتامين C، الزنك، السيلينيوم، الكروم، وفعالية الإنزيمات Superoxide Dismutase، Catalase، Creatine Kinase، في مصول دم المرضى المدخنين المصابين بالنوع الأول والثاني من مرض السكري عن مستوياتها التي ظهرت لدى المرضى غير المدخنين. كذلك، لوحظ ارتفاع طفيف ولكن غير معنوي في مستوى فيتامين E في مصول دم المرضى المدخنين المصابين بالنوع الأول من مرض السكري ومستوى فيتامين A في مصول دم المرضى المدخنين المصابين بالنوع الثاني من مرض السكري عن مستوياتها في المرضى غير المدخنين ($P \leq 0.05$). لكن كان هنالك انخفاضا معنويا في مستويات فيتامين A في مصول دم المرضى المدخنين المصابين بالنوع الأول من مرض السكري وفيتامين E في مصول دم المرضى المدخنين المصابين بالنوع الثاني من هذا المرض بالمقارنة مع المجموعات الضابطة ($P \leq 0.05$).

توصلت الدراسة إلى أن مرض السكري هو أحد عناصر المتلازمة لضغط المؤكسدات، وهو يختزل بعض مضادات الأكسدة الإنزيمية وغير الإنزيمية. كما استنتجت الدراسة أن انخفاض مستويات مضادات الأكسدة (الكلوتاثايون و Catalase) يعتبر من أفضل الدلائل على ارتفاع المتلازمة لضغط المؤكسدات في مرض السكري. ويمكن استخدام جميع مؤشرات الجذور الحرة في هذه الدراسة للكشف المبكر عن مضاعفات مرض السكري. يعمل التدخين على اختزال مستويات مضادات الأكسدة، لذا تزداد المتلازمة لضغط المؤكسدات ومضاعفات مرض السكري لدى المرضى المدخنين المصابين بهذا المرض عن مستوياتها لدى المرضى غير المدخنين.

EVALUATION OF THE OXIDATIVE STRESS IN PATIENTS WITH DIABETES MILLITUS USING SOME ENZYMATIC ACTIVITIES

A THESIS

**SUBMITTED TO COUNCIL OF COLLEGE OF SCIENCE
BABYLON UNEVERISITY**

**IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE
AWARD OF THE DEGREE OF DOCTOR OF PHILOSOPHY
IN CHEMISTRY-BIOCHEMISTRY**

**BY
FERDOUS JABIR**

October-۲۰۰۵

Ramadan- ۱۴۲۶

Certification

We certify that this thesis was prepared under our supervision at the Department of chemistry, College of science, University of Babylon as partial requirements for the degree of Doctor of philosophy of Science in Biochemistry at this work.

Signature:

Name :*Dr.Oda M. Yasser*

Title :*Prof. in biochemistry*

Address: **Department of chemistry**

College of science, University of Babylon

Date: / / ٢٠٠٥

Supervisor

Signature:

Name :*Dr.Mufeed J.Ewadh*

Title :*Prof. in biochemistry*

Address: **University of Karbala**

Date: / / ٢٠٠٥

Supervisor

In the view of the available recommendation, I forward this thesis for debate by the Examining Committee.

Signature:

Name :*Prof. Dr. Hussien A. Mohammad*

Address :*Head of department of Chemistry, College of science,*

University of Babylon.

Date: / / ٢٠٠٥

Dedication

To my husband.....

My Family and

Diabetic Patients especially,

Hussam F. Abbas

Ferdous

Summary

Diabetes mellitus is a common health problem characterized by hyperglycemia resulted from absolute or relative decrease in insulin secretion from β -cells of the islets of Langerhans in pancreas. Diabetes mellitus is considered as a member of oxidative stress syndrome. It is associated with an imbalance between types of free radicals and scavengers system. This study is aimed to assess the oxidative stress status in patients with type 1 or 2 diabetes mellitus disease, and to explore the good free radical marker in this state.

This research was conducted in Al-Diwaniya General Hospital; Department of Chemistry, College of Sciences, Babylon University; Department of Chemistry, College of Medicine, Al-Nahrain University; Iraq. This study is designed to screen the serum for certain biochemical variables.

The subjects of this study were 50 patients with type 1 diabetes mellitus, 50 patients with type 2 diabetes mellitus, and 50 apparent healthy subjects were enrolled in this study.

The main outcome measurement were assessment of specific biological alterations in oxidative stress syndrome: Lipid peroxidation, and hyperhomocystienemia, assessment of some enzymatic antioxidants: Extracellular superoxide dismutase, catalase, glutathione S-transferase, and creatine kinase, assessment of some non-enzymatic antioxidants: Glutathione, vitamin E, vitamin C, and vitamin A, and assessment of minerals: Iron, Copper, Zinc, Chromium, and Selenium.

The results pointed out elevated levels of malondialdehyde, and total homocystiene significantly in serum of patients with type 1 and 2 diabetes mellitus (DM) disease compared to control, $P \leq 0.05$. Levels of lipid peroxidation showed a significant negative correlation with levels of vitamin E ($r = -0.345$, $P \leq 0.05$), whereas there is not significant negative

correlation with vitamin C and A in serum of patients with type 1 DM. While in patients with type 2 DM, the results showed a significant negative correlation with levels of vitamin C ($r = -0.284$, $P \leq 0.05$), and a negative correlation but not significant with vitamins E and A.


This study reported that extracellular superoxide dismutase, and glutathione S-transferase activities are significantly higher in serum of patients with type 1 and 2 diabetes mellitus disease than that of controls, $P \leq 0.05$. But there is a significant decrease in levels of catalase and creatine kinase enzyme activities in both types of diabetic patients, $P \leq 0.05$. However extracellular superoxide dismutase enzyme activity in both types of diabetic patients tend to be altered and did not show a significant correlation with levels of copper or catalase enzyme activity, while there is a significant negative correlation with level of zinc, $P \leq 0.05$.

This study showed that serum glutathione, vitamin E, vitamin C, and vitamin A are significantly decreased in patients with type 1 and 2 DM when they are compared with controls, $P \leq 0.05$. The levels of glutathione showed different correlation, but not significant with levels of malondialdehyde, total homocystiene, and creatine kinase enzyme activity in serum of diabetic patients (with type 1 and 2 DM). Furthermore, glutathione shows a significant negative correlation with level of glutathione S-transferase activity in serum of patients with type 2 DM ($r = -0.309$, $P \leq 0.05$), but this correlation is not significant in patients with type 1 DM.

The results of this study also indicated that diabetes results in disturbance of trace elements. Thus there is a significant decrease in levels of serum iron, zinc, chromium, and selenium in patients with type 1 and 2 DM from control, $P \leq 0.05$. As well as there is a significant increase in levels of copper in serum of patients with type 1 and 2 DM from control, $P \leq 0.05$.

In this study, the results reported no significant difference in levels of Malondialdehyde, total homocystiene, glutathione, vitamin C, copper, iron, zinc, selenium, chromium and glutathione S-transferase, extracellular superoxide dismutase, creatine kinase, catalase activities in serum of smokers diabetic patients with type 1 and 2 DM than that of non-smokers diabetic patients, as well as levels of vitamin E in serum of smokers with type 1 DM, and levels of vitamin A in serum of smokers with type 2 DM than that of non-smokers diabetic patients. But there is a significant difference in levels of vitamin A in serum of smokers with type 1 DM, and vitamin E in serum of smokers with type 2 DM, $P \leq 0.05$ than that of control.

This study concluded that diabetes mellitus is a member of oxidative stress syndrome, it reduces some enzymatic and non-enzymatic antioxidants. As well as decreased levels of the antioxidants (catalase, and glutathione) are the good indicators to evaluate the oxidative stress syndrome in diabetic patients, and all of free radical markers in this study can be used for early detection of diabetic complications. Smoking reduces the levels of antioxidants, thus increases oxidative stress syndrome, and diabetic complications in diabetic smokers are more than diabetic non-smokers.



Acknowledgement

First of all, I would like to express my deep thanks and gratitude to my supervisors, Prof. Dr. Mufeed J. Awadh and Prof. Dr. Oda M. Yasser for their great support, guidance, advice, and assistance throughout the various courses of the present work.

I would like also to thank the Deanery of the College of Science, Babylon University for providing me with the necessary facilities.

Sincere thanks are due to head and all staff members of Chemistry Department at the College of Science, Babylon University for helping me in this work.

My thanks and appreciation are also due to staff members of Diabetes Mellitus and Chemistry Units in Al-Diwaniya General Hospital especially Dr. Ali S. Al-Hilli, Mrs. Zina and Heyam for their kind help and invaluable advice.

Last but not least, I would like to thank Dr. Falah H. husein for his guidance, advice, and great support.

Finally, I would like to express my thanks to my husband for his inspiration, encouragement and support through the period of research.

Contents

	Contents	Page
	Abstract	
	Chapter One – Introduction & Literature Review	
۱.۱	Diabetes Mellitus (DM)	۱
۱.۲	Criteria for the Diagnosis of DM	۲
۱.۳.	Classification and Etiology of DM	۴
۱.۴.	Free Radicals	۶
۱.۴.۱.	The Source of Free Radicals in Human Body	۶
۱.۴.۲.	Effects of Free Radicals	۹
۱.۴.۳.	Free Radicals and Pathogenesis of DM	۱۰
۱.۴.۴.	Free Radicals and Diabetic Complications	۱۲
۱.۵.	Oxidative Stress Syndrome	۱۳
۱.۵.۱.	Diabetes Mellitus and Oxidative Stress Syndrome	۱۳
۱.۵.۱.۱.	Glycation of Protein	۱۵
۱.۵.۱.۲.	Glucose Auto-oxidation	۱۷
۱.۵.۱.۳.	Polyol Pathways	۱۸
۱.۵.۲.	Specific Biological Alterations in Oxidative Stress Syndrome	۱۹
۱.۵.۲.۱.	Lipid Peroxidation	۱۹
۱.۵.۲.۲.	Hyperhomocysteinemia	۲۱
۱.۵.۳.	Smoking Effect	۲۵
۱.۶.	Antioxidant Defense Systems	۲۶
۱.۶. ۱.	Enzymatic Antioxidants	۲۸
۱.۶.۱.۱.	Superoxide Dismutase (SOD)	۲۸
۱.۶.۱.۲.	Catalase (CAT)	۳۱
۱.۶.۱.۳.	Glutathione S-Transferase (GST)	۳۱

1.6.1.4.	Creatine Kinase (CK)	32
1.6.2.	Non-enzymatic Antioxidants	34
1.6.2.1.	Glutathione (GSH)	34
1.6.2.2.	Vitamin E (α -Tocopherol)	36
1.6.2.3.	Vitamin C (Ascorbic Acid)	39
1.6.2.4.	Vitamin A (Retinol)	40
1.7.	Minerals	41
1.7.1.	Iron	42
1.7.2.	Copper (Cu)	43
1.7.3.	Zinc (Zn)	44
1.7.4.	Chromium (Cr)	44
1.7.5.	Selenium (Se)	45
	Aim of the Study	48
	Chapter two: Materials and Methods	50
	Chemicals and instruments	50
2.1.	Place of work	50
2.2.	Subjects	51
2.3.	Samples	53
2.4.	Determination of Serum Malondialdehyde	55
2.5.	Determination of Serum Total Homocysteine (tHcy)	59
2.6.	Assay the Activity of Serum Superoxide Dismutase (SOD)	60
2.7.	Assay the activity of serum Catalase (CAT)	62
2.8.	Assay the activity of serum Glutathione S-Transferase (GST)	64
2.9.	Assay the activity of serum Creatine Kinase (CK) by Using Commercially available Kit	67
2.10.	Determination of Serum Glutathione	68
		70
		71

۲.۱۱.	Determination of Serum Antioxidant Vitamins	۷۱
۲.۱۱.۱.	Determination of Serum Vitamin E by HPLC Technique	
۲.۱۱.۲.	Determination of Serum Vitamin A by HPLC Technique	۷۳
۲.۱۱.۳.	Determination of Serum Vitamin C by HPLC Technique	
۲.۱۲.	Determination of Serum Trace Element	۷۴
۲.۱۲.۱.	Determination of Serum Iron by Using Commercially Available Kit	۷۵
۲.۱۲.۲.	Determination of Serum Copper by Using Commercially Available Kit	۷۵
۲.۱۲.۳.	Determination of Serum Zinc by Atomic Absorption Technique	۷۶
۲.۱۲.۴.	Determination of Serum Chromium by Atomic Absorption Technique	۷۷ ۷۷
۲.۱۲.۵.	Determination of Serum Selenium by Flameless Atomic Absorption Spectrophotometer (FAAS)	۷۷ ۷۷
۲.۱۳.	Statistical Analysis	۷۸ ۸۰
	Chapter three:Results and Discussions	۸۲
۳.۱	Sampling characteristics	۸۴
۳.۲.	Age	۸۴
۳.۳.	Duration of DM disease	۸۶
۳.۴.	Assessment of Reactive Oxygen species	۸۷
۳.۴.۱.	Lipid Peroxidation Activity	۸۸ ۹۰
۳.۴.۲.	Total Homocysteine (tHcy) Level	۹۰
۳.۵.	Assessment of Scavenger System	۹۵
۳.۵.۱.	Enzymatic Antioxidants	۹۶
۳.۵.۱.۱.	Extracellular Superoxide Dismutase (Ec-SOD) Activity.	۹۷
۳.۵.۱.۲.	Catalase (CAT) Activity	۹۸
۳.۵.۱.۳.	Glutathione S-Transferase (GST)Activity	۱۰۲

۳.۵.۱.۴.	Creatine Kinase (CK) Activity	۱۰۵
۳.۵.۲.	Non-Enzymatic Antioxidants	
۳.۵.۲.۱.	Glutathione (GSH) Level	۱۰۸
۳.۵.۲.۲.	Vitamin E (α -tocopherol) Level	
۳.۵.۲.۳.	Vitamin C (Ascorbic Acid) Level	۱۱۳
۳.۵.۲.۴.	Vitamin A (Retinol) Level	۱۱۳
۳.۵.۲.۵.	Trace Elements (Iron, Zinc, Copper, Chromium, and Selenium) Levels	۱۱۴
۳.۶.	Lipid Peroxidation and Antioxidant Vitamins	
۳.۷.	Correlation of Ec-Cu/Zn SOD Activity with Levels of Zinc, Copper, and CAT Activity	
۳.۸.	Effect of Smoking on Oxidative Stress Status in Diabetics	
	Conclusions	
	Recommendations	
	References	

Conclusions

The results found in this study enable for concluding the following points:

١. Diabetes Mellitus disease is associated with increased free radicals generation, which has been observed through increased MDA, tHcy, and Cu, and decreased GSH, CAT, CK, antioxidant vitamins (E, A, C), zinc, chromium, and selenium.
٢. We could use the above markers for early detection of diabetic complications.
٣. Decreased levels of CAT activity and glutathione are the good indicators to evaluate the oxidative stress syndrome in diabetics than non-diabetics.
٤. Increased level of Ec-Cu/Zn SOD activity in diabetic patients more than the other antioxidants is indicating to presence high level of superoxide radical ($O_2^{\cdot-}$) that generating in DM.
٥. Smoke reduces levels of total antioxidant especially fat soluble vitamins (E and A), thus smoke increases oxidative stress syndrome and diabetic complications in diabetic smokers than diabetic non-smokers.

Recommendations

١. Hyperhomocysteinemia is one of the important biochemical markers altered to diabetic complications and death, thus this marker requires more study, especially its correlation with vitamin B_٦, B_{١٢}, and folic acid to reduce and manage diabetic complications.
٢. Supplementation of antioxidant vitamins and zinc are necessary to reduce oxidative stress syndrome and lipid peroxidation degree, thus reduced atheroscleropathy complications in diabetics.
٣. Iron require more study in Iraq country to found the reasons for decreased its level in Iraqi diabetic patients especially when all research found elevated level of iron in diabetic patients in other countries.

Abbreviations

ADP	Adenosine Diphosphate
ATP	Adenosine Triphosphate
AGEs	Advanced Glycosylation End-products
AR	Aldose Reductase
ROOH	Alkyl hydroperoxide
ADA	American Diabetes Association
AAS	Atomic Absorption Spectrophotometer
CVD	Cardiovascular disease
CAT	Catalase
CDNB	1-Chloro-2,4-dinitrobenzene
CK	Creatine Kinase
CK-BB	Creatine Kinase-Brain Type
CK-MB	Creatine Kinase-Myocardial Type
CK-MM	Creatine Kinase-Muscle Type
DNA	Deoxyribose Nucleic Acid
DM	Diabetes Mellitus
DTNB	5,5-Dithiobis (2-nitrobenzoic acid)
DDT	Dithiothreitol
EDRF	Endothelial Derived Relaxation Factor
ENOS	Endothelial Nitric Oxide Synthase
Ec-Cu/Zn SOD	Extracellular Superoxide Dismutase
FBS	Fasting Blood Sugar
FPG	Fasting Plasma Glucose
FAAS	Flameless Atomic Absorption Spectrophotometer
GDM	Gestational Diabetes Mellitus
GPx	Glutathione Peroxidase

GS [•]	Glutathione radical
GR	Glutathione Reductase
GST	Glutathione S-Transferase
GHb	Glycosylated Hemoglobin
HbA _{1c}	Hemoglobin A _{1c}
COHb	Hemoglobin carbon monoxide
HK	Hexokinase
HDL-Ch	High-Density Lipoprotein- Cholesterol
HPLC	High Performance Liquid Chromatography
Hcy	Homocysteine
^ ⁻ -OHdG	^ ⁻ -hydroxydeoxyguanine
OH [•]	Hydroxyl radical
HHcy	Hyperhomocysteinemia
IDDM	Insulin Dependent Diabetes Mellitus
ITF γ	Interferron γ
IL- γ	Interleukin γ
LOOH	Lipid hydroperoxide
LO	Lipoxygenase
LDL	Low-Density Lipoprotein
LDL-Ch	Low Density Lipoprotein- Cholesterol
MDA	Malondialdehyde
MODY	Maturity-Onset Diabetes of Youth
NDDG	National Diabetes Data Group
NO [•]	Nitric Oxide radical
NOS	Nitric Oxide Synthase
NBT	Nitroblue Tetrazolium
NIDDM	Non-Insulin Dependent Diabetes Mellitus
OGTT	Oral Glucose Tolerance Test

GSSG	Oxidized glutathione
Ox-LDL	Oxidized low-density lipoprotein
λ -oxoG	λ -oxo- γ , λ -dihydroguanine
ONOO ⁻	Peroxynitrite
PMN	Polymorphonuclear
PUFA	Polyunsaturated fatty acid
PGG _γ	Prostaglandin G _γ
ROS	Reactive oxygen species
NADPH NADP	Reduced, and Oxidized Nicotinamide Adnine Dinucleotide Phosphate
GSH	Reduced glutathione
¹ O _γ	Singlet Oxygen
SDH	Sorbitol Dehydrogenase
SOD	Superoxide Dismutase
O _γ ^{-•}	Superoxide radical
TBA	Thiobarbituric Acid
TBARS	Thiobarbituric acid reactive substance
α -TQ	α -Tochopherol
TCA	Trichloroacetic Acid
³ O _γ	Triplet Oxygen
TNF	Tumor Necrosis Factor
VSMC	Vascular Smooth Muscle Cell
WHO	World Health Organization

Normal Values of Variables from References

Serum Malodialdehyde (MDA)	1.70 ± 0.3 nmol/L
Serum Total Homocystiene (tHcy)	9.171 ± 1.49 μmol/L
Serum Superoxide Dismutase (Ec-Cu/Zn-SOD)	0.48 ± 0.2 μg/dL
Serum Catalase (CAT)	6.14 ± 0.2 kU/ml
Serum Creatine Kinase (CK)	181.1 ± 2.86 U/L
Serum Glutathione S-Transferase (GST)	1.96 ± 0.41 U/L
Serum Glutathione (GSH)	12.39 ± 1.22 μmol/L
Serum Vitamin E	8-10 mg/dL
Serum Vitamin A	800-1000 μg/dL
Serum Vitamin C	0.4-0.6 mg/dL
Serum Copper	
Male	11.0-24.0 μmol/L
Female	12.0-24.4 μmol/L
Serum Iron	7.34-23.6 μmol/L
Serum Zinc	11.0-24 μmol/L
Serum Chromium	0.1-0.2 μg/L
Serum Selenium	87-100 μg/L

1.1. Diabetes Mellitus (DM)

Diabetes mellitus is a very complex chronic disease with syndrome of hyperglycemia (Zhao, 2001). It is result from absolute or relative decrease in insulin secretion from β -cell of the islets of Langerhans. Insulin is a polypeptide hormone that consists of a total of 51 amino acids in two chains connected by two disulfide bridges; figure (1-1a). Insulin is synthesized as a large single chain preproinsulin that is cleaved to a more immediate precursor proinsulin in the rough endoplasmic reticulum. Proinsulin is then packed into secretory granules, where it is broken down into equimolar amounts of insulin and an inactive C-peptide (Bishop *et al.*, 2000), figure (1-1b).





Figure (1-1a): Structure of human insulin (Champe & Harvey, 1994)



Figure(1-1b): Formation of human insulin from preproinsulin (Champe & Harvey, 1994)

Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, high glucose in urine, increased appetite, ketoacidosis (ketone bodies in blood), acid/base imbalance, and diabetic coma.

Long-term complications of diabetes include blindness, neuropathy, kidney failure, lower extremity amputations, cardiovascular complication and pregnancy complication (Bishop *et al.*, 2000).

1.2. Criteria for the Diagnosis of DM

The old criteria for diagnosis of DM recommended by the World Health Organization (WHO) (1985) were:

1. Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L).
2. 2-hours postload glucose (2-hPG) ≥ 200 mg/dL (11.1 mmol/L).

According to the new American Diabetes Association (ADA) recommendations to allow for earlier detection of the disease, all adults older than age 40 years should have a measurement of fasting blood sugar every 3 years unless the individual is otherwise diagnosed with diabetes (Bishop *et al.*, 2000).

The modified criteria for diagnosis of DM recommended by an expert committee to allow earlier detection of the disease were:

1. FPG (Fasting Plasma Glucose) < 100 mg/dL (5.6 mmol/L) = normal fasting glucose.
2. FPG ≥ 100 mg/dL (5.6 mmol/L) and < 126 mg/dL (7.0 mmol/L) = impaired fasting glucose (IFG).
3. FPG ≥ 126 mg/dL (7.0 mmol/L) = provisional diagnosis of diabetes.

The corresponding criteria when the oral glucose tolerance test (OGTT) is used are the following:

1. 2-h PG < 140 mg/dL (7.8 mmol/L) = normal glucose tolerance.
2. 2-h PG ≥ 140 mg/dL (7.8 mmol/L) and < 200 mg/dL (11.1 mmol/L) = impaired glucose tolerance.
3. 2-h ≥ 200 mg/dL (11.1 mmol/L) = provisional diagnosis of diabetes.

Glycosylated hemoglobin (GHb) is the term used to describe the formation of a glucose reacts with the amino group of hemoglobin (Bishop *et al.*, 2000), figure (1-2).




Figure (1-2): The non-enzymatic glycosylation of HbA to HbA_{1c} (Higgs & Bunn, 1981)

Therefore, measuring the glycosylated hemoglobin provides the clinician with a time-average picture of the patient's blood glucose concentration over the past three months. Hemoglobin A_{1c} (HbA_{1c}) is a reliable method of monitoring long-term diabetic control rather than

fasting plasma glucose (FPG). Normal values range from 4.0-8.0; and two factors determine the glycosylated hemoglobin levels: the average glucose concentration and the red blood cell life span. If the red blood cell life span is decreased because of another disease state such as hemoglobinopathies, the hemoglobin will have less time to become glycosylated and the glycosylated hemoglobin level will be lower (Lehninger, 1970).

1.3. Classification and Etiology of DM

In 1979, the National Diabetes Data Group (NDDG) developed a classification and diagnosis scheme for diabetes mellitus. This scheme included dividing diabetes into two broad categories: type 1, insulin-dependent diabetes mellitus (IDDM), and type 2, non-insulin-dependent diabetes mellitus (NIDDM).

Established in 1990, the International Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, working under the sponsorship of the American Diabetes Association (ADA), was given the task of updating the 1979 classification system. The changes they proposed included eliminating the older terms of IDDM and NIDDM. The categories of type 1 and type 2 were retained with the adoption of Arabic numerals instead of Roman numerals.

Therefore, the ADA/WHO guidelines recommend the following categories of diabetes (Bishop *et al.*, 2000):

- Type 1 diabetes; is a result of cellular-mediated autoimmune destruction of the β -cells of the pancreas, causing an absolute deficiency of insulin secretion. Type 1 constitutes only 10% to 20% of all diabetes and commonly occurs in childhood and adolescence. This disease is usually initiated by an environmental factor or infection (usually a virus) in individuals with a genetic predisposition and

causes the immune destruction of the β -cells of the pancreas and therefore, a decreased production of insulin.

- Type 2 diabetes; is characterized by hyperglycemia due to an individual's resistance to insulin with an insulin secretory defect. This resistance results in a relative, not an absolute, insulin deficiency. Type 2 constitutes the majority of the diabetes cases. Most patients in this type are obese or have an increased percentage of body fat distribution in the abdominal region. This type of diabetes is associated with a strong genetic predisposition with patients at an increased risk with an increase in age, obesity and lack of physical exercise, and often goes undiagnosed for many years. Characteristics usually include an adult onset of the disease and milder symptoms than in type 1. Type 2 commonly occurs after age 30 years.


- Other specific types of diabetes are associated with certain conditions (secondary) including genetic defects of β -cell function or insulin action, pancreatic disease, disease of endocrine origin, drug or chemical induced insulin receptor abnormalities, and certain genetic syndromes. Maturity-onset diabetes of youth (MODY) is a very rare form of diabetes that is inherited in an autosomal dominant fashion (Tripathi, 1988; Malchoff, 1991).

- Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy. Causes of GDM include metabolic and hormonal changes. Patients with GDM frequently return to normal postpartum. However, this disease is associated with increased perinatal complications and an increased risk for development of diabetes in later years (Bishop *et al.*, 2000).

1.4. Free Radicals

Oxidation is a constant natural process that produces atoms or molecules with unpaired electrons, known as free radicals. A free radical can be defined as an atom or molecule that contains one or more unpaired electrons in its outer orbit. If an electron is lost from the outer orbit, the molecule becomes a free radical. Free radicals are unstable chemicals, which are produced during the many oxidative biochemical reactions in the body (Howard, 1972; Oberley, 1988).

A compound becomes a free radical through either oxidation i.e., the loss of an electron or through reduction i.e., the gain of an electron, however, a free radical is unstable and highly reactive in nature and may react with other nearby molecule also converting that molecule to a free radical, which can then initiate another reaction (Sinclair, 1990).




Theoretically, a single free radical can ultimately causes an endless number of reactions. This chain reaction is terminated either by the free radicals reaction with another free radical or by the free radicals reaction with an antioxidant (Oberley, 1988).


1.4.1. The Source of Free Radicals in Human Body

Free radicals are continuously produced in our body as a byproduct of metabolism. Oxygen is the most important source of free radicals in the body. Most of the oxygen taken into the body is excreted as carbon dioxide; however, some oxygen is converted to water. To convert oxygen

to water, four electrons must be added to it at once (Murray *et al.*, 2000; Kelly *et al.*, 2000).




Approximately 5% of the oxygen are reduced to water by adding one electron at a time. When a single electron is added, an unstable free radical is formed. Superoxide ($O_2^{\cdot-}$), hydrogen peroxide (H_2O_2) and hydroxyl radicals ($OH^{\cdot-}$) are produced from oxygen by addition of one, two, or three electrons respectively (Champe *et al.*, 1994).



The sources of the free radicals are:


A- Internally generated sources of free radicals are (Bagchi & Puri, 1998):


1. Mitochondrial electron transport



2. Phagocytes

3. Xanthine oxidase





ξ. NADP oxidase

ο. Arachidonate Pathways

ϕ. Auto-oxidation of several biological important molecules such as adrenaline, cysteine, and homocysteine.



ϗ. Peroxisomes

λ. Exercise: It induces oxidative stress as measured by oxidative damage of lipid, proteins, and even the genetic material (Sen, 1999; Khanna et al., 1999; Atalay, 2000; Atalay et al., 2000). On the other hand, exercise training—both endurance and interval type—appears to induce antioxidant protection and decrease oxidative insult. Thus regular physical exercise protects against exercise-induced oxidative stress (Khanna et al., 1999; Sen, 1999).

ρ. Inflammation

σ. Ischaemia / reperfusion

τ. Reactions involving iron, copper, and other transition metals such as Fenton and Haber-Weiss reactions



$\text{H}_2\text{O}_2 + \text{Fe}^{\gamma+} \longrightarrow \text{Fe}^{\gamma+} + \text{OH}^\bullet + \bar{\text{O}}\text{H}$ (Haber-Weiss reaction)




B- Externally generated sources of free radicals are (Bagchi & Puri, 1998):

1. Cigarette smoke.
2. Environmental pollutant.
3. Radiation.
4. Ultraviolet light.
5. Certain drugs, pesticides, anesthetics, and industrial solvents.
6. Ozone.

1.4.2. Effects of Free Radicals

The effects of free radicals are:

1. The most common and most hazardous reaction encountered as a result of free radical oxidation is lipid peroxidation (Domingues *et al.*, 1998). Free radical such as hydroxyl radical react with lipids of the cell membrane to form intermediate free radicals and peroxides. The latter initiator leads to subsequent free radical reactions that result in membrane damage (Halliwell & Gutteridge, 1999).




2. Protein exposed to free radicals may fragment, crosslink or aggregate.

This leads to interference with ion channels, failure of cell receptors

and failure of oxidative phosphorylation (Stadtman & Berlett, 1997).

3. DNA free radical damages DNA and causes destruction of base deoxyribose sugars or single and double strand breaks (Cerutti, 1994; Imlay & Linn, 1988). The most frequent oxidative damage to DNA is believed to be the 8-hydroxylation/oxidation of the guanine base to 8-hydroxydeoxyguanosine (8-OHdG), a molecule, which is equivalent to 8-oxo-dG, 8-dihydroguanine (8-oxoG) because the hydroxy hydrogen can easily move to the position-8 leaving a double-bonded oxygen at the position-8 (a resonance form of the two structures). 8-OHdG/8-oxoG is the most commonly studied biomarker of DNA oxidation, figure (1-3). These events lead to



mutagenesis, carcinogenesis, and cell death.

Figure (1-3): Oxidative Damage to DNA: Formation of 8-OHdG/8-

oxoG, dR: deoxyribose (Cerutti, 1994).

1.4.3. Free Radicals and Pathogenesis of DM

The cause of diabetes mellitus is not fully understood. Recently, increasing evidence suggest that free radicals formation are involved in the pathogenesis of diabetes and the development of diabetic complications (Colman *et al.*, 1989; Giugliano *et al.*, 1995).

In type 1; β -cells are prone to be destroyed by free radicals because of the low antioxidant enzyme nature. Immune-effect cells such as macrophages, T-cells, nature killer cells and B-cells are believed to produce free radicals that cause damage to β -cells. There are two mechanisms of free radicals in β -cells destruction (Zhao, 2001):

1. Infiltration macrophages produce superoxide as primary source of free radicals. The superoxide can be further converted to more active radical, hydroxyl radical; which attacks cellular membrane and cause DNA breaks, the consequence of DNA breaks leads to cells death if cells fail to repair the damage. Also, the activation of DNA repair enzymes deplete the DNA levels in cells, inhibiting proinsulin synthesis and causing cells more sensitive to free radicals (Colman *et al.*, 1989).

2. Cytokines are released by T-cells, macrophages, NK cells in the insulinitis and induce the formation of intracellular free radicals causing selective damage to β -cells. Interleukin 1 (IL-1) is the major factor in the damage of β -cells. In addition, interferon γ (ITF γ) and tumor necrosis factor (TNF) are released macrophages during the insulinitis (Gerbitz, 1992). These cytokines induce intracellular free radicals in endothelial cells, fibroblasts, and β -cells. Three types of free radicals are induced from these cells,

$O_2^{\cdot-}$, OH^{\cdot} , and NO^{\cdot} radicals (Corbett & McDaniel, 1990). IL-1 can induce the production of nitric oxide synthase (NOS), which is the enzyme in charge of the synthesis of NO^{\cdot} , therefore, IL-1 induces NO^{\cdot} formation. Many evidence have suggested that NO^{\cdot} results indirectly inhibitory effect on β -cells mitochondria function (Gerbitz, 1992), thus NO^{\cdot} can directly destroy β -cells.

Type 2 DM is a heterogeneous disorder, that is, very different pathologic events result in the same clinical symptom (Leahy & Weir, 1989). Genetic abnormalities, or environmental factors, or obesity, which may induce β -cells malfunction and/or insulin resistance, can cause mild hyperglycemia which further develops to type 2 DM. Some studies indicate that there are alterations in free radicals generation and antioxidant enzymes. The free radicals activity in type 2 DM patients was increased as measured by the markers of free radicals activity (Collier *et al.*, 1992).

1.4.4. Free Radicals and Diabetic Complications

Free radicals perform beneficial tasks such as aiding in the destruction of microorganisms and cancer cells. Excessive production of free radicals or inadequate antioxidant defense mechanisms, however, can lead to damage of cellular structure and enzymes (Sinclair *et al.*, 1990).

Damage to entire tissues can result from free radical-mediated oxidative alteration of fatty acids, also known as lipid peroxidation. There are well-characterized reactions that lead to the formation of the $O_2^{\cdot-}$, H_2O_2 , and the highly toxic OH^{\cdot} . The cytotoxic potential of the $O_2^{\cdot-}$ is mainly from its ability to be converted to the OH^{\cdot} directly or via interaction with H_2O_2 . The $O_2^{\cdot-}$ can also interact with NO^{\cdot} to form peroxynitrite ($ONOO^{\cdot}$) which can degrade to form the OH^{\cdot} (Atalay & Laaksonen, 2002).

Peroxy radicals can remove hydrogen from lipids, such as polyunsaturated fatty acids, resulting in the formation of lipid hydroperoxides and further propagation of the radical pathway by regeneration of alkyl radicals. Hydroperoxides have direct toxic effects for endothelial cells and can also degrade to form the OH^{\cdot} ; hydroperoxides may also form stable aldehyde, such as malondialdehyde (MDA), which damage membranes by facilitating the formation of protein cross-links and other end products (Halliwell & Gutteridge, 1999).

Reactive oxygen species (ROS) can stimulate vascular smooth muscle cell (VSMC) growth. Active free oxygen production, arterial injury, and VSMC proliferation are strongly related to each other. New evidence suggests that certain enzymatic pathways of arachidonic or linoleic acid metabolism can participate in the formation of free radicals and lipid peroxides in the vascular and renal systems. It has been suggested that certain lipoxygenase (LO) enzymes that react with arachidonic or linoleic acid play an important role in atherosclerosis by

inducing the oxidation of low-density lipoprotein (LDL) (Glugliano *et al.*, 1996).

A series of free radical catalyzed peroxidation products of arachidonic acid, called isoprostanes, can be formed in a cyclooxygenase-independent manner and remain associated with membrane phospholipids until they are released by phospholipase. One isoprostan PGF₂ is potentially relevant to diabetic vascular disease based on its potent to contraction of vascular smooth muscle. Antioxidant defense mechanisms are critically important for the ultimate effect of oxidative stress and free radicals on cells and tissues (Murray *et al.*, 2000).

1.5. Oxidative Stress Syndrome

Oxidative stress, an imbalance between the generation of free radicals and antioxidant defense capacity of the body. This resulted in the alteration of the cellular components in term of; DNA break down, protein and lipid Peroxidation, cytotoxicity etc... (Atalay & Laaksonen, 2002).

1.5.1. Diabetes Mellitus and Oxidative Stress Syndrome

The oxidative stress is significantly increased in diabetes because prolonged exposure to hyperglycemia. Many evidence have indicated that some biochemical pathways strictly associated with hyperglycemia (non-enzymatic glycosylation, glucose auto-oxidation, polyol pathways) can increase the production of free radicals (Glugliano *et al.*, 1996), figure (1-ξ).





Figure (1-2): Possible links between hyperglycemia-induced oxidative stress and diabetic complications (Glugliano *et al.*, 1996).

1.5.1.1. Glycation of Protein


H₂O₂ can be formed from glycated of protein. Initially, glucose undergoes a nucleophilic addition reaction with protein to form the schiff base. Formed early glycosylation product, ketamine is chemically reversible and thus is dissociated when blood glucose level returns to normal. However, it subsequently undergoes an Amadori compound. Further reactions, rearrangements, dehydration and cleavage irreversibly results in the formation of brown, insoluble, cross-linking complexes called advanced glycosylation end-products (AGEs) (Glugliano *et al.*,



1996), figure (1-a).

Figure (1-a): Non-enzymatic glycation (Wolff *et al.*, 1991).

Degradation of Amadori product and H₂O₂ formation via both 1,2- and 2,3-enolization pathway and oxidation of enolate anion, figure (1-^ob)



^ob)

Figure (1-^ob): Degradation of Amadori product and H₂O₂ formation (Elgawish *et al.*, 1990)

AGEs tend to accumulate on long-lived macromolecules in tissues. Cross-linking AGE-protein with other macromolecules in tissues results in abnormalities of cell and tissue function. In addition, AGEs contribute to increased vascular permeability in both micro- and macro-vascular structure by binding to a specific macrophage receptor. This process

induced the synthesis and secretion of cytokines such as TNF and IL-1, which causes endothelial dysfunction and induces free radicals generation (Brownlee, 1989).

1.5.1.2. Glucose Auto-oxidation

Radicals can be formed through glucose auto-oxidation. Through one-enolization and two oxidation reactions the α -hydroxyaldehyde part of glucose forms an α -ketoaldehyde whereby superoxide is produced in a process requiring oxygen and transition metal ions. The oxidizing intermediates formed by autooxidation process is proposed to be the cause of some the structures found in diabetes (Wolff & Dean, 1987). There is some evidence in vivo that transition metals chelating agents can prevent auto-oxidation in animal diabetes. (Cameron & Cotter, 1990), figure(1-6).




Figure (1-6): Auto-oxidation of monosaccharide, (Wolff & Dean, 1987)

1.5.1.3. Polyol Pathways

Polyol pathway can also be generated free radicals, which occurs because elevated glucose levels increases intracellular sorbitol and fructose content due to aldose reductase (AR) and sorbitol dehydrogenase (SDH) activity (Baynes, 1991), figure (1-7). AR catalyzes the reduction of glucose by NADPH to sorbitol, which can, in turn, be oxidized to fructose by SDH leading to redox imbalance ($\text{NAD}^+ / \text{NADH}$ ratio). Oxidation of sorbitol to fructose is coupled with reduction of NAD^+ to NADH. An increase in $\text{NAD}^+ / \text{NADH}$ ratio is linked to $\text{O}_2^{\cdot-}$ formation via the reduction of prostaglandin G_γ (PGG_γ) to PGH_γ by prostaglandine hydroperoxidase that uses NADH or NADPH as reducing cosubstrate (Tesfamarian, 1993).





Figure (١-٧): Polyol pathway (Tesfamarian, ١٩٩٣).

١.٥.٢. Specific Biological Alterations in Oxidative Stress Syndrome

١.٥.٢.١. Lipid Peroxidation

Lipid peroxidation is formed by oxidation of membrane



polyunsaturated fatty acids (PUFA) that contain double or triple bonds (interaction of peroxidation aldehyde with phospholipids) leads to release of short-chain aldehydes such as malondialdehyde (MDA) (Lim *et al.*, 2000), figure (1-8).

Figure (1-8): Mechanism of formation of lipid hydroperoxide (MDA) (Halliwell & Gutteridge, 1999).

Lipid peroxidation end products very commonly detected by the measurement of thiobarbituric acid reactive substance (TBARS). This assay has, however, been criticized for the lack of specificity.

Lipid peroxidation as measured by lipid hydroperoxides (Hermes-Lima *et al.*, 1990) have been shown to correlate closely with TBARS data in tissue and samples. With proper caution TBARS measurement may provide meaningful information (Draper *et al.*, 1993).

A low density lipoprotein (LDL) particles has 2200 molecules of free fatty acid, half of which is PUFA which is a highly susceptible substrate for free radical reaction. Patient with DM have an increased risk of premature atherosclerosis, which may be due in part to increased oxidizability of LDL (Fuller *et al.*, 1996).

LDL initially accumulates in the extracellular space of subendothelial space of arteries and through the action of resident vascular cell is mildly oxidized to form minimally oxidized LDL (ox-LDL). Ox-LDL is internalized by the macrophages through scavenger receptor pathway. Native LDL is internalized by the classical receptor pathway with negative feedback so that internalized cholesterol down regulate LDL receptor and prevent further internalization. Such negative feedback does not exist for scavenger pathway. Hence, cholesterol accumulates in the arterial wall (Champe & Harvey, 1994).

In addition, ox-LDL inhibits release of Endothelial Derived Relaxation Factor (EDRF) and reduces the action of EDRF on the vessel wall. Ox-LDL stimulates endothelial cells to release a number of biologically active factors like growth factor for vascular cell chemotactic factors (so that resident monocytes are attracted). Ox-LDL causes disturbance of eicosanoid homeostasis and platelets aggregation, activates T lymphocytes in the atherosclerotic lesion stimulating proliferation of smooth muscle cells. Taken all these together, ox-LDL is atherogenic (Akkus *et al.*, ۱۹۹۶).

Most studies have found increased susceptibility of LDL cholesterol to oxidation in DM patients and elevated levels of plasma, serum, and erythrocyte MDA compared with the control group (Rabini *et al.*, ۱۹۹۴; Peuchant *et al.*, ۱۹۹۷; Nourooz Zadeh *et al.*, ۱۹۹۷; Al-Mashhedani, ۲۰۰۰; Salman, ۲۰۰۱).


۱.۵.۲.۲. Hyperhomocysteinemia

Homocysteine (Hcy) has become widely accepted as a novel risk marker associated with atherosclerotic cardiovascular disease (CVD) in the coronary, cerebral and peripheral vascular beds (Boers, ۲۰۰۰).


The important role of oxidative-redox stress and hyperhomocysteinemia is biologically plausible because Hcy promotes oxidant in the cells, particularly the endothelium and endothelial nitric oxide synthase (eNOS) reaction through the auto-oxidation of Hcy, formation compounds of disulfide interaction of Hcy thiolactones, and protein homocysteinylation (Blom, ۲۰۰۰).

Homocysteine is a nonessential nonprotein sulfur-containing amino acid and an intermediary metabolic product derived from demethylated essential amino acid methionine.

The oxidation of two Hcy molecules yields the oxidized disulfide (homocystine), two protons (H^+), and two electrons, which promoting the formation of (ROS).




Also, formation of mixed disulfides contributes to the additional formation of ROS.



R = any organic compound in the plasma with a thiol group (-SH) accessible to react with Hcy, such as protein, cysteine glutathione, gamma-glutamylcysteine or cystinylglycine (Hayden & Tyagi, 2004).

Additionally, Hcy may undergo complicated rearrangement to form Hcy thiolactone (acyclic thioester), which is chemically reactive and acylates free amino groups such as the side chain lysin groups in proteins. In the process of forming homocysteinylated protein further oxidative stress develops and may lose their biological activity. This results in the modification of protein and in particular the modification of (LDL-cholesterol), which contributes to their retention within the intima and subsequent inflammatory foam cell formation associated with atherogenesis (Hayden & Tyagi, 2004).



The various oxidized forms of Hcy are free and protein-bound Hcy, homocysteine, and Hcy-Cys mixed disulfide, which are defined as total Hcy (tHcy) (Mudd *et al.*, 2000).

The results of many recent studies have indicated that elevated plasma levels of Hcy in patients with DM are associated with increased risk of atherosclerosis (Gazzaruso *et al.*, 2002; Hayden & Tyagi, 2003; Becker *et al.*, 2003; Soinio *et al.*, 2004; Hayden & Tyagi, 2004).

Cordoba and coworkers (1996) suggested that cysteine and Hcy can induce oxidative modification of LDL. This suggestion is relevant because lipoprotein oxidation is thought to play a key role in the development of atherosclerosis and in the triggering of thrombotic events; and Ewadh and Jabir (2002) suggested that extracellular glutathione levels are lowering intracellular glutathione levels of endothelial cells presumably by membrane mediated uptake of Hcy and leading to an accumulation of intracellular Hcy which is induce endothelial cells damage due to glutathione level depletion.

At present, many studies hypothesize that there may exist a folate shuttle, which is operative in the atheroscleropathy associated with diabetic as well as, non-diabetic atherosclerosis. This folate shuttle effect may operate as an effective mechanism in the endothelial microenvironment to recouple the oxidatively stressed, uncoupled, and dysfunctional eNOS reaction (Hayden & Tyagi, 2002; Hayden & Tyagi, 2002; Hayden & Tyagi, 2003; Hayden & Tyagi, 2003; Hayden & Tyagi, 2004), figure (1-9).

There are three critical arms associated with eNOS reaction: the eNOS enzyme, the L-arginine substrate, and the BH₄ cofactor. The eNOS reaction may be uncoupled due to oxidative-redox stress associated with DM atheroscleropathy and non-diabetic atherosclerosis.

When the eNOS reaction is uncoupled, the reaction will become a net producer of O₂⁻ (instead of eNO[•] via the eNOS reaction) through the reaction of membranous NADPH, oxygen and the NADPH oxidase enzyme (Hayden & Tyagi, 2004).




Figure (1-9): Folate shuttle. MS: methionine synthase, 5MTHF: 5-methyltetrahydrofolate, eNOS: endothelial nitric oxide synthase, BH₄: tetrahydrobiopterin, BH₂:

dihydrobiopterin, BH₂: trihydrobiopterin, (Hayden & Tyagi, 2004).

The activated-dysfunctional-uncoupled endothelium is a net producer of O₂^{•-} associated with DM and atherosclerosis. The net production of O₂^{•-} by the uncoupled eNOS reaction in addition to the production of ROS via the auto-oxidation of Hcy results in an excessive oxidative-redox stress (Hayden & Tyagi, 2004).

1.5.3. Smoking Effect

The smoke of cigarettes reduces the activity of antioxidant system, this may lead to imbalance between oxidant-antioxidant in favor of the prooxidant leading to potential damage and dominant risk factor of many disease (Michiels *et al.*, 1994).

In smokers, the mitochondrial respiratory chain function of lymphocyte is disturbed; and it correlates with the degree of oxidative damage of membranes. This mitochondrial dysfunction could contribute to increased endogenous production of ROS (Miro *et al.*, 1999).

Tobacco smoke as a source of exposure to carbon monoxide (CO), to give high level of hemoglobin carbon monoxide (COHb), which were found to be associated with the prevalence of coronary heart disease (Kannel, 1981).

Evidence for increased oxidation in smokers compared with non-smokers were also provided by the presence of increased prooxidation products in blood and urine (Morrow *et al.*, 1990; Mezzetti *et al.*, 1990).

Effect of smoke nicotine on the function of human polymorphnuclear (PMN) leukocytes was the inhibition of microbeidal function of PMN through inhibition of O₂ production and release of lysosomal enzymes, but nicotine has no effect on migration of PMN to inflammatory sites.

Oxidative damage may also results from ROS generated by the increased and activated phygocytes following cigarette smoking (Chow, 1993), and associated with significant increase in circulating nutrophils count and phygocyte derived ROS (Van-Antwerpan *et al.*, 1990; Sharma *et al.*, 1997).

Smoking has also been identified as a risk factor for insulin resistance, which can lead to diabetes. Catecholamines, is a type of hormone, are produced in greater quantity in smoker and act as an antagonist to insulin action (Targher, 1997).

Cigarette smoke results in the formation of more than a billion oxyradicals in each puff (Borck, 1997), therefore, smoking is associated with multiple complications of diabetes-nephropathy (kidney disease) has been shown to be common in type 1 diabetic patients who smoke (Mulhauser, 1996), and smoking increases the risk of heart disease in both types of diabetes (Suarez & Barrett-Conner, 1984); as well as smoking increases the risk of microalbuminurea in diabetic patients (Chase, 1991; Ritz *et al.*, 1996) (microalbuminurea refers to the presence of protein in the urine and can indicate signs of kidney disease).

1.6. Antioxidant Defense Systems

To refer protection against free radicals and prevent damage to vital biological structures such as cell membranes, proteins, and DNA, nature has provided a defense system in the body. This defense system consists of antioxidants.

Antioxidants can be defined as substances whose presence in relatively low concentrations significantly inhibits the rate of oxidation of lipids, proteins, carbohydrates, and DNA. Antioxidants act as potent electron donors, they donate hydrogen atoms to pair up with unpaired electrons on free radicals. Thus they convert reactive free radicals to inactive substances (Bagchi & Puri, 1998).

Antioxidants react with free radicals before more important target molecules like lipids, DNA, etc. are damaged. In doing so the antioxidant is sacrificed (oxidized) and must be regenerated or replaced. The antioxidant radical generated during this process is relatively unreactive and unable to attack vital molecules. Antioxidants prevent damage induced by free radicals and play a very crucial role in preventing or delaying the onset of disease (Langseth, 1996), figure (1-10).




Figure (1-10): The interaction of free radicals and antioxidants

The antioxidant defense of the body consists of two main systems (enzymatic antioxidants and non-enzymatic antioxidants).

1.1.1. Enzymatic Antioxidants

Several antioxidant enzymes are made by various cells in the body. The most three important antioxidant enzymes are superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) which are made in the body in response to the presence of certain free radicals. Thus, if a body is under higher oxidative stress, and is producing more free radicals, more of the antioxidant enzymes will be made to counterbalance the stress like glutathione S-transferase (GST), and glutathione reductase (GR), figure (1-11).




Figure (1-11): Co-operation of antioxidant enzymes. GSH: glutathione, GSSG: oxidized glutathione, Me^{2+} : transition metal, GR: glutathione reductase, GPx: glutathione peroxidase (Cedeberg, 2001).

1.6.1.1. Superoxide Dismutase (SOD)

SOD (EC.1.15.1.1) is a metalloenzyme. There are three major isoforms of SOD; intracellular Cu/Zn-SOD, Extracellular Cu/Zn-SOD (Ec-SOD), and Mn-SOD, with copper and zinc or manganese ions at the active sites, respectively (Cedeberg, 2001).

The enzymes are structurally different; Mn-SOD has a molecular weight of 80,000 and Cu/Zn-SOD 32,000 dalton. Despite different structures, the three isoforms catalyse the same reaction, that is dismutase O_2^- to H_2O_2 (Cedeberg, 2001).



Cu/Zn-SOD is mostly in the cytosol of the cell but also to a lesser extent in the lysosomes and the nucleus. Mn-SOD is considered to be a mitochondrial enzyme only. Ec-SOD is found in the plasma and extracellular space (Atalay & Laaksonen, 2002).

O_2^- may react with other ROS such as NO^\bullet to form highly toxic species such as peroxynitrite ($ONOO^\bullet$), in addition to direct toxic effects (Tasfamarian, 1994). Peroxynitrite reacts with the tyrosine residues in proteins resulting with the nitrotyrosine production in plasma proteins, which is considered as an indirect evidence of ($ONOO^\bullet$) production and increased oxidative stress. Furthermore, exposure of endothelial cells to high glucose leads to augmented production of O_2^- , which may quench

NO[•]. Decreased NO[•] levels result with impaired endothelial functions, vasodilation and delayed cell replication (Glugliano *et al.*, 1996). Alternatively, O₂^{•-} can be dismutated to much more reactive H₂O₂, which through the Fenton reaction can then lead to highly toxic OH[•] formation (Wolff *et al.*, 1991), figure (1-12).




Figure (1-12): Suggested pathways for the formation of reactive oxygen species in vivo, (Wolff *et al.*, 1991).

In diabetic, the wide variability among studies, which are shown decreased, increased and unchanged in SOD isoforms activity (Jennings *et al.*, 1991; Walter *et al.*, 1991; MacRury *et al.*, 1993; Adachi *et al.*, 1996; Kaneto *et al.*, 1996) which does not allow conclusions to be drawn as to whether SOD isoform activities are abnormal in diabetic patients, again differences in methodology or study design do not completely explain the conflicting findings among studies.

1.6.1.2. Catalase (CAT)

Catalase (EC 1.11.1.6) is an oligomer with four 60,000 dalton subunits. It is a hemo protein containing four heme groups. Subcellularly, CAT is mainly localized to the peroxisomes, as much as 4% of the total protein content of the peroxisomes has been estimated to be CAT (Murray *et al.*, 2000).

The peroxisomes are cytoplasmic organelles in which several oxidative processes occur, e.g. the oxidation and detoxification of several toxic compounds resulting in large amounts of H₂O₂ (Cedeberg, 2001).

CAT is found in blood, bone marrow, mucous membranes, kidney, and liver. CAT catalyses the direct composition of H₂O₂ to ground state O₂:



Many studies are found decreased levels of CAT in patients with DM (Kashiwagi *et al.*, 1994; Vijayalingam *et al.*, 1997; Peuchant *et al.*, 1997; Szaleezky *et al.*, 1999; Cedeberg, 2001).

1.6.1.3. Glutathione S-Transferase (GST)

The glutathione transferase are recognized as important catalysts in the bio-transformation of xenobiotics, including drugs as well as environmental pollutants. Multiple forms exist, and numerous transferase from mammalian tissues, insects, and plants have been isolated and characterized. Enzymatic properties, reactions with antibodies, and structural characteristics have been used for classification of the glutathione transferase (Mannervik & Danielson, 1988).

Mammalian cytosolic GSTs (EC 2.5.1.18) are homodimeric, and the monomers are in the range of 22,000 – 29,000 dalton. They could be grouped into three distinct classes - α , μ , and π . They are active over a wide variety of substrates with considerable overlap (Goughlin & Hall, 2002).

GST contributes in conjugating drugs, poisons, and other compounds with reduced glutathione and naturalizes the electrophilic side and dissolution in the aqueous cellular and extracellular media, and from there, out of the body (Raza *et al.*, 2002).

The transferases increase the nucleophilic properties of reduced glutathione (GSH) and they catalyze the formation of thioether bond by conjugated hydrophobic compounds with GSH to form products consist very stable thioether bond; these products excreted by the bile as GSH conjugates and then cleavage glycine or glutamate and acetylation the

free amino group of cysteinyl residue to give the end product (Mercapturic acid) (Cedeberg, 2001).

Some recent studies have found increase in the activity of GST in diabetic patients (Salman, 2001; Raza *et al.*, 2004).

1.6.1.4. Creatine Kinase (CK)

Creatine Kinase (CK, EC 2, 7.3.2) is a dimer consisting of two sub-units. There are three isoenzymes have been designated as CK-BB (brain type), CK-MB (hybrid type), and CK-MM (muscle type) (Bishop *et al.*, 2000).

CK is a major phosphotransfer system in cells with high-energy demand, and it acts in concert with other enzymatic system to facilitate intracellular energetic communication (Neumann *et al.*, 2003), thus CK is an enzyme that is associated with ATP regeneration in contractile or transport systems. Its predominant physiologic function occurs in muscle cells, where it is involved in the storage of high-energy creatine phosphate. Every contraction cycle of muscle results in creatine phosphate use, with the production of ATP (Dzeja & Terzic, 2003).



CK is widely distributed in tissues, with highest activities found in skeletal muscle, heart muscle, and brain tissue. Other tissue sources in which CK is present in much smaller quantities include the bladder,

placenta, gastrointestinal tract, thyroid, uterus, kidney, lung, prostate, spleen, liver, and pancreas (Bishop *et al.*, 2000).

During conditions of oxidative stress, the enzyme CK appears to be inactivated via oxidation of the active-site thiol (Reddy *et al.*, 2000). Ck is relatively unstable, and its activity is apparently lost as a result of internal disulfide formation (Gunst *et al.*, 1998).

Gunst and coworkers (1998) investigated the effect of endogenous extracellular glutathione concentration on serum CK activity, and they found in patients with multiple organ failure, low serum CK activities were accompanied by extremely low serum glutathione concentration.

Serum CK activity is an indicator commonly used in the diagnosis of heart and skeletal muscle disorders (Bishop *et al.*, 2000). Many studies have found that diabetes leads to decrease total CK activity by 30% and also decreased CK-BB mRNA levels (Popovich *et al.*, 1989; Popovich *et al.*, 1991; Kelley *et al.*, 2002).

1.6.2. Non-enzymatic Antioxidants


1.6.2.1. Glutathione (GSH)

GSH is γ -glutamylcysteinylglycine, the most abundant non-protein thiol compound in mammalian cells, is biosynthesized from amino acid precursors (Murray *et al.*, 2000)



Tissue glutathione plays a central role in antioxidant defense. The hydrogen atom of SH group abstraction is one of the most important aspects of GSH reactivity considering its function as an antioxidant.

GSH can undergo oxidation reactions with free radicals through two types of process:


1. One-electron Process; in which GSH is oxidized to form a sulfur-centered glutathione radical (GS^\bullet) (Halliwell & Gutteridge, 1999) as shown in reaction (1):



GS^\bullet can also be formed through photoionization of glutathione anion (GS^-) (reaction 2) or through electron transfer to a metal ion (reaction 3) (Buettner & Oberley, 2001):




2. Two-electron Processes; in which two molecules of reduced GSH are oxidized to the oxidized form of GSH (reaction 4) (Buettner & Oberley, 2001):




The action of GSH are:

1. Reduced GSH detoxifies ROS such as H_2O_2 and lipid peroxides directly or in a GPx catalyzed mechanism (Murray *et al.*, 2000)



2. GSH also regenerates the major aqueous and lipid phase antioxidants, ascorbate and α -tocopherol (Atalay & Laaksonen, 2002):



۳. GSH as a product of glutathione reductase (GR)-catalyzed reactions to maintain the balance between GSH and GSSG. In fact, the ratio of reduced to oxidized GSH within cells is often used scientifically as a measure of cellular toxicity. GSSG is reduced to GSH by GR which uses NADPH as a cofactor:



glutathione reductase (GR) can also catalyze reduction of certain “mixed” disulfides, such as that between GSH and coenzyme A (Peuchant *et al.*, ۱۹۹۷).

۴. GSH as a direct free radical scavenger.
۵. GSH participates non-enzymatically and enzymatically.

Many recent studies have found decrease plasma GSH levels in different disease states especially those associated with oxidative stress like DM (Thornalley *et al.*, ۱۹۹۶; Peuchant *et al.*, ۱۹۹۷; Al-Mashhadani, ۲۰۰۰; Salman, ۲۰۰۱; Cedeberg, ۲۰۰۱;).

In diabetic patient GSH deficiency resulting from reduced concentration of NADPH is used by polyol pathway where glucose is reduced to sorbitol by aldose reductase. An increased activity in this pathway causes a depletion of reduced GSH, which may weaken the antioxidant defense (Cedeberg, ۲۰۰۱; Buettner & Oberley, ۲۰۰۱), figure (۱-۷).

۱.۶.۲.۲. Vitamin E (α -Tocopherol)

Vitamin E is a fat-soluble powerful antioxidant and is the primary defense against potentially harmful oxidation that causes disease and aging (Bishop *et al.*, 2000).

Vitamin E is the collective name for eight compounds, four tocopherol and tocotrienols, found in nature. It is a fat-soluble substance present in all cellular membranes and is mainly stored in adipose tissue, the liver and muscle (Bagchi & Puri, 1998).

α -tocopherol is the predominant isomer in plasma. The actions of vitamin E are:

1. It is essential for the integrity, stability and function of cell membranes, and nerve cells. Vitamin E provides protection to lipid present in cell membranes against free radicals.
2. It scavengers intracellular as well as extracellular free radicals.
3. Vitamin E protects polyunsaturated fatty acids in cell membranes from peroxidation. It prevents oxidation of LDL-cholesterol particles, the most crucial step in the development of atherosclerosis.
4. It increases insulin sensitivity. Thus Vitamin E helps in improving control of diabetes.
5. It also lowers plasma fibrinogen levels.
6. Vitamin E improves endothelial function by increasing release of NO, which dilates blood vessels.
7. It enhances body's immune system.
8. Vitamin E decreases platelet adhesion and platelet aggregation.

9. It decreases the risk of cancer, ischemia and reperfusion injury, cataract, arthritis and certain neurological disorders.
10. It also inhibits the conversion of nitrites in stomach to nitrosamines.
11. It is a singlet oxygen quencher; singlet oxygen (1O_2) is very active non-radical species, which is an excited form of O_2 . 1O_2 is generated by activation of peroxidase enzyme in biological systems and under aerobic condition, as a result of oxidation of hypoxanthine by xanthine oxidase enzyme (Keith, 1999):



1O_2 can damage DNA and be mutagenic, but vitamin E inhibits this process by neutralizing these highly reactive and unstable 1O_2 molecules.

12. Vitamin E protects double bonds of β -carotene from oxidation and thus exhibits a sparing effect.

The mechanism of action vitamin E is that it exhibits its antioxidant action by providing hydrogen atom to pair up with unpaired electrons on free radicals. Thus it converts free radicals to stable and inactive substances (Gillham *et al.*, 2000), figure (1-13).




Figure (1-13). The mechanism of action vitamin E, (Gillham *et al.*, 1999).

During this process, vitamin E is oxidized. Vitamin E does not have antioxidant action. Vitamin C helps in regeneration of oxidized E and converts it to active form. Thus there is a synergistic action between vitamin C and vitamin E (Murray *et al.*, 1999).

1.6.2.3. Vitamin C (Ascorbic Acid)

Vitamin C is a water-soluble antioxidant vitamin. It neutralizes free radicals in the plasma, cytoplasm and extracellular fluid. Vitamin C is not synthesized in the body. Vitamin C is taken from the diet and absorbed from small intestines and it is transported through leukocytes and platelets (Murray *et al.*, 1999).

The actions of vitamin C are:

1. Vitamin C helps in regeneration of oxidized vitamin E in cell membranes (Cedeberg, 2001), figure (1-14).




Figure (1-14): The interactions between ascorbate and α -tocopherol in trapping free radicals (Murray *et al.*, 2000)

2. Vitamin C effects on plasma lipids by reduction in total cholesterol and LDL-Ch, increase in HDL-Ch levels, and decrease in serum triglyceride levels, thus reducing the risk of cardiovascular disease (Tousoulis *et al.*, 2003).
3. It also lowers blood pressure (Murray *et al.*, 2000).
4. Vitamin C improves endothelial function (Cedeberg, 2001).

- It reduces the incidence of cataract and certain cancers.

The mechanism of action of vitamin C in diabetic patients is that vitamin C exhibits its antioxidant action by donating hydrogen atom to free radicals (Atalay & Laaksonen, 2002), figure (1-15).




Figure (1-15): Mechanism of vitamin C to scavenger of free radicals (Atalay & Laaksonen, 2002).


1.6.2.4. Vitamin A (Retinol)

Vitamin A is often used as a collective term for several related biologically active molecules (retinoids). They are retinol, retinal, retinoic acid (all trans), and 11-cis-retinal (formed by photoisomerization of all trans-retinal). Retinol is a primary alcohol containing an β -ionone ring with an unsaturated side chain. Retinol is found in animal tissues as a retinyl ester with long-chain fatty acids. Retinal is the aldehyde derived from the oxidation of retinol. Retinal and retinol can readily be interconverted. Retinoic acid is the acid derived from the oxidation of retinal. Retinoic acid cannot be reduced in the body and therefore cannot give rise to either retinol or retinal (Champe & Harvey, 1994).

Some carotenoids (provitamin A) like β -carotene act as a precursor of vitamin A; which are synthesized by all plants and by some animals, but not by man (Murray *et al.*, 2000).

Scission of β -carotene at the central double bond results in the formation of retinal, which is reduced to retinol (vitamin A) by an NADH-dependent enzymatic reaction. This conversion takes place mainly in the liver (Tietz *et al.*, 1999).

Retinol and its provitamin, β -carotene, are effective antioxidants and considered the most powerful singlet oxygen quenchers (Handelman, 2001). β -carotene can dissipate the energy of 1O_2 , thus preventing this active molecule from generating free radicals. It is efficient at low oxygen pressure (Murray *et al.*, 2000).



1.4. Minerals

Minerals may be divided into two groups: (1) macro-minerals, which are required in amount greater than 100 mg/dL, and (2) micro-minerals (trace elements), which are required in amount less than 100 mg/dL (Bishop *et al.*, 2000).

Trace elements appear to play a key role in most biological functions. The effect of these elements cannot be replaced by another element. It has been reported that action of every small amount of trace and ultratrace elements are necessary for optimal performance of whole organism, and the lack of a small amount of them can result in clinical abnormalities (Luxton, 1999). On the other hand, deficient of these

elements is associated with impairment of function and excess concentrations may be toxic (Bishop *et al.*, 2000).

Trace elements are required in very small amounts to maintain health and they often form essential parts of enzymes and hormones, which regulate metabolism (Luxton, 1999).

Some of the trace and ultratrace elements have a scavenging property as antioxidant to free radical generation, thus the alteration in their levels may be considered a biochemical marker of free radical generation, such as zinc, selenium, copper, iron, and chromium.

1.7.1. Iron

Iron is an essential trace element. Most iron in the body is incorporated into heme of hemoglobin and a smaller proportion as myoglobin, heme-containing enzyme like catalase, and iron-sulfur proteins (Bishop *et al.*, 2000).

Iron is a first-line prooxidant, it contributes to regulate the clinical manifestations of numerous systemic diseases, including diabetes, atherosclerosis, and deoxyribonucleic acid (DNA) damage (Halliwell & Aruma, 1991; Meneghini, 1997; Fernandez-Real *et al.*, 2002).

Iron is intimately linked to oxidative stress. It participates through the Fenton reaction, in the formation of highly toxic free radicals such as OH^\bullet and $\text{O}_2^{\bullet-}$ and causes oxidative damage (McCord, 1991). Oxidative stress influences both glucose and iron metabolism (by decreasing internalization of insulin and increased ferritin synthesis) (Reif, 1992).

1.7.2. Copper (Cu)

Copper is an essential trace element, a small amount of circulating copper is bound to albumin, whereas most is incorporated into ceruloplasmin (Murray *et al.*, 2000).

An important role for copper is as a component of enzymes or proteins involved in redox reaction (Noto *et al.*, 1983) like:

1. Cytochrome c oxidase catalyzes the reduction of oxygen to water in the last step of the electron transport chain (Murray *et al.*, 2000).
2. Cytosolic SOD, containing copper and zinc, catalyzes the conversion of $\text{O}_2^{\cdot-}$ to O_2 and H_2O_2 .

Copper deficiency associated with low concentration of ceruloplasmin and leads to accumulation iron in the liver and causes increase free radical production (Harris, 1990), and lack of the copper-containing antioxidant enzyme related to the shortened life of erythrocytes and neutrophils (Percival, 1990), and excess copper can cause free radicals production and damage tissues (Bishop *et al.*, 2000).

1.7.3. Zinc (Zn)

Zinc is an essential trace element. It is cofactor for more than 300 enzymes, and zinc-containing enzymes are found in every enzyme class. Alkaline phosphatase, alcohol dehydrogenase, carbonic anhydrase, DNA polymerase, and SOD are containing zinc (Murray *et al.*, 2000).

Zinc enzymes are essential to growth, wound healing, reproductive function, the immune system, and protection from free radicals damage (Cunningham-Rundles, 1996).

Oxidative stress syndrome in human with DM results in disturbance of zinc (Kinlaw *et al.*, 1983). Zinc has an important role in modulating the immune system and its dysfunction in DM may be related in part to the status of zinc (Murray *et al.*, 2000). Zinc is found in biological systems only in the (+2) valance state. This is the result of the extra stability associated with a filled d-orbital electron configuration (Luxton, 1999). Diet low in zinc are associated with zinc deficiency include skin lesion, diarrhea, dwarfish, and susceptibility to infection (Burtis & Ashwood, 1999; Bishop *et al.*, 2000)

1.7.4. Chromium (Cr)

Trivalent chromium (Cr^{3+}) is an essential trace element for animals and humans. Its deficiency in organisms causes e.g. disturbance of carbohydrate and lipid metabolism, hypoglycemia, impaired glucose tolerance (Terpilowska & Zaporwska, 2004).

Cr^{3+} may improve insulin sensitivity, which can modify the risk of diabetes and cardiovascular disease (CVD), therefore, when chromium supplementation is beneficial for preventing CVD among people with diabetes (Rajpathak *et al.*, 2004).

The determination of clinical chromium deficiency is difficult, because there is no accurate biochemical indicator of chromium status (Belinda & Connell, 2001; Vincent, 2004).

Mechanism of Action

Chromium appears to act by enhancing or potentiating insulin's actions. No chromium-containing enzyme has been discovered, and the biologically active form of chromium is still uncertain. The actions of chromium have been attributed to an increase in the number of insulin receptors (Belinda & Connell, 2001; Rajpathak *et al.*, 2004).

Numerous researchers have been investigating the effects of chromium supplements on glycemic control in type 1, and 2 diabetes mellitus disease (Anderson *et al.*, 1997; Franz & Bantle, 1999; Javanovic *et al.*, 1999; Ravina *et al.*, 1999; Trow *et al.*, 2000).

1.4.5. Selenium (Se)

Selenium is an essential trace element. The essentiality of selenium results from its presence as a necessary component to form the active center, seleno group (-SeH), of GPx, thioredoxin reductase and of other seleno-enzymes (Tihant *et al.*, 1989; Murray *et al.*, 2000). Selenium is widely distributed in nature and found in combination with sulfide and other minerals (Hayes, 2001).

Selenium is a component as a cofactor of the enzyme GPx, which protects polyunsaturated fatty acid in the cell membrane from oxidative damaging effect of peroxide by decomposing these oxidizing compounds. GPx catalyzes the reduction of H_2O_2 and organic hydroperoxides in the presence of GSH (Bedwal *et al.*, 1993), figure (1-16).




Figure (1-16): The relationship between GPx, Se, and Vitamin E (Gillham *et al.*, 2000).

Thus selenium deficient cells are less capable of scavenging intracellular peroxides after exposure to exogenous H_2O_2 (Knight, 1999). Therefore, selenium was suggested as antioxidant acting as a free radicals scavenger (Palmer & Paulson, 1997).

In addition, selenium and vitamin E have been demonstrated to spare one another antioxidant requirements against lipid peroxides (Beckg, 1998).

Aim of the Study

The aim of the present work is to investigate different aspects of reactive oxygen species (ROS) involvement in diabetes mellitus disease.

Since the objective of this work to study the oxidative stress of patients with DM by test the following hypotheses:

١. Oxidative stress influences on the activity of antioxidant enzymes and concentration of antioxidant vitamins, glutathione, trace elements and homocysteine levels in serum of diabetic patients.
٢. Diabetes mellitus is generator of oxidative stress, therefore the concentration of diabetes mellitus markers of oxidative stress damage correlates with diabetic complications.
٣. Indicate the predominant free radical in type ١ and ٢ diabetes mellitus indirectly by some free radical markers.
٤. Smoking influences on the enzymatic, and non-enzymatic antioxidants.
٥. Investigate the correlation between different variables of antioxidants and which is the high related changes with diabetes mellitus, and represented as important marker of diabetes mellitus.

٢.١. Place of work

This research was conducted in Al-Qadisiya Governorate, Al-Diwaniya General Hospital; Department of Biochemistry, College of Medicine, Al-Nahrain University, and Department of Chemistry, College of Sciences, Babylon University.

٢.٢. Subjects

The study samples included ٥٠ Patients suffering from type ٢ of diabetes (٢٨ males, and ٢٢ females) aged between ٣٥ and ٦٥ years; and ٥٠ patients with type ١ diabetes (٣٢ males and ١٨ females) aged between ١٢ and ٦٥ years, controlled with ٥٠ healthy individuals (٣٨ males and ١٢ females) aged between ١٥ and ٦٥ years. The practical work was expended ١٥ months period, beginning in October ٢٠٠٣ and ending in December ٢٠٠٤.

٢.٣. Samples

The study samples of patients were collected from Al-Diwaniya General Hospital between October ٢٠٠٣ to December ٢٠٠٤, and the blood was drawn from venous of fasting patients recently diagnosed with diabetes mellitus (type ١ and type ٢) and healthy subjects were used as control.

All tests were performed on serum, some of the blood was allowed to clot on crushed ice, and then centrifuged (٤٥٠ X g for ١٠ minutes) to be used serum samples immediately for detection of variable in this study, and others was stored at deep freezing (-٢٠°C) until using.

2.4. Determination of Serum Malondialdehyde (Burtis & Ashwood, 1999)

Principle: -

The principle of the following method was based on the spectrophotometric measurement of the color, occurred during the reaction with thiobarbituric acid (TBA) with MDA, figure (2-1).




Figure (2-1): Schematic diagram for assessment lipid peroxidation via determination the byproduct; malodialdehyde (Luenc J., 1990)

Reagents: -

1- 17.5% Trichloroacetic acid (TCA).

2- 0.6 % Thiobarbutric acid (TBA).

3- 70 % Trichloroacetic acid.

Procedure: -

1. Two set of tubes were prepared as follow:

Reagent	Sample	Blank
Serum	100 µl	-
TCA (17.5%)	1 ml	1 ml
TBA (0.6%)	1 ml	1 ml
All tubes were mixed well by vortex, incubated it in boiling water bath for (10) minutes, then allowed to cool		
TCA (70%)	1 ml	1 ml

2. The mixture was let to stand at room temperature for 20 minutes and centrifuged at 4000 X g for 10 minutes, and the supernatant was taken out to read the absorbance of sample at 522 nm by using spectrophotometer instrument (type CE 101, CECIL Company, France).

Calculation: -

$$\text{The conc. of MDA} = \frac{A \text{ of sample at } 522 \text{ nm}}{L \times \epsilon} \times D$$

where:

L = light path (1 cm)

ε = Extinction coefficient (1.06 X 10⁵ M⁻¹ cm⁻¹)

D = Dilution factor

$$D = \frac{1 \text{ ml (volume used in reference)}}{0.10 \text{ (volume of the sample)}} = 10$$

2.5. Determination of Serum Total Homocysteine (tHcy)

(Pastore *et al.*, 1998; Shanshel *et al.*, 2003)

Reagents: -


Reagents were prepared for total and free thiol concentrations, with the exception of the ammonium formate nitrate buffer. This solvent was prepared by the addition of 3.0 ml of formic acid (M.Wt.= 46.03 gm/mole) and 4.0 ml of nitric acid (M.Wt.= 63.01 gm/mole) to 1000 ml of HPLC-grade water followed by the addition of ammonium hydroxide to bring the pH to 3.00. HPLC-grade water was used to adjust the final volume to 2000 ml.

Procedure: -

All test were performed on serum, which was stored at -20°C until HPLC analysis. The separation was carried out on shimadzu LC-1A system with two pumps and SCI-1A system controller, 100 μl of sample was injected on to shimpack CIC-ODS column (250 X 4.6 mm i.d) protected by ODS guard column (50 X 4.6 mm i.d) . A linear gradient from 0.1 M formate-ammonium nitrate buffer (pH 3.3) and acetonitrile from (0 - 10.0 % in 11 minutes).

The Column elutes were monitored by Rf X 1A Fluorescent detector operating at an excitation wavelength of 360 nm and an emission wavelength of 470nm. The detector coupled to chromatopack CR-1A data processor. The peak of homocysteine was separated and the recoveries of total homocysteine added to serum were 99.2%.

Calibration curve for tHcy analyze was prepared by dissolving 1.5 mg of DL-Hcy in 100 ml of 0.1 mol/L of HCl containing 100 mM/L of DTT. Calibration curve was established by serial diluting the mixed working solution. The linearity of the assays was studied in the 0-200 μmol/L range. The calibration curve shows a linear relationship between peak area and concentration as shown in Figure (2-2).



As well as figure (2-3) shows the chromatogram of homocysteine for samples and standard.




Figure (2-3): Chromatogram of homocysteine samples and standard.

Operating condition: -

Column: Shimpack CIC – ODS (250 x 4.6 mm i.d.)

Protected by ODSC_{1A} (50 x 4.6 mm i.d.)

Mobile Phase: Acetonitrile + Ammonium format nitrate buffer, pH 4.3.

۲.۶. Assay the Activity of Serum Superoxide Dismutase (SOD) (Winterboun *et al.*, ۱۹۷۵)

Principle: -

Ec-SOD activity in serum was determined using a modified Photochemical nitroblue tetrazolium (NBT) method utilizing sodium cyanide as peroxidase inhibitor, figure (۲-۴).




Figure (۲-۴): Schematic diagram showed the of detection SOD activity based upon nitroblue tetrazolium stain (Al-Zamely, ۲۰۰۱).

Reagents: -

1. Working phosphate buffer: 0.1 mM, pH 7.4 containing (0.1 mM) and triton x-100 (0.2%). This solution was prepared as follow:

Solution A: Dipotassium hydrogen orthophosphate (K_2HPO_4) (0.1 mM).

This solution was prepared by dissolving 0.174 gm of K_2HPO_4 in about 200 ml deionized water and then total volume is completed to 1 L.

Solution B: Potassium dihydrogen orthophosphate (KH_2PO_4) (0.1 mM).

This solution was prepared by dissolving 0.136 gm of KH_2PO_4 in about 200 ml of deionized water, then total volume is completed to 1 L.

Then 100 ml of solution A was mixed with 200 ml of solution B, the pH was adjusted to 7.4. The working buffer solution was prepared by adding 0.370 gm EDTA, and 0.20 ml of triton x-100 in phosphate buffer (0.1 mM), pH 7.4 and the total volume was completed up to 1 L with phosphate buffer.

2- Triton x-100 (1% w/v) in deionized water.

3- Nitrobluetetrazolium -HCl (NBT-HCl) (0.1 mM) was prepared by dissolving 0.141 gm of NBT -HCl in small amount of deionized water, and then total volume is completed to 100 ml.

4- L-Methionine solution (0.1 M) was prepared by dissolving 0.1 gm of L-methionine in small amount of deionized water, and then total volume is completed to 100 ml.

5- Sodium cyanide solution (1 mM) was prepared by dissolving 0.01 gm of sodium cyanide in small amount of deionized water, and then total volume is completed to 100 ml.

6- Riboflavin solution (0.1 mM) was prepared by dissolving 0.01 gm of riboflavin in small amount of deionized water, and then total volume is completed to 200 ml.

7- Reacting mixture solution was prepared by mixing 100.0 ml of reagent 1; 0.20 ml of reagent 2; 1 ml of reagent 3, and 0.20 ml of reagent 4.

Procedure: -

1. Three set of tubs were prepared as follows:

Reagents	Sample	Control	Blank
Reacting mixture	3 ml	3 ml	3 ml
Sodium cyanide	0.04 ml	0.04 ml	0.04 ml
Serum	0.10 ml	-	-
Working buffer solution	0.02 ml	0.02 ml	0.02 ml
Mix by vortex in a glass test tube			
Riboflavine	0.038 ml	0.038 ml	0.038 ml

2. All tubes were mixed, and the absorbance of sample and control was read immediately at 260 nm by using spectrophotometer instrument (model 21, Milton Roy Company, France).
3. All tubes, except blank test tube, were illuminated for 10 minutes at 200°C by two fluorescent lamps (20 watts each) incubated in an aluminum foil lined box (70 X 50 X 20) cm³ (Al-Zamely, 2001).
4. At the end of illumination time, the tubs were removed and immediately read absorbance at 260 nm.
5. The standard curve for the inhibition of SSOD enzyme activity was prepared by using different volumes of serum from normal person (20, 40, 60, 80, 100, 120, 160, 200, 240, 260, 300 µl), then repeated the above steps, and the absorbance before and after illumination was read at 260 nm for each volume.

Calculation: -

1- Calculated the percentage of enzyme inhibition for different volume of serum from normal person by using the following equation


$$\text{Inhibition \%} = \frac{[C] - [T]}{[C]} \times 100$$

Where:

$/C/$ = absorbance of control after illumination - absorbance of control before illumination

$/T/$ = absorbance of sample after illumination - absorbance of sample before illumination

ϣ. The standard curve of SOD enzyme was drawn between the percentage of enzyme inhibition and the different volume of serum from normal individual, figure (ϣ-ε).



ϣ. The half of the inhibition was calculated from the standard curve, which it is equal to the unit of SOD enzyme, so that

$$\frac{1}{2} \text{ inhibition} = 37.0\%$$


ε. Then the activity of the SOD enzyme can be calculated from the following equation:

$$\text{Activity of SOD enzyme (U/ml)} = \frac{\text{Inhibition \% of sample}}{\frac{1}{2} \text{ of the inhibition \% from the standard curve, } 37\%}$$

2.7. Assay the activity of serum Catalase (CAT) (Aebi, 1984)

Principle: -

Catalase (CAT) activity was determined by the decrease in absorbance due to H_2O_2 consumption ($\epsilon = 0.04 \text{ mM}^{-1} \text{ cm}^{-1}$) (Mueller *et al.*, 1997)



Reagents: -

1. Phosphate buffer solution: 0.1 mM, pH 7.4, this solution was prepared as follow:

A- Potassium dihydrogen orthophosphate (KH_2PO_4) (0.1 mM). This solution was prepared by dissolving 6.81 gm of KH_2PO_4 (136.09 gm/mole) in small amount of distilled water, and then total volume is completed to 1L.

B- Disodium hydrogen orthophosphate (Na_2HPO_4) (38.772 mM). This solution was prepared by dissolving 6.9 gm of Na_2HPO_4 (141.96 gm/mole) in small amount of distilled water, and then total volume is completed to 1L.

Then 39. ml of solution A was mixed with 11. ml of solution B, and the pH was adjusted to 7.4.

2. Hydrogen peroxide (H_2O_2) (3.0 mM).

Fresh solution of hydrogen peroxide was prepared by dilution 0.34 ml of 3.0% H_2O_2 with phosphate buffer to 100 ml.

Procedure: -

1. 0.1 μ l of serum was diluted with 0 ml of phosphate buffer solution (0.1 mM), pH 7.4 immediately prior to assay.

2. Two sets of tubes were prepared as follow:

Reagents	Sample	Blank
Phosphate buffer solution, pH 7.4	-	1 ml
Diluting serum	2 ml	2 ml

H ₂ O ₂	1 ml	-
-------------------------------	------	---

The reaction was started by adding hydrogen peroxide (freshly prepared), then all tubes were mixed immediately and the initial absorbance after 10 seconds (t₁) and the final absorbance after (30) seconds (t₂) were read at 410 nm by using spectrophotometer (model 21, Milton Roy Company, France).

Calculations: -

Enzyme activity in unit (U) was expressed as the rate constant of first reaction (K) is used according to the following equation:

$$K = \frac{V_t}{V_s} \times \frac{2.3}{\Delta_t} \times \log \frac{E_1}{E_2}$$

Where:

K: is rate constant

Δ_t : is (t₂ - t₁) and it is equal to 10 seconds.

E₁: is the initial absorbance at 10 seconds.

E₂: is the final absorbance at 30 seconds.

V_t: is total assay volume.

V_s: is sample volume in the assay mixture.

2.8. Assay the activity of serum Glutathione S-Transferase (GST) (Habig *et al.*, 1974)

Principle: -

The activity was determined using 1-chloro-2,4-dinitrobenzene (CDNB) as substrate, figure (2-6).




Figure (2-6): Reaction between 1-chloro-2,4-dinitrobenzene (CDNB) and glutathione in the presence of glutathione S-transferase (GST) enzyme, (Yildiz & Kurman, 2004).

Reagents: -

1. Glutathione solution (29.93 mM).

This solution was prepared by dissolving 0.092 gm of glutathione (307.33 gm/mole) in small amount of distilled water, and then total volume is completed to 1 ml.

2. 1-chloro-2,4-dinitrobenzene (CDNB) (22.463 mM).

This solution was prepared by dissolving 0.450 gm of CDNB (M.Wt=202.00 gm/mole) in small amount of ethanol (90%), and then total volume is completed to 10 ml.

3. Phosphate buffer solution, pH 6.20.

This solution was prepared by dissolving 0.430 gm of dipotassium hydrogen orthophosphate and 3.16 gm of potassium dihydrogen orthophosphate in small amount of distilled water, and then total volume is completed to 20 ml. Then the pH was adjusted to 6.20.

Procedure: -

1. Two sets of tubes were prepared as follow:

Reagents	Sample	Blank
Phosphate buffer pH 6.20	2.7 ml	2.7 ml
Serum	100 µl	-
Distilled water	-	100 µl
CDNB solution	100 µl	100 µl
After 3 minutes add GSH solution	100 µl	100 µl

2. Then, all tubes were mixed and the absorbance after each 1 minute for 10 minutes was read at 340 nm by using spectrophotometer (model 21, Milton Roy Company, France).

Calculation: -

Enzyme activity was expressed as (U/L) is calculated according to the following equation:

$$\text{Activity of GST (U/L)} = \frac{\Delta A / 10 \times V_t \times 1000}{\epsilon \times V_s \times d}$$

Where:

ΔA : the difference between the first absorbance at 1st minute and tenth absorbance at 10th minute.

V_t : the total volume.

V_s : the sample volume

ϵ : extinction coefficient ($9.7 \text{ mM}^{-1} \text{ cm}^{-1}$).

d : light path (1 cm).



$$\text{Activity of GST (U/L)} = \frac{\Delta A / 10 \times 1000}{9.7 \times 0.1 \times 1}$$

2.9. Assay the activity of serum Creatine Kinase (CK) by Using Commercially available Kit (Randox-U.K.)

Principle: -

Creatine Kinase (CK) utilizes creatine phosphate as substrate to act as the initial catalyst for series of reactions resulting in the formation of

NADPH as outlined in the coupled enzyme assay to CK activity and it is used to reduce nitro blue tetrazolium (NBT), in the presence of diaphorase, to give the blue, violet color of diformazan which has an absorption maximum around 660 nm. The reaction is stopped by the addition of hydrochloric acid.



Reagents: -

1. Buffer /Glucose solution, pH 7.4

This solution was prepared from imidazole buffer (0.1 mol/L), glucose (20 mm/L), magnesium acetate (10 mm/L), EDTA (20 mm/L), and NBT (0.03 mm/L)

2. Color Reagent

This solution was prepared from ADP (1.1 mm/l), AMP (4.1 mm/L), diadenosine (10.63 mM/L), NADP (0.1 mm/L), creatine phosphate (20 mm/L), glutathione (15 mm/L), hexokinase (HK)(200 U/L), glucose 6-phosphate dehydrogenase(G6P-DH)(100 U/L), and diaphorase (200 U/L)

3. Hydrochloric acid, (0.1N).

4. Standard of creatine kinase (100 U/L)

Procedure: -

1. Four sets of tubes were prepared as follow:

Reagents	Sample	Standard	Reagent blank	Sample blank
Color reagent solution	0.0 ml	0.0 ml	0.0 ml	0.0 ml
All tubes were incubated for (3) minutes at 37°C				
Serum	0.00 ml	-	-	-
Standard	-	0.00 ml	-	-
Distilled water	-	-	-	0.00 ml
All tubes were incubated for (10) minutes at 37°C				
HCl 0.1 N	0 ml	0 ml	0 ml	0 ml
Serum	-	-	-	0.00 ml

The absorbance of the sample (A_{sample}), standard (A_{standard}), and sample blank ($A_{\text{sample blank}}$) were measured against the reagent blank at 560 nm by using spectrophotometer (type CE 111, CECIL Company, France).

Calculation: -

$$\text{CK activity in sample} = \frac{A_{\text{sample}} - A_{\text{sample blank}}}{A_{\text{standard}}} \times \text{Conc. of standard}$$

$$\text{Concentration of standard} = \text{U/L}$$

2.1.1. Determination of Serum Glutathione

(Burtis & Ashwood, 1999)

Principle: -

5,5-Dithiobis (2-nitrobenzoic acid) (DTNB) is a disulfide chromogen that is readily reduced by sulfhydryl group of GSH to an intensely yellow compound. The absorbance of the reduced chromogen is measured at 412 nm and is directly proportional to the GSH concentration, figure (2-1).




Figure (2-7): Reaction between glutathione (GSH) and o,o-Dithiobis (2-nitrobenzoic acid) (DTNB) (Sedlak & Lindsay, 1968).

Reagents: -

1. 4% o-sulfosalicylic acid.
2. 0.1 mM Ellman's reagent was prepared from DTNB (o,o-dithiobis (2-nitrobenzoic acid).; M.Wt = 396.3 gm/mole) in phosphate buffer pH 7.
3. Phosphate buffer pH 7 (this solution was prepared by a mixture of 0.6 M KH_2PO_4 and 0.4 M Na_2HPO_4).
4. 0 mM Glutathione standard solution was prepared by dissolving 0.103 gm of glutathione (M.Wt.=307.33) in small amount of distilled water, then total volume is completed to 1 ml.

Procedure: -

1. Two sets of tubes were prepared as follow:

Reagent	Sample	Blank
Serum	100 µl	-
4% o-sulfosalicylic acid	100 µl	100 µl
sample test tube was mixed, and centrifuged at 400 X g at 4°C for (5) minutes, then:		
Supernatant	100 µl	-
Ellman's Reagent	4.0 ml	4.0 ml


All tubes were mixed, and the absorbance of sample was read at 412 nm

by using spectrophotometer instrument (type CE 101), CECIL Company, France).

٢. The calibration curve of glutathione was prepared from dilution the glutathione standard solution in distilled water to prepare the following concentration: ١, ٥, ١٥, ٢٠, ٣٠, ٤٠, ٥٠, ١٠٠, ٢٠٠, ٣٠٠, ٥٠٠ μM , then the above steps were repeated and the absorbance was read at ٤١٢nm for each concentration.

Calculation: -

The calibration curve of glutathione was drawn between absorbance and different concentration of glutathione, then concentration of serum glutathione of sample was calculated from it, figure (٢-٨).



There is another way to calculate the concentration of serum glutathione by using the following equation:

$$\text{The concentration of GSH} = \frac{A_{\text{of sample}}}{\epsilon \times L}$$

Where:

ϵ = Extinction coefficient ($13600 \text{ M}^{-1} \text{ cm}^{-1}$)

L = Light path (cm).

2.11. Determination of Serum Antioxidant Vitamins

2.11.1. Determination of Serum Vitamin (E) by HPLC

Technique (Vatassery *et al.*, 1983 cited in Salman, 2001)

Reagents: -

1. Antioxidant Solution:

This solution was prepared by dissolving 10 gm of ascorbic acid and 0.1 gm of pyrogallol in small amount of ethanol and distilled water in proportional (1:9), then total volume is completed to 100 ml.

2. Standard Solution of Vitamin E:

This solution was prepared by dissolving 0.01 gm of tocopherol acetate in small amount of hexane then total volume is completed to 100 ml.


3. The mobile phase contains 99% of hexane and 1% of distilled water.

Procedure: -

1. 2 ml of antioxidant solution was added to 100 μ l of serum.

2. The above solution was mixed well and dried by nitrogen gas.

- ϣ. 100 μl of hexane was added, mixed well and centrifuged, then the supernatant was taken out.
- ξ. It was dried again by nitrogen gas, then 0.5 ml of chloroform and methanol mixture in proportional (1:2) was added.
- ο. The supernatant was injected onto silica column (200 x 4.6 mm i.d.), flow rate 2 ml / min.
- ϛ. The column elutes were monitored by UV spectrophotometer at 287 nm.
- Ϝ. The concentration of serum vitamin E was expressed as μmol / L.
- ∧. 2 ml of standard solution of vitamin E (0.01 gm/dl) was injected onto silica column flow rate 2 ml/min., then the column elutes were monitored by UV spectrophotometer at 287 nm, figure (2-9).



2.11.2. Determination of Serum Vitamin A by HPLC Technique (Chow & Omaye, 1983 cited in Salman, 2001)


Reagents: -

1. Standard Solution of Vitamin A
 This solution was prepared by dissolving 0.1 gm of retinyl-palmitate in small amount of hexane, then total volume is completed to 10 ml.
2. Methanol 99% was represented the mobile phase.

Procedure: -

1. 200 µl of serum was pipette into test tube, and a mixture of chloroform and methanol (1:2) was added for test tube.

2. The above mixture was mixed well and centrifuged at $1000 \times g$ for 10 minutes, then the chloroform was taken out.
3. 100 μl of chloroform phase was mixed with 100 μl of standard solution of vitamin A, then injected on to ODSC₁₈ column, flow rate 1 ml / minutes.
4. The column elutes were monitored by UV spectrophotometer at 330 nm.
5. The concentration of vitamin A was expressed as $\mu\text{mol/L}$.
6. 200 μl of standard solution of vitamin A (100 mg/dl) was injected onto ODSC₁₈ column, flow rate 1 ml/min., and the elutes were monitored by UV spectrophotometer at 330 nm, figure (2-10).



2.11.3. Determination of Serum Vitamin C by HPLC Technique (Rose & Nahrwold, 1981 cited in Salman, 2001)


Reagents: -

1. Perchloric acid solution (0.30 mol/L).
This solution was prepared by taking out 0 ml of concentrated perchloric acid, and the volume was completed to 1L with distilled water.
2. Mobile Phase
This solution was prepared by dissolving 1.08 gm of sodium acetate trihydrate and 0.2 gm of disodium EDTA in small amount of distilled water, then total volume is completed to 1L. The pH was adjusted to 6.0 by glacial acetic acid, then filtered with 0.45 µm milliporfilter.
3. Standard Solution of Vitamin C:
This solution was prepared by dissolving 0.0 mg of ascorbic acid in 0.0 ml of perchloric acid and EDTA mixture (prepared by dissolving 100 mg of EDTA in small amount of distilled water, then total volume is completed to 1L) and addition of 0.2 ml of concentrated perchloric acid.

Procedure: -

1. 0.0 ml of perchloric acid solution was added (0.26 mole/L) to 0.0 ml of serum.
2. The above solution was mixed well, then centrifuged at 1900 X g for 1 minute.
3. 20 µl of supernatant was taken out, and injected on to ODSC_{1A} column, flow rate 1 ml/minute.
4. The column elutes were monitored by UV spectrophotometer at 204 nm.

- 5. The concentration of vitamin C was expressed as $\mu\text{mol/L}$.
- 6. $100 \mu\text{l}$ of standard solution of vitamin C (100 mg/dl) was injected onto ODSC₁₈ column, flow rate 1 ml/min. , and the column elutes were monitored by UV spectrophotometer at 254 nm , figure (2-11)



2.12. Determination of Serum Trace Element

2.12.1. Determination of Serum Iron by Using Commercially Available Kit (Randox – UK)

Principle: -

Ferric iron is dissociated from its carrier protein, transferrin, in an acid medium and simultaneously reduced to the ferrous form. The ferrous iron is then complexed with the chromogen, a sensitive iron indicator, to reduce blue chromophore, which absorbs maximally at 590 nm .

Reagents: -

- 1. Chromogen, 22.2 mmol/L .

It was prepared from feren(3-(2-pyridyl)-5,6-bis(4-sulfo-2-furyl)-1,2,4-triazine, disodium salt hydrate)

2. Reductant (ascorbic acid) 1.5 mol/L.
3. Acetate buffer solution, 0.1M mol/L, pH 4.60.

It was prepared from dimethyl sulphoxide and sodium azide.

4. Standard was prepared from ferric sulfate 30 μmol/L.

Procedure: -

1. Three sets of tubs were prepared as follows:

Reagents	Reagent blank	Sample	Standard
Buffer solution, pH 4.60	2.0 ml	2.0 ml	2.0 ml
Reductant, 1.5 mol/L	0.1 ml	0.1 ml	0.1 ml
Double distilled water	0.0 ml	-	-
Standard, 30.0 μmol/L	-	-	0.0 ml
Serum	-	0.0 ml	-
All tubes were mixed, and the initial absorbance of the sample and of the standard were read at 590 nm against the reagent blank by using spectrophotometer (type CE 1011, CECIL Company, France).			
Chromogen, 22.2 mm/L	0.1 ml	0.1 ml	0.1 ml

2. Then, all tubes were mixed, and incubated for 0 minutes at 20 – 25°C. The final absorbance was read against reagent blank. Initial absorbance was subtracted from final absorbance to give ΔA for sample and standard.

Calculation: -

$$\Delta A = A_2 - A_1$$

$$\Delta A_{\text{sample}}$$

Concentration of Iron (μmol/L) = _____ X Conc. Of standard

$$\Delta A_{\text{standard}}$$

Where the concentration of standard is 30.0 μmol/L.

2.12.2. Determination of Serum Copper by Using Commercially Available Kit (Randox – UK)

Principle: -

Copper is an essential trace element in human nutrition and a component of many metalloenzymes. At pH 4.5 copper, which is bound to ceruloplasmin, is released by reducing agent, it then reacts with a specific color reagent, ϵ -(3,5-Dibromo-2-pyridylazo)-N-Ethyl-N-(3-Sulphopropyl) aniline, to form a stable, colored chelate.

Reagents:-

1. Acetate buffer solution (0.2 mm/L), pH 4.5.
2. Chromogen (0.2 mm/L): It was prepared by dissolving ϵ -(3,5-Dibromo-2-pyridylazo)-N-Ethyl-N-(3-sulphopropyl) aniline in acetate buffer, pH 4.5.
3. Ascorbic acid (1.3 mol/L). It was prepared by dissolving 4.888 gm of ascorbic acid with 20 ml of acetate buffer, pH 4.5.
4. Standard was prepared from copper sulfate (31.0 μ m/L)

Procedure: -

1. Three sets of tubes were prepared as follows:

Reagents	Reagent Blank	Standard	Sample
Double distilled water	20 μ l	-	-
Serum	-	-	20 μ l
Standard (31.0 μ m/L)	-	20 μ l	-
Ascorbic acid (1.3 mol/L)	1000 μ l	1000 μ l	1000 μ l
All test tubes were mixed, and allowed to stand for 20 seconds at 37°C. The initial absorbance (A_1) of sample and standard were read at 680 nm against the reagent blank by using spectrophotometer (type CE 1011, CECIL Company, France).			
Chromogen (0.2 mm/L)	200 μ l	200 μ l	200 μ l

2. Then, all tubes were mixed, incubated for 5 minutes at 37°C and the final absorbance (A_2) was read against reagent blank.

Calculation: -

$$\text{Concentration of copper } (\mu\text{mol/L}) = \frac{\Delta A_{\text{sample}}}{\Delta A_{\text{standard}}} \times \text{Conc. Of standard}$$

Where:

ΔA_{sample} : refers to $(A_{\gamma} - A_{\lambda})$ of sample

$\Delta A_{\text{standard}}$: refers to $(A_{\gamma} - A_{\lambda})$ of standard

Concentration of standard is $31.0 \mu\text{mol/L}$.

2.12.3. Determination of Serum Zinc by Atomic Absorption Technique (Burtis & Ashwood, 1999)

Principle: -

Zinc is essential trace element, and deficiencies cause profound clinical consequences. The determination of sample or serum zinc concentration by atomic absorption spectrophotometer (AAS) is the simplest and analytically most reliable test for the routine assessment of zinc. In AAS, the element is merely dissociated from its chemical bonds and placed in an unexcited or ground state (neutral atom). Thus, the neutral atom is at a low energy level in which it is capable of absorbing radiation at a very narrow band width corresponding to its own line spectrum.

Procedure: -

1. Different concentrations of working zinc standard solutions were prepared from stock zinc sulfate solution (10 mg/L) to be used for drawing the standard curve of zinc.
2. The standards, samples, and quality control specimens were diluted 10-fold with distilled water. They were mixed well and taken for the

measurement of zinc concentration at 213.9 nm by using atomic absorption spectrophotometer (Buck model scientific 210 UGP).

2.12.4. Determination of Serum Chromium by Atomic Absorption Technique (Burtis & Ashwood, 1999)

Principle: -

Chromium (Cr^{+3}) is an essential trace element for animals and humans. The commonly used instrumental technique for determination chromium in biological specimens is AAS.

Procedure: -

1. The working standards, samples were diluted and taken out 10 μl of diluted solutions, which were aspirated directly to the flame and measurement of chromium concentration at 370.9nm by using atomic absorption spectrophotometer (Buck Model Scientific 210 UGP).
2. Different concentrations of working chromium standard solutions were prepared from stock chromium chloride solution (1mg/ml) to be used for drawing the standard curve of chromium.

2.12.5. Determination of Serum Selenium by Flameless Atomic Absorption Spectrophotometer (FAAS) (Burtis & Ashwood, 1999)

Principle: -

Atomic absorption measurement suffers from physical, chemical, and spectral interference, which can significantly affect accuracy if they are not adequately overcome. In order to overcome these problems using FAAS technique to determination of selenium, with Zeeman effect background correction. However selenium deficiency can be determined by measuring it by using FAAS, Shimadzu AA-760. Oven thermostat is put at

2000°C for 3 seconds (atomization temperature) and 2200°C for 3 seconds (cleaning temperature); the instrument is equipped with a heated graphite furnace model HGA 2200. Argon gas (99.999% purity) was used as purge gas at a flow rate of 50 ml/min argon gas flow was maintained continuously through drying and charring steps and the gas stop mode was used during atomization stage. Lamp special for selenium with wavelength 196 nm.

Procedure: -

The standards and samples specimens were diluted 2-fold with deionized water, and taken out 10 µl of diluted solutions, which were dispensed into graphite furnace. Standard solutions of selenium (0.40, 0.30, 0.20, 0.10, 0.05, and 0.01) µmol/L were prepared from H₂SeO₄ and analyzed sequentially.

2.13. Statistical Analysis

The data were analyzed by using student's T-test taking $P \leq 0.05$ as the lowest limit of significant of difference and simple linear correlation between two quantitative parameters, and correlation considered significant at $P \leq 0.05$.

3.1. Sampling characteristics

One hundred patients with DM (50 with type 1 DM, and 50 with type 2 DM), and 50 healthy individuals served as control were enrolled in the present study. Table (3-1) shows the demographic sampling characteristics of the study.

Table (3-1): The demographic sampling characteristics of the study.

The characteristics	Type 1 No.=50	Control No.=50	Type 2 No.=50	Control No.=50
Age (mean \pm SE)	32.08 \pm 2.327	27.04 \pm 1.196	51.24 \pm 1.228	47.04 \pm 1.700
Duration of DM (mean \pm SE)	10.364 \pm 1.394	-	5.616 \pm 0.846	-
Family history (No.)	17	-	38	-
Smokers (No.)	11	11	17	13
Non-smokers (No.)	39	39	33	37
Males (No.)	32	21	28	17
Females (No.)	18	29	22	33

3.2. Age

The mean age \pm SE of patients with type 1 DM was (32.08 \pm 2.327 years vs 27.04 \pm 1.196 years of control), while in type 2 DM was (51.24 \pm 1.228 years vs 47.04 \pm 1.700 years of control). There was no significant difference in age of control and diabetic patients with type 1 DM and type 2 DM as shown in table (3-1).

3.3. Duration of DM disease

The mean \pm SE of duration of DM was (10.364 \pm 1.394 years) in patients with type 1 DM, while in type 2 DM was (5.616 \pm 0.846 years).

3.4. Assessment of reactive oxygen species

The assessment of generation of reactive oxygen species (ROD) in DM disease was achieved via determining the level of total homocysteine (tHcy), and MDA; the end product of lipid peroxidation as shown in table (۳-۲).


Table (۳-۲): Results of specific biochemical tests in serum of patients with type ۱ or type ۲ DM and control .

		MDA (μmol/L)	tHcy (μmol/L)	
Type ۱ DM No.=۵۰	Mean±SE	۰.۳۹۷±۰.۰۵۶	۲.۷۶۸±۰.۳۹۱	
	SD	۰.۳۹۷	۲.۷۶۸	
	Range	۱.۶۰۵ – ۰.۳۸۶	۲۶.۲۵ – ۱۴.۶۶	
	۹۰% C.I.	Lower	۰.۸۶۹	۱۹.۶۲۴
		Upper	۱.۰۵۷	۲۰.۹۳۶
Control no.=۲۵	mean±SE	۰.۴۸۶ ± ۰.۰۳۱	۱۰.۷۴۱ ± ۰.۱۹۷	
P-Value		S	S	
Type ۲ DM No.=۵۰	mean±SE	۰.۹۴۸±۰.۳۶۳	۲۱.۹۷±۰.۳۹۵	
	SD	۰.۰۵۱	۲.۷۹۹	
	Range	۱.۸۱ – ۰.۳۸۳	۳۰.۱۱ – ۱۸.۱	
	۹۰% C.I.	Lower	۰.۸۶۳	۲۱.۳۰۷
		Upper	۱.۰۳۳	۲۲.۶۳۳
Control No.=۲۵	mean±SE	۰.۵۴۵±۰.۰۲۹	۱۰.۶۳۳±۰.۱۸۱	
P-Value		S	S	

۳.۴.۱. Lipid Peroxidation

Dien Conjugation (DC) and thiobarbituric acid reactive species (TBARS) are widely used as indicators of lipid peroxidation. DC is a measure of early events of lipid peroxidation reactions whereas TBARS measure end products of lipid peroxidation; MDA, (Vasankari *et al.*, ۱۹۹۵).

In this work, there was significant difference in malondialdehyde (MDA) levels between controls and diabetic patients (with type 1, and type 2 DM) $P \leq 0.05$, but there was no significant difference between type 1 DM and type 2 DM. Therefore serum MDA levels in patients with type 1, and type 2 DM are higher than control by 1.981 and 1.739 times of control levels respectively, figure (3-1), table (3-2).




Elevated levels of lipid peroxidation products in serum of diabetic subjects and rats have been shown in several studies (Dominguez *et al.*, 1998; Al-Mashhadani, 2000; Salman, 2001; Marra *et al.*, 2002; Hadwan, 2005). The results of this study indicated that serum MDA levels are elevated in diabetic patients. Higher levels of MDA is associated with reduced of antioxidant activity and increased oxidative stress (Marangon *et al.*, 1998; Al-Zamely, 2000; Al-Mashhadani, 2000; Sahin *et al.*, 2001). Low density lipoprotein particles has 2200 molecules of free fatty acids, half of which is PUFA which is a highly susceptible substrate for free radical reaction to form a short-chain aldehyde such as malondialdehyde, therefore elevated level of MDA might increase susceptibility of diabetic patients to premature atherosclerosis, which may be due in part to increased oxidizability of LDL.

3.4.2. Total Homocysteine (tHcy) Level

In plasma, about 80% of homocysteine is bound to proteins (especially albumin), the remainder being present in a free form, either as a disulphide with itself or cysteine, or as reduced homocysteine itself. Usually the sum of these fractions is measured in the laboratory and called serum tHcy concentration.

Hyperhomocysteinemia (elevated level of tHcy) plays an extremely important role for additional oxidative-redox stress regarding the accelerated cardiovascular complications in diabetic patients (Fodinger *et al.*, 1997). There is no obvious direct biochemical link between methionine-homocysteine metabolism and glucose/carbohydrate metabolism other than insulin induced protein synthesis, which may decrease serum methionine level (Zinneman *et al.*, 1966). Therefore, elevated level of tHcy may be associated with insulin deficiency that leads to enhanced homocysteine catabolism in the liver, a phenomenon that was reversible upon insulin administration (Jacobs *et al.*, 1998). As well as elevated level of tHcy in diabetic patients may be associated with low folate levels or cobalamin concentration or renal dysfunction as one of diabetic complications probably also contributes to the higher homocysteine levels (VanGuldener *et al.*, 2001). Presence of hyperhomocysteinemia (HHcy) may be a predictor for the development of DM (Hayden & Tyagi, 2004). Therefore, there is an interrelationship between Hhcy and DM and/or its complications (Smulders *et al.*, 1999).

As shown in table (3-2), the mean \pm SE of serum tHcy levels in patients with type 1 DM was ($20.28 \pm 0.391 \mu\text{mol/L}$ vs $10.741 \pm 0.197 \mu\text{mol/L}$ of control), while in patients with type 2 DM was ($21.970 \pm 0.390 \mu\text{mol/L}$ vs $10.633 \pm 0.905 \mu\text{mol/L}$ of control). There was significant elevation in serum tHcy levels of diabetic patients (with type 1 and type 2 DM) by about 50% from control, $P \leq 0.05$, figure (3-2).



Several studies pointed out elevated levels of serum tHcy in diabetic patients and suggested that homocysteine (Hcy) shows stronger relationship with cardiovascular complications and death in patients with diabetes than in non-diabetics.


1. The mortality risk associated with HHcy is about 2 times stronger in diabetics than in non-diabetics (Hoogeveen *et al.*, 2000).
2. The association between retinopathy and HHcy is much stronger in patients with diabetes compared to subjects without diabetes (Hoogeveen *et al.*, 2000).
3. Despite similar plasma Hcy levels, a strong correlation between the extent of coronary abnormalities and plasma Hcy level is found in diabetics, while this relationship is not significant in non-diabetics. (Okada *et al.*, 1999).

3.5. Assessment of Scavenger System

The results of this study indicate the percentage (%) of antioxidant that assessed in this study table(3-3),(figure 3-3).

Table (3-3): Percentage of antioxidants that assessment in this study for diabetic patients (with type 1 or 2 DM), and control.

Antioxidants	%			
	Type 1 DM	Control	Type 2 DM	Control
SOD	31.04	20.00	27.90	20.96
CAT	9.20	39.28	12.22	39.20
CK	22.60	20.74	21.20	30.41
GST	32.00	20.21	27.10	20.74
GSH	14.93	33.30	19.94	31.83
Vitamin E	10.91	32.99	17.78	24.42
Vitamin A	17.77	29.94	19.11	24.18
Vitamin C	17.70	31.70	17.77	33.88
Zinc	19.79	29.20	20.98	29.98
Chromium	17.76	32.37	18.00	31.87
Selenium	20.16	29.77	20.06	29.71



The results obtained in the present study confirmed that diabetic patients were presented with depletion of scavengers in a sequence compatible with those reported in any disease related to the oxidative stress syndrome in humans. Figure (3-4) demonstrates that antioxidants are depleted from serum at different rates upon exposure to oxidative stress in both type 1 and 2 DM, with catalase (CAT) activity being depleted first, followed by glutathione (GSH), then α -tocopherol, ascorbate, chromium, vitamin A, zinc, selenium, and lastly CK activity.




Figure (٣-٤): Depleted of serum antioxidants at different rat upon exposure to oxidative stress in patients with type ١ and ٢ DM.

٢.٥.١. Enzymatic Antioxidants

Table (٣-٤) shows the levels of some antioxidant enzyme.

Table (٣-٤): Levels of several enzymatic antioxidants in serum of patients with type ١ or type ٢ DM and control.

		SOD (U/ml)	CAT (K/ml)	CK (U/L)	GST (U/L)	
Type ١ DM No.=٥٠	Mean±SE	١.٥٥٣ ± ٠.٠٣٩	٠.٣٨٣ ± ٠.٠١٠	١٦٨.٥٦ ± ٣.٨٩٧	٤.٧٣١ ± ٠.١٩٩	
	SD	٠.٢٧٦	٠.٠٧٤	٢٧.٥٦٢	١.٤١٣	
	Range	٢.٨٧٥ – ٠.٥٧٩	٠.٥٩٥ – ٠.٠٨٤	٢٥٩ – ٧٥	٧.٥٩ – ٢.٢	
	%٩٥C.I.	Lower	١.٤٨٧	٠.٣٦٦	١٦٢.٠٢٩	٣.٠٥٦
		Upper	١.٦١٨	٠.٤٠٠	١٧٥.٠٩٠	٥.٠٦٤
Contr ol No.=٢	Mean±SE	١.٠١٢ ± ٠.٠٥٤	١.٦٢٦ ± ٠.٠٦٢	١٩٢ ± ٥.٩٥٥	٢.٩٨٨ ± ٠.٠٥١	
P- Value		S	S	S	S	
Type ٢ DM No.=٥٠	Mean±SE	١.٣٢٧ ± ٠.٠٢٧	٠.٥٠٦ ± ٠.٠١٨	١٥٨.٥٢ ± ٣.٠٢٦	٤.٠١٤ ± ٠.١٩٧	
	SD	٠.١٩٧	٠.١٣٣	٢١.٤٠٢	١.٣٩٨	
	Range	٢.٥٢٦ – ٠.١٣٧	٠.٧٧٦ – ٠.٣٣٢	١٨٤ – ٨٦	٧.٦٩١ – ٢.٣٢	
	%٩٥C.I.	Lower	١.٢٨١	٠.٤٧٥	١٥٣.٤٤٨	٣.٦٨٣
		Upper	١.٣٧٣	٠.٥٣٧	١٦٣.٥٩٢	٤.٣٤٥
Control No.=٢٥	Mean±SE	١.٠٣٢ ± ٠.٠٣٠	١.٦٢٥ ± ٠.٠٥٩	٢٢٦.٨ ± ٥.٦٦٢	٣.٠٥٣ ± ٠.٠٣٣	
P- Value		S	S	S	S	


٢.٥.١.١. Extracellular Souperoxide Dismutase (Ec-SOD) Activity.

The primary natural defense against free radicals is to prevent their formation by various enzymes, especially SOD, which is regulating superoxide anion ($O_2^{\cdot-}$) levels in catalyzing the dismutation of $O_2^{\cdot-}$ to H_2O_2 (Frank *et al.*, ٢٠٠٠). The activity of Cu/Zn-SOD increases in many disease

causing oxidative stress (Knight, 1999). Therefore, several studies pointed out high levels of Ec-Cu/Zn-SOD activity in diabetic patients (with type 1

and type 2 DM) (MacRury *et al.*, 1993; Adochi *et al.*, 1996; Dominguez *et al.*, 1998; Hristosozova *et al.*, 2000; Salman, 2001).

The activity of Ec-Cu/Zn-SOD is measured by the degree of inhibition of reaction between nitrobluetetrazolome and superoxide anion ($O_2^{\cdot-}$) that is generating during illumination of riboflavin in the presence of electron donor substance (Winterboun *et al.*, 1970). However, as seen in the present study, there is a significant increase in serum Cu/Zn-SOD activity levels in patients with type 1 and type 2 DM, $P \leq 0.05$, figure (3-5). Table (3-4) shows the mean \pm SE of serum Cu/Zn-SOD activity in patients with type 1 DM was (1.003 ± 0.39 U/ml vs 1.12 ± 0.04 U/ml of control), while type 2 DM was (1.327 ± 0.27 U/ml vs 1.32 ± 0.30 U/ml of control).




The results of this study reports that high levels of serum Cu/Zn-SOD activity in diabetic patients are indicating to the presence of high level of superoxide anion ($O_2^{\cdot-}$), which represents an indicator to high degree oxidative stress in those patients, therefore increased amounts of substrate of $O_2^{\cdot-}$ this results in a stimulant to increase synthesis of serum Cu/Zn-SOD

in diabetic patients and may protect against free radicals damage (Hristosozova *et al.*, 2000).

3.5.1.2. Catalase (CAT) Activity

CAT is a hydrogen peroxide decomposition catalyzing enzyme mainly localized to peroxisomes or microperoxisomes (Atalay & Laaksonen, 2002). Therefore, measurement of CAT could be a valuable biomarker for the generation of H₂O₂ and the degree of oxidative stress (Mueller *et al.*, 1997; Banerjee *et al.*, 2002).

In this study, the results reported that measurement of serum CAT activity in diabetic patients represents the powerful indicator to evaluation of the oxidative stress. However, there was a significant reduction in serum CAT activity levels of diabetic patients (with type 1 and type 2 DM) than controls, $P \leq 0.05$, figure (3-6), therefore the mean \pm SE of serum CAT activity levels in patients with type 1 DM was (0.383 ± 0.010 K/ml vs 1.626 ± 0.062 K/ml of control), while in patients with type 2 DM was (0.506 ± 0.018 K/ml vs 1.620 ± 0.059 K/ml of control), table (3-4), these found results were in agreement with a great number of previous publications (Ou & Wolff, 1994; Szaleczky *et al.*, 1999; Hristosozova *et al.*, 2000; Atalay & Laaksonen, 2000).




The present results indicate that decrease levels of serum CAT activity in diabetic patients may be due to hyperglycemia that causes degradation of peroxisomes (Hristosozova *et al.*, 2000) or may be due to inactivation of the enzyme CAT that may occur through glycation governed by prevailing glucose concentration. Thus increased glycation in diabetics and subsequent reactions of proteins may effect amino acids close to the active site of the enzyme or disturb the stereochemical configuration and causes structural and functional changes in the molecules (Rahbani *et al.*, 1999). Furthermore decline levels of serum CAT activity is a good indicator to high concentration of hydrogen peroxide (H_2O_2) in diabetics that increases oxidative stress and diabetic complications.

2.5.1.3. Glutathione S-Transferase (GST)Activity

GST is an antioxidant enzyme that catalyzes the reaction between reduced glutathione (GSH) and drugs, xenobiotics and other toxic compounds, rendering them more water soluble and finally excreted from the body (Coughlin & Hall, 2002). Previous studies have shown that some chemical compounds, which augments oxygen products, have generated toxic effect such as many drugs and xenobiotics, which contain quinone groups cause free radical. The metabolism of quinone compounds includes formation of semiquinone radical. This radical reduces the molecule oxygen immediately, the superoxide anion ($O_2^{\cdot-}$) comes into existence and, following that other ROS are generated (Mayesca & Holden, 1990; Kanbak *et al.*, 1996; Inal & Kanbak, 1997). However, most studies have reported increased levels of serum GST activity contributed to the increased oxidative stress found in type 1 and type 2 DM subjects (Ioannides *et al.*, 1990; Salman, 2000; Mari & Cederbaum, 2001; Raza *et al.*, 2004).

The results of this study indicate a significant difference was observed in serum GST activity levels between control and diabetic patients (with type 1 and type 2 DM), $P \leq 0.05$, figure (3-7).




Thus the mean \pm SE of serum GST activity levels of patients with type 1 DM was (4.73 ± 0.199 U/L vs 2.988 ± 0.051 U/L of control), while in patients with type 2 DM was (4.014 ± 0.197 U/L vs 3.053 ± 0.33 U/L of control), table (3-4), this higher levels of serum GST activity in diabetic patients may be due to increased synthesis of this enzyme under oxidative stress to protect the body from toxic compounds (Delmas *et al.*, 1996).

3.5.1.5. Creatine Kinase (CK) Activity

Serum CK activity is an indicator commonly used in the diagnosis of heart and skeletal muscle disorder (Gunst *et al.*, 1998). Several studies pointed out that levels of serum CK is decreased in diabetic patients and suggested that decreased levels of serum CK may contribute to diabetic cardiomyopathy complications (Popovich *et al.*, 1989; Popovich *et al.*, 1991; Hadwan, 2005).

In this work, serum CK activity in diabetic patients (with type 1 and type 2 DM) was significantly lower than controls activity, $P \leq 0.05$, figure (3-8). The mean \pm SE of serum CK activity levels of patients with type 1 DM was (168.06 ± 3.897 U/L vs 192 ± 0.900 U/L of control), while in patients with type 2 DM was (108.02 ± 3.026 U/L vs 226.8 ± 0.662 U/L of control), table (3-4).



Serum CK is a protein contain thiol groups that is particularly susceptible to oxidation (Reddy *et al.*, 2000), therefore decreased the activity of serum CK results from the oxidation of the essential -SH group of CK by ROS that generated in diabetic patients because prolonged exposure to hyperglycemia and inducing an inactivation of the enzyme (Mekhfi *et al.*, 1996).

3.5.2. Non-Enzymatic Antioxidants

Table (3-5) shows the levels of some non-enzymatic antioxidants.

Table (3-5): Levels of several non-enzymatic antioxidants in serum of patients with type 1 or type 2 DM and control .

		GSH ($\mu\text{mol/L}$)	Vitamin E ($\mu\text{mol/L}$)	Vitamin A ($\mu\text{mol/L}$)	Vitamin C ($\mu\text{mol/L}$)
Type 1 DM No.=50	Mean \pm SE	1.603 \pm 0.027	3.16 \pm 0.82	1.212 \pm 0.087	3.402 \pm 0.160
	SD	0.193	0.08	1.212	1.170
	Range	1.24 – 0.17	4.220 – 1.98	2.30 – 0.23	0.40 – 1.2
	%95 C.I.				
	Lower	0.607	3.023	1.066	3.170
	Upper	0.698	3.297	1.308	3.729
Control No.=70	Mean \pm SE	1.406 \pm 0.070	6.001 \pm 0.222	2.163 \pm 0.140	6.034 \pm 0.242
P-Value		S	S	S	S
Type 2 DM No.=50	Mean \pm SE	0.872 \pm 0.041	3.312 \pm 0.106	1.381 \pm 0.080	3.642 \pm 0.148
	SD	0.296	0.702	0.071	1.003
	Range	1.9 – 0.17	2.67 – 1.067	2.67 – 0.240	0.719 – 1.7
	%95 C.I.				
	Lower	0.803	3.143	1.246	3.393
	Upper	0.940	3.49	1.016	3.891
Control No.=70	Mean \pm SE	1.392 \pm 0.060	6.834 \pm 0.239	2.470 \pm 0.124	6.984 \pm 0.248
P-Value		S	S	S	S


3.5.2.1. Glutathione (GSH) Level

Serum GSH plays a central role in antioxidant defense (Sen & Hanniuen, 1994; Meister, 1990). GSH detoxifies ROS such as H_2O_2 and lipid peroxides directly or in a glutathione peroxidase (GPX) catalyzed mechanism. GSH also regenerates the major aqueous and lipid phase antioxidant, ascorbate and α -tocopherol. Glutathione reductase (GRD) catalyzes the NADPH dependent reduction of oxidized glutathione (GSSG)

servicing to maintain intracellular GSH stores and a favorable redox status GSH catalyzes the reaction between the –SH group and potential alkylating agents (Murray *et al.*, 2000).

Thornalley *et al.* (1996) found an inverse correlation between GSH level and the presence of DM complications in type 1 and type 2 DM patients. However, most studies have also found decreased level of serum GSH in diabetic patients (Jain & McVie, 1994; Akkus *et al.*, 1996; Delmas *et al.*, 1998; Paolisso *et al.*, 2000; Salman, 2001; Atalay & Laaksonen, 2002; Hadwan, 2000).

In this work, serum GSH level was significantly decreased in patients with type 1 and type 2 DM when it is compared with control, $P \leq 0.05$. Hence, serum GSH level is approximately 40% than that of control in patients with type 1 DM, while serum GSH level in patients with type 2 DM was approximately 62% than that of control, figure (3-9), table (3-5).



Decreased level of serum GSH in diabetic patients could represent an adaptive response to increased oxidative stress and free radicals generation that oxidized thiol group of GSH and decline reduced glutathione level, therefore it is a good indicator to diabetic complications.

The results of this study show different negative correlation, but not significant between serum GSH level and serum MDA, and tHcy levels, whereas a positive correlation, but not significant, with level of serum CK activity in diabetic patients (with type 1 and type 2 DM). Furthermore, there was a significant negative correlation ($r = -0.309$, $P \leq 0.05$) between levels of GSH and levels of GST activity in serum of patients with type 2 DM, but this correlation was not significant in patients with type 1 DM, table (3-6), figure (3-10).

Table(3-6): The correlation between the level of glutathione and several biochemical markers related to oxidative stress syndrome.

The correlation of glutathione ($\mu\text{mol/L}$) vs. other variables	Type 1 DM, No.= 50		Type 2 DM, No.= 50	
	Correlation coefficient (r)	P-Value	Correlation coefficient (r)	P-Value
vs. MDA ($\mu\text{mol/L}$)	-0.0002	NS	-0.0046	NS
vs. tHcy ($\mu\text{mol/L}$)	-0.1275	NS	-0.1864	NS
vs. GST (U/L)	-0.2045	NS	-0.3099	S
vs. CK (U/L)	0.0581	NS	0.1223	NS

These results probably were due to the following:

١. Depletion serum GSH levels lead to slightly accumulation of intracellular total homocysteine, which induces endothelial cells damage and slightly increases risk of cardiovascular disease in diabetic patients. These results go with the results of the study of (Ewadh and Jabir, ٢٠٠٢).
٢. Serum GSH has an important role in the protection of cells from the peroxidation injury, therefore decreases the degree of lipid peroxidation via end products; MDA in diabetic patients, these results are in agreement with the results of (Delmas *et al.*, ١٩٩٦; Dominguez *et al.*, ١٩٩٨).
٣. Presence of high level of toxic compounds in diabetic patients, especially with type ٢ DM (treatment with of hypoglycemic oral such as tablets of daonil, glucophage...etc) induced accumulation of GST enzyme and altered GSH metabolism, therefore toxic compounds increase ROS production that decreases levels of GSH, while increases synthesis of GST enzyme to play a protective role (Inal & Kanbak, ١٩٩٧; Raza *et al.*, ٢٠٠٤).
٤. Increased levels of GSH could be slightly reversible loss in activity of CK enzyme through S-glutathionylation mechanism for regeneration of active CK from S-glutathionylated CK and increased level of CK activity (Reddy *et al.*, ٢٠٠٠).







Figure (3-10): Correlation of glutathione (GSH) with level of malondialdehyde (MDA), total homocystiene (tHcy), glutathione S-transferase (GST) activity, and creatine kinase (CK) activity in serum of patients (A) with type 1 diabetes mellitus, and (B) with type 2 diabetes mellitus disease.

3.5.2.2. Vitamin E (α -tocopherol) Level

Serum vitamin E is a principle modulator of free radicals activity, it is a potent antioxidant acting as scavenger of reactive oxygen species (ROS) and reduces oxidative stress in DM disease (Paolisso *et al.*, 2000). Numerous studies have shown decrease in vitamin E level in diabetic tissue and blood (Salman, 2001; Paolisso *et al.*, 2000; Anderson *et al.*, 1999; Bursell *et al.*, 1999; Dominguez *et al.*, 1998; Tutuncu *et al.*, 1998; Fuller *et al.*, 1996).

This study indicated that serum vitamin E levels was significantly reduced in diabetic patients compared with control $P \leq 0.05$, figure (3-11), therefore the mean \pm SE of serum vitamin E levels in patients with type 1 DM was ($3.16 \pm 0.82 \mu\text{mol/L}$ vs $6.001 \pm 0.222 \mu\text{mol/L}$ of control), while in patients with type 2 DM was ($3.312 \pm 0.106 \mu\text{mol/L}$ vs $6.834 \pm 0.239 \mu\text{mol/L}$ of control), table (3-5).




Reduced level of serum vitamin E possibly is due to increased utilization of this antioxidant in neutralizing free radicals in diabetic patients, thus supplementation of vitamin E to diabetic patients could reduce level of oxidative stress and diabetic complications.

3.5.2.3. Vitamin C (Ascorbic Acid) Level

Serum vitamin C is a free radical scavenger and interacts with free radicals in the water compartment of cells as well as in the fluid between cells. It is considered to be one of the most important antioxidants in extracellular fluids. Several studies have been shown that patients with diabetes have lower serum levels of vitamin C than non-diabetic subjects, and this is believed to be an important factor contributing to the increase of oxidative stress status and endothelial dysfunction in diabetes (Tousoulis *et al.*, 2003; Ceriello, 1999; Will & Byers, 1996; Paolisso *et al.*, 1990; Wang *et al.*, 1994).

The results of this study show the mean \pm SE of serum vitamin C in patients with type 1 DM, which was ($3.402 \pm 0.160 \mu\text{mol/L}$ vs $6.034 \pm 0.242 \mu\text{mol/L}$ of control), while in patients with type 2 DM, it was ($3.742 \pm 0.148 \mu\text{mol/L}$ vs $6.984 \pm 0.248 \mu\text{mol/L}$ of control), table (3-5). There was a significantly decreased vitamin C levels in serum of diabetic patients than that of control, $P \leq 0.05$, figure (3-12).




This decline in levels of serum vitamin C in diabetic patients may be due to (1) reduce renal re-absorption of vitamin C induced by hyperglycemia, (2) the competition between glucose and vitamin C for the uptake into certain cells and tissues, (3) the activity of polyol pathway that inhibited affectivity by utilizing high level of vitamin C to avoid hyperglycemia, (4) and possible secondary depletion due to increased oxidative stress have been proposed (Wang *et al.*, 1994; Will & Byers, 1996).

3.5.2.4. Vitamin A (Retinol) Level

Serum vitamin A is an important antioxidant. It is a biomarker of oxidative stress in DM disease (Dominguez *et al.*, 1998).

The present study indicates a significant decrease in serum vitamin A levels in diabetic patients than that of control, $P \leq 0.05$, figure (3-13). The mean \pm SE of serum vitamin A in patients with type 1 DM was ($1.212 \pm 0.087 \mu\text{mol/L}$ vs $2.163 \pm 0.140 \mu\text{mol/L}$ of control), while in patients with type 2 DM was ($1.381 \pm 0.080 \mu\text{mol/L}$ vs $2.457 \pm 0.124 \mu\text{mol/L}$ of control), table (3-5).



These results may be due to the increased utilization of this vitamin in the neutralization of free radicals induced by hyperglycemia, thus depletion of serum vitamin A in diabetic patients is due to the increased oxidative stress and diabetic complications. These results are in agreement with the findings of many studies (Delmas *et al.*, 1996; Domingues *et al.*, 1998; Bursell *et al.*, 1999). Therefore, supplementation of vitamin A or its precursor B-carotene to diabetic patients help in the reduction of oxidative stress and diabetic complications.

3.5.2.5. Trace Elements (Iron, Zinc, Copper, Chromium, and Selenium) Levels.

Some serum trace elements act as antioxidants and prevent membrane peroxidation. Others act directly on glucose metabolism. Ceruloplasmin, the major plasma copper transporting protein, possesses a potent oxidant property. Chromium trivalent (Cr^{3+}) plays an important role in insulin-receptor activation (Terpilowska & Zaporowska, 2004). The function of zinc (Zn) in the body metabolism is based on its enzymatic affinity, way of a Zn-enzyme complex or Zn metalloenzyme. Iron (Fe^{2+}) is stored in the ferritin and iron is released from it by the action of reducing agents that convert Fe^{3+} to Fe^{2+} , thus ferritin can act as a source of iron, which induces oxidative stress, and as a mechanism that protects against iron toxicity (Fern *et al.*, 2002). Selenium (Se) plays important role in antioxidant defense system (Ulus & Turan, 2005).

The several studies pointed out that diabetes results in disturbance of these trace elements. Present study indicates a significant decrease in levels of serum iron, Zinc, chromium, and selenium in diabetic patients with type 1 DM by about 51%, 33.7%, 50%, and 33% respectively from that of control, $P \leq 0.001$, figure (3-14); while in patients with type 2 DM there was a significant decrease in about 66%, 30%, 50%, and 21% respectively from that of control, $P \leq 0.005$, figure (3-14), table (3-7).

Table (٣-٧): Levels of several trace elements in serum of patients with type ١ or type ٢ DM and control.

		Fe ($\mu\text{mol/L}$)	Cu ($\mu\text{mol/L}$)	Zn ($\mu\text{mol/L}$)	Cr ($\mu\text{mol/L}$)	Se ($\mu\text{mol/L}$)
Type ١ DM, No.=٥٠	mean \pm SE	٨.٦٤٢ \pm ٠.٣٢٠	١٧.٠٣ \pm ٠.٥٢٢	١٠.٤٩٤ \pm ٠.١٢٢	٠.٥٦٢ \pm ٠.٠٠٩	٠.٨٥ \pm ٠.٠١٣
	SD	٢.٢٦٤	٣.٦٩٤	٠.٩١٨	٠.٠٦٣	٠.٠٨٨
	Range	١٧.٢٥٢ - ٥.٠٠٣	٢٦.٦٨٧ - ٢.٣٨١	١٢.٠٦٩ - ٨.٢٦	٠.٦٩٣ - ٠.٤٦٦	٠.٩٧٧ - ٠.٦٩٢
	٩٥% C.I.	Lower	٨.١٠٥	١٦.١٥٥	١٠.٢٨	٠.٥٤٥
Upper		٩.١٧٨	١٧.٩٠٤	١٠.٧٠٨	٠.٥٧٧	٠.٨٧١
Control No.=٢٥	mean \pm SE	١٧.٦٠٣ \pm ٠.٦١٣	١٢.٩٩١ \pm ٠.٥٨٢	١٥.٥١١ \pm ٠.١٩٩	١.٠٢٣ \pm ٠.١٨	١.٢٥١ \pm ٠.١١
P-Value		S	S	S	S	S
Type ٢ DM, No.=٥٠	mean \pm SE	٦.٨٥٦ \pm ٠.٣٠٦	١٥.٨٦ \pm ٠.٤١٠	١١.١٢١ \pm ٠.١٢٢	٠.٥٦٩ \pm ٠.٠٠٩	٠.٨٦٦ \pm ٠.٠١٠
	SD	٢.١٦٩	٢.٩٠٥	٠.٨٨٧	٠.٠٦٢	٠.٠٧٢
	Range	١٣.٨٦١ - ٢.١٩٦	٣٣.٤٠٨ - ٧.٦٩٧	٨.٨٧٢ - ٩.٣٣١	٠.٦٨٩ - ٠.٤٥	١.٠٠٥ - ٠.٧٠٢
	٩٥% C.I.	Lower	٦.٣٤٣	١٥.١٧٢	١٠.٩٢٢	٠.٥٥٥
Upper		٧.٣٦٨	١٦.٥٤٧	١١.٣٢	٠.٥٨٤	٠.٨٨٤
Control No.=٢٥	mean \pm SE	٢٠.١٠٧ \pm ٠.٧٩٩	١٢.٩٢٦ \pm ٠.٥٩٤	١٥.٨٩٤ \pm ٠.٢٢٩	١.٠٠٨ \pm ٠.١٦	١.٢٤٨ \pm ٠.٠٠٩
P-Value		S	S	S	S	S

The results also indicate a significant increase in levels of serum copper (Cu) in patients with type ١ and type ٢ DM from control by about ٢٤% and ٣٨% respectively, $P \leq ٠.٠٠١$, figure (٣-١٤).




Figure (3-14): Level of some trace elements in serum of healthy control and patients with type 1 and 2 diabetes mellitus (DM) disease. The values are the mean \pm SE.

However, these results may be due to:

١. All studies found increased level of serum iron in diabetic patients but in this work pointed out decreased levels of serum iron in diabetic patients than control may be due to increased drinking tea in Iraq that inhibits iron absorption (Kim & Miller, ٢٠٠٥), thus tea and its phenolic constituent are reported to have antioxidant activity in vitro (Luo *et al.*, ١٩٩٧), the antioxidant action of tea was dependant on the ability of their constituent phenolic compounds to scavenger free radicals and to chelate iron (reduce the utilization of dietary iron), (Samman *et al.*, ٢٠٠١). Or may be due to their low iron diet, treatment of diabetic patients by either insulin or oral hypoglycemia agents could stimulate the increase synthesis of ferritin or act as iron chelator, or may be due to the presence of high level of oxidative stress induced by hyperglycemia, which leads to glycation of transferrin and decreases its ability to bind ferrous iron (Fe^{2+}) (Fujimoto *et al.*, ١٩٩٥), and by increasing the pool of free iron stimulating ferritin synthesis (Juckett *et al.*, ١٩٩٥; Fernandez *et al.*, ٢٠٠٥).
٢. Decreased levels of serum zinc in diabetic patients may be due to reduced level antioxidant enzyme alkaline phosphatase or due to excessive urinary output especially in patients with diabetic nephropathy, gastrointestinal malabsorption or genetic factors or signs of infection during which Zn will act as defense mechanism (Walter *et al.*, ١٩٩١). The antioxidant properties of zinc have been demonstrated in vitro. Zinc may exert its antioxidant effect by decreasing the susceptibility of essential sulfhydryl groups of proteins to oxidation and by competing with prooxidant metals such as iron and copper for biological binding sites (Lokitch *et al.*, ١٩٨٣), these results agree with the results of (Zargar *et al.*, ١٩٩٨).

- ϣ. Decreased levels of serum chromium in diabetic patients may be due to increase in glucose and insulin concentration, which increases urinary Cr output (Vincent, 2004). These results go with the results of (Terpilowska & Zaporowska, 2004).
- ε. Decreased levels of serum selenium in diabetes mellitus disease may be due to increased oxidative stress that requires increased utilization of selenium as antioxidant by binding with vitamin E and as a cofactor of glutathione peroxidase (GPx) to scavenge free radical, which acting to detoxify tissue peroxidation (Hayes, 2001; Beckg, 1998). These results agree with the results of (Ulus & Turan, 2005)
- ο. Increased levels of serum copper in diabetic patients may be due to the presence of oxidative stress by hyperglycemia, which leads to the glycation of ceruloplasmin enzyme, whereas most of copper is incorporated into it, and releases high level of serum copper that is associated with low concentration of ceruloplasmin and iron in the liver and causes increased free radical production in diabetic patients. These results go with the results of the study of (Walter *et al.*, 1991; Zargar *et al.*, 1998; Salman, 2001).

3.6. Lipid Peroxidation and Antioxidant Vitamins

The new trend in management of diabetes and decrease lipid peroxidation degree is to use therapeutic antioxidant and scavengers like vitamin A (Fulle *et al.*, 1996; Tuluncu *et al.*, 1998;; Bagchi & Puri, 1998; Belinda & Connell, 2001; Franz *et al.*, 2002).

The results of this study reported different negative correlation between serum MDA and serum vitamin E, vitamin C, and vitamin A in patients with type 1 and type 2 DM. The reason for studies these correlations between MDA and antioxidant vitamins because MDA represented the important indicator for lipid peroxidation, table (3-8).

Table (3-8): The correlation between the level of lipid peroxidation via MDA and some antioxidant vitamins in diabetics.

The correlation of malondialdehyde(MDA) ($\mu\text{mol/L}$) vs. other variables	Type 1 DM, No.= 55		Type 2 DM, No.= 55	
	Correlation coefficient (r)	P-Value	Correlation coefficient (r)	P-Value
vs. vitamin E ($\mu\text{mol/L}$)	-0.345	S	-0.197	NS
vs. vitamin A ($\mu\text{mol/L}$)	-0.186	NS	-0.206	NS
vs. vitamin C ($\mu\text{mol/L}$)	-0.097	NS	-0.305	S

However, there was a significant negative correlation between serum MDA level and serum vitamin E ($r = -0.345$, $P \leq 0.05$), whereas there was negative correlation but not significant with vitamin C and vitamin A in serum of patients with type 1 DM, figure (3-10)A, while in patients with type 2 DM, there was a significant negative correlation between levels of serum MDA and levels of serum vitamin C ($r = -0.305$, $P \leq 0.05$), and negative correlation but not significant with serum vitamin E and serum vitamin A, figure (3-10)B.




Figure (3-10): Correlation between level of malondialdehyde (MDA) and level of antioxidant vitamins in serum of patients (A) with type 1 diabetes mellitus and (B) with type 2 diabetes mellitus.

Antioxidant vitamins act as quenchers for free radicals (Paolisso *et al.*, 1990). Thus, increased levels of serum antioxidant vitamins could reduce the level of MDA, the end product of lipid peroxidation in diabetic patients. However, our results reported that supplementation of vitamin E to patients with type 1 DM and vitamin C to patients with type 2 DM could reduce lipid peroxidation degree and then reduce the cardiovascular disease complications.

3.7. Correlation of Ec-Cu/Zn SOD Activity with Levels of Zinc, Copper, and CAT Activity

Ec-Cu/Zn SOD and CAT are antioxidant enzymes that are cooperative in their action, while copper (Cu), and zinc (Zn) act as cofactors for Ec-Cu/Zn SOD enzyme in humans. In the present study, table(3-9) shows the correlation of Ec-Cu/Zn SOD activity with levels of zinc, copper, and CAT activity.

Table(3-9): The correlation between the levels of Ec-Cu/Zn SOD activity and levels of CAT activity and some trace elements (copper, and zinc) in diabetics.

The correlation of Ec-Cu/Zn SOD(U/ml) vs. other variables	Type 1 DM, No.= 00		Type 2 DM, No.= 00	
	Correlation coefficient (r)	P-Value	Correlation coefficient (r)	P-Value
vs. Zinc (µmol/L)	-0.28	S	-0.300	S
vs. Copper (µmol/L)	0.16	NS	0.179	NS
vs. Catalase (CAT), (K/ml)	-0.126	NS	-0.130	NS


However their was a significant negative correlation between levels of Ec-Cu/Zn SOD activity and levels of zinc in serum of patients with type 1 DM ($r = -0.280$, $P \leq 0.005$), figure (3-16) A, and in serum of patients with type 2 DM ($r = -0.300$, $P \leq 0.005$), figure (3-16) B, table (3-9). These

results may be due to that zinc acts as a cofactor for Ec-Cu/Zn SOD enzyme or could be linked to the protective effect of zinc on the protein itself, therefore serum zinc level decreases with the increased synthesis of Ec-Cu/Zn SOD (Faure *et al.*, 1990).

As well as, there was a positive correlation, but not significant, between levels of Ec-Cu/Zn SOD activity and levels of copper in serum of patients with type 1 DM, figure (3-16)A, and in serum of patients with type 2 DM, figure (3-16)B, table (3-9). These results may be due to increase levels of copper in diabetic and healthy individuals lead to increase in free radicals generation, thus increased levels of copper lead to slightly increase in levels of Ec-Cu/Zn SOD activity to defense against ROS damage.

Furthermore, there was a negative correlation, but not significant, between levels of Ec-Cu/Zn SOD activity and levels of CAT activity in serum of patients with type 1 DM, figure (3-16)A, and in serum of patients with type 2 DM, figure (3-16)B, table (3-9). In contrast with controls, there was a positive correlation; this may be due to the presence of oxidative stress syndrome in diabetic patients. This finding is in accordance with that of (Singh & Pathak, 1990). Thus, increased levels of Ec-Cu/Zn SOD activity was slightly decreased levels of serum CAT activity in diabetic patients probably due to the presence of high levels of superoxide anion ($O_2^{\cdot-}$) that required high levels of Ec-Cu/Zn SOD activity to stimulate it to high level of hydrogen peroxide (H_2O_2) that consume high levels of CAT activity that is responsible for the decomposition to oxygen molecule and water.

A



B








Figure (3-16): Correlation of Ec-Cu/Zn SOD activity with level of catalase (CAT) activity and some trace elements

(copper, and zinc) in serum of patients (A) with type 1 diabetes mellitus and (B) with type 2 diabetes mellitus disease.

3.8. Effect of Smoking on Oxidative Stress Status in Diabetics

Evidence for increased oxidation in smokers compared with non-smokers were proved by the presence of increased prooxidant products in blood and urine (Morrow *et al.*, 1990; Mezzetti *et al.*, 1990).


In this work, the results reported no significant difference in levels of serum MDA, tHcy, Cu, Fe, Zn, Se, Cr, GSH, vitamin C, and GST, Ec-Cu/Zn SOD, CK, CAT activities in serum of smokers with type 1, and 2 DM than diabetic non-smokers as well as in levels of serum vitamin E of smokers with type 1 DM, and levels of serum vitamin A of smokers with type 2 DM than that of diabetic non-smokers, table (3-10).

Table (3-10): Effect of smoking on the levels of some biochemical markers related to oxidative stress syndrome in diabetics.

Variables	Type 1 DM, No.=00			Type 2 DM, No.=00		
	Smokers No.= 11 Mean±SE	Non-smokers No.= 39 Mean±SE	P- Value	Smokers No.= 17 Mean±SE	Non-smokers No.= 33 Mean±SE	P- Value
Age(Years)	33±3.734	31.82±2.772	NS	48.176±2.054	53.272±1.49	NS
Duration of DM (Years)	9.320±2.21 7	1.607±1.68 0	NS	0.284±1.006	0.787±1.017	NS
MDA (µmol/L)			NS	0.999±0.68		NS
tHcy (µmol/L)	0.966±0.09	0.962±0.034	NS	22.401±0.663	0.848±0.037	NS
Ec-SOD (U/ml)	9	19.470±0.48	NS	1.288±0.096	21.037±0.48	NS
CAT (K/ml)	2.007±0.8	4	NS	0.488±0.031	1	NS
GST (U/l)	10	1.080±0.007	NS	4.172±0.277	1.402±0.081	NS
GSH (µmol/L)	1.043±0.10	0.387±0.016	NS	147.176±7.24	0.042±0.024	NS
Vitamin E (µmol/L)	8	4.689±0.216	NS	0	3.709±0.210	S
Vitamin A (µmol/L)	0.382±0.00	171.012±0.8	NS	0.816±0.060	106.787±3.1	NS
Vitamin C (µmol/L)	4	0.7	NS	2.930±0.171	97	NS
Iron (µmol/L)	4.879±0.00	0.694±0.024	NS	1.324±0.089	0.901±0.047	NS
Copper (µmol/L)	4	3.429±0.086	NS	3.618±0.217	3.066±0.123	NS
Zinc (µmol/L)	108.09±1.0	1.340±0.096	NS	6.96±0.060	1.41±0.114	NS
Chromium (µmol/L)	10	3.400±0.202	NS	10.883±1.083	3.689±0.232	NS
Selenium (µmol/L)	0.641±0.08	8.202±0.323	NS	11.106±0.214	6.603±0.332	NS
	4	16.96±0.693	NS	0.066±0.016	10.814±0.67	NS
	3.084±0.17	1.0024±0.13	NS	0.862±0.019	4	NS
	3	7	NS		11.136±0.13	NS
	0.742±0.12	0.083±0.011	NS		7	NS
	3	0.807±0.017	NS		0.090±0.008	NS
	3.439±0.23		NS		0.870±0.009	NS
	3		NS			NS
	10.2±1.130		NS			NS


	17.281 ± 1.1 \wedge 10.387 ± 0.2 \wedge 0.064 ± 0.01 \wedge 0.847 ± 0.02 \circ					
--	---	--	--	--	--	--

But there was a significant decrease in level of vitamin A in serum of smokers with type 1 DM, $P \leq 0.05$, figure (3-23), and vitamin C in serum of smokers with type 2 DM, $P \leq 0.05$, figure (3-24) than diabetic non-smokers.



These results may probably be due to the following:

1. Smoking may be enhance oxidative stress through the production of free radicals and weaken antioxidant defense mechanism (Maragnon *et al.*, 1998; Zhao & Yu, 1998; James *et al.*, 2000; Al-Meshhadani, 2003). Therefore, smoking slightly increases level of MDA in serum of diabetic smokers than diabetic non-smokers.



2. Some toxic components of tobacco smoke could interact with thiol rich compounds leading to structural and functional changes of these molecules (Zappacosta *et al.*, 2002). Therefore, smoking could be slightly depletion level of GSH and accumulation of tHcy in serum of diabetic smokers than diabetic non-smokers, or decreased level of GSH may be due to increase GSH utilization in neutralizing smoking induced free radicals.
3. Cigarette smoke contains an extremely high concentration of various free radicals (Shurch & Pryor, 1980), which are increased

susceptibility of –SH groups of CK enzyme to be oxidized and inhibition or probably due to the interaction between smoke aldehydes and –SH groups; the active sites of enzyme molecules and reduced its activity (Zappacosta *et al.*, 2002), therefore smoking could be slightly decreased level of CK activity in serum of diabetic smokers than diabetic non-smokers.

- ε. Smoke contains $O_2^{\cdot-}$, and in response to the increase amounts of substrate of $O_2^{\cdot-}$, this results in an increase in Ec-Cu/Zn SOD activity probably through induction (Gregorg *et al.*, 1979). In addition nicotine (0.1×10^{-3} to 0.1×10^{-11} M) in cigarette was found to inhibit of $O_2^{\cdot-}$ production from polymorphonuclear cells (Sasagawa *et al.*, 1980). But because $O_2^{\cdot-}$ considered as a stimulant to increase synthesis of SOD (Lunec *et al.*, 1981), therefore this explanation could be the cause behind the slight decrease in Ec-Cu/Zn SOD level in diabetic smokers, also lead (Pb) and cyanide is considered as a component of cigarette smoke (Mawin-Mateo *et al.*, 1997) and the coprozinc enzymes are inhibited by cyanide (Borders & Fridovich, 1980), while Pb causes non-competitive inhibition of a covalent bond at the enzyme and decrease in V_{max} of enzyme reaction (Mawin-Mateo *et al.*, 1997).
- ϵ. Increased CAT enzyme utilization in neutralizing smoking induced free radicals (Muhlhauser *et al.*, 1996; Ritz *et al.*, 1996; Al-Delaimy, 2001) lead to slightly decreased levels of CAT activity in serum of diabetic smokers than diabetic non-smokers.
- ϶. Presence of toxic compounds in the cigarette smoke such as semiquinones (Kasai & Nishimura, 1986) induced accumulation of GST enzyme by increase its synthesis to play a protective role, therefore smoking may be slightly increases level of GST activity in serum of diabetic smokers than diabetic non-smokers.
- Ϸ. Utilizing high level of vitamin C in diabetic smokers to neutralize free radicals generation through smoking results in slightly reduced

levels of vitamin C in serum of diabetic smokers than non-smokers, while vitamin A levels were slightly reduced in serum of smokers with type 2 DM than diabetic non-smokers, but is reduced significantly in serum of smokers with type 1 DM, these results are due to that gas phase of cigarette smoke is a complex oxidizing milieu processing an array of free radical species including peroxy radicals (ROO \cdot), and O $_2^{\cdot-}$ (Pryor & Ston, 1993), which has been shown to deplete lipid phase. Furthermore, vitamin E levels were slightly reduced in serum of smokers with type 1 DM than diabetic non-smokers, while are reduced significantly in serum of smokers with type 2 DM. This may be due to increase production of catecholamines hormone in smokers with type 2 DM and act as an antagonist to insulin action (Targher, 1997), thus increase free radicals production under hyperglycemia that require high level of vitamin E to be neutralization.

4. Smoking is increasing oxidative stress and weakening defense system, therefore it increases disturbance in trace elements levels in diabetic smokers than diabetic non-smokers, thus there was a slightly increase in levels of copper and iron and slightly decrease in levels of zinc, selenium and chromium in serum of diabetic smokers than diabetic non-smokers.

List of Figures

No.	Subject	Page
1-1a	Structure of human insulin	1
1-1b	Formation of human insulin from preproinsulin	1
1-2	The non-enzymatic glycosylation of HbA to HbA _{1c}	3
1-3	Oxidative Damage to DNA: Formation of 8-OHdG/8-oxoG	10
1-4	Possible links between hyperglycemia-induced oxidative stress and diabetic complications	14
1-5a	Non-enzymatic glycosylation	15
1-5b	Degradation of Amadori product and H ₂ O ₂ formation	16
1-6	Auto-oxidation of monosaccharide	17
1-7	Polyol pathway	18
1-8	Mechanism of formation of lipid hydroperoxide (MDA)	19
1-9	Folate shuttle.	24
1-10	The interaction of free radicals and antioxidants	27
1-11	Co-operation of antioxidant enzymes	28
1-12	Suggested pathways for the formation of reactive oxygen species in vivo	30
1-13	The mechanism of action vitamin E	38
1-14	The interactions between ascorbate and α -tocopherol in trapping free radicals	39
1-15	Mechanism of vitamin C to scavenger of free radicals	40
1-16	The relationship between GPx and Se and vitamin E	46
2-1	Schematic diagram for assessment lipid peroxidation via determination the byproduct; malodialdehyde	51
2-2	Calibration curve of tHcy against time	54
2-3	Chromatogram of homocysteine samples and standard	54

٢-٤	Schematic diagram showed the detection of SOD activity based upon nitroblue tetrazolium stain	٥٥
٢-٥	Standard curve of superoxide dismutase enzyme	٥٨
٢-٦	Reaction between ١-chloro-٢,٤-dinitrobenzene (CDNB) and glutathione in the presence of glutathione S-transferase (GST) enzyme	٦٠
٢-٧	Reaction between glutathione (GSH) and ٥,٥-dithiobis (٢-nitrobenzoic acid) (DTNB)	٦٤
٢-٨	Calibration curve of glutathione (GSH)	٦٦
٢-٩	Analysis of standard fat-soluble vitamin E	٦٨
٢-١٠	Analysis of standard fat-soluble vitamin A	٦٩
٢-١١	Analysis of standard water-soluble vitamin C	٧١
٣-١	Level of malondialdehyde (MDA) in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٧٩
٣-٢	Level of total homocysteine (tHcy) in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٨١
٣-٣	Percentage of total antioxidants in serum of healthy control and patients with diabetes mellitus disease. ١:GSH, ٢:Vit.E, ٣:Vit.A, ٤:Vit.C, ٥:Zinc, ٦:Selenium, ٧:Chromium, ٨:SOD, ٩:CAT, ١٠:GST, ١١:CK	٨٢
٣-٤	Depleted of serum antioxidants at different rate upon exposure to oxidative stress in patients with type ١ and ٢ DM.	٨٣
٣-٥	Level of superoxide dismutase (SOD) in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٨٥

٣-٦	Level of calase (CAT) activity in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٨٦
٣-٧	Level of glutathione S-tranferase (GST) activity in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٨٨
٣-٨	Level of creatine kinase (CK) activity in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٨٩
٣-٩	Level of glutathione (GSH) in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٩١
٣-١٠	Correlation of glutathione (GSH) with level of malondialdehyde (MDA), total homocysteine (tHcy), glutathione S-transferase (GST) activity, and creatine kinase (CK) activity in serum of patients (A) with type ١ diabetes mellitus, and (B)with type ٢ diabetes mellitus disease.	٩٤
٣-١١	Level of vitamin E in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٩٥
٣-١٢	Level of vitamin C in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٩٦
٣-١٣	Level of vitamin A in serum of healthy control and patients with type ١ and ٢ diabetes mellitus (DM) disease. The values are the mean \pm SE.	٩٧
٣-١٤	Level of some trace elements in serum of healthy	١٠٠

	control and patients with type 1 and 2 diabetes mellitus (DM) disease. The values are the mean \pm SE.	
3-15	Correlation between level of malondialdehyde (MDA) and level of antioxidant vitamins in serum of patients (A) with type 1 diabetes mellitus, and (B) with type 2 diabetes mellitus	1.4
3-16	Correlation of Ec-Cu/Zn SOD activity with level of catalase (CAT) activity and some trace elements (copper, and zinc) in serum of patients (A) with type 1 diabetes mellitus, and (B) with type 2 diabetes mellitus disease.	1.7
3-17	Level of vitamin A in serum of smokers and non-smokers patients with type 1 diabetes mellitus (DM) disease. The values are the mean \pm SE.	1.9
3-18	Level of vitamin E in serum of smokers and non-smokers patients with type 2 diabetes mellitus (DM) disease. The values are the mean \pm SE.	1.9

List of Tables

No.	Subject	Page
٢-١	Chemicals	٤٨
٢-٢	Instruments	٤٩
٣-١	The demographic sampling characteristics of the study	٧٧
٣-٢	Results of specific biochemical tests in serum of patients with type ١ or type ٢ DM and control.	٧٨
٣-٣	Percentage of antioxidants that assessment in this study for diabetic patients (with type ١ or ٢ DM), and control.	٨٢
٣-٤	Levels of several enzymatic antioxidants in serum of patients with type ١ or type ٢ DM, and control.	٨٤
٣-٥	Levels of several non-enzymatic antioxidants in serum of patients with type ١ or type ٢ DM, and control.	٩٠
٣-٦	The correlation between the level of glutathione and several biochemical markers related to oxidative stress syndrome	٩٢
٣-٧	Levels of several trace elements in serum of patients with type ١ or type ٢ DM and control.	٩٩
٣-٨	The correlation between the level of lipid peroxidation via MDA and some antioxidant vitamins in diabetics	١٠٣
٣-٩	The correlation between the levels of Ec-Cu/Zn SOD activity and levels of CAT activity and some trace elements (copper, and zinc) in diabetics	١٠٥
٣-١٠	Effect of smoking on the levels of some biochemical markers related to oxidative stress syndrome in diabetics	١٠٨

References

- Adachi, T.; Yamada, H.; Yamada, Y.; Morihara, N.; Hirano, K.; Murakami, T.; Futenma, A.; and Kato, K. Substitution of Glycine for Arginino-213 in Extracellular-Superoxide Dismutase Surface. *Biochemical Journal*, 1996; 313(1): 235-239.
- Aebi, H. "Methods of Enzymatic Analysis", ed. New York, Academic Press, 1974(2): 674-84.
- Akkus, I.; Kalak, S.; Vural, H.; Caglayan, O.; Menekse, E.; Can, G., and Durmus, B. Leukocyte Lipid Peroxidation, Superoxide Dismutase, Glutathione Peroxide, and Serum and Leukocyte Vitamin C Levels of Patients with Type II Diabetes Mellitus. *Clinica Chimica Acta.*, 1996; 244: 221-227.
- Al-Delaimy, W.K. Smoking and Mortality among Women with Type 2 Diabetes: The Nurse Health Study Cohort. *Diabetes Care*. 2001; 12: 2043-8.
- Al-Meshhedani, Q.H. "Blood Markers in Relation to Atherosclerosis in Iraq Smokers" (Thesis), Ph.D., Iraq, Al-Mustansiriya University, 2003.
- Al-Meshhadani, W.M.S. "A Study on the Attenuation of Vascular Response in Non-Insulin Dependent Diabetic Patients with Microalbuminuria." (Thesis), Ph.D., Iraq, Al-Mustansiriya University, 2000.
- Al-Zamely, Oda.M.Yasser. "Ischemic Heart Disease Via Oxidative Hypothesis" (Thesis), Ph.D., Iraq, Mustansiriya University, 2001.

- Anderson, R.A.; Cheng, N.; Bryden, N.A.; Polansky, M.M.; Chi, J.; Feng, J. Beneficial Effects of Chromium for People with Diabetes. *Diabetes*, 1997; 46: 1786-1791.
- Anderson, G.W.; Gowri, M.S.; Turner, J.; Nichols, L.; Diwadkar, V.A.; Chow, C.K., and Oettgen, P.R. Antioxidant Supplementation Effects on Low-Density Lipoprotein Oxidation for Individuals with Type 2 Diabetes Mellitus. *J. Am. Coll. Nutr.*, 1999; 18(5): 451-61.
- Atalay, M.; and Laaksonen, D.E. Diabetes, Oxidative Stress and Physical Exercise. *J. Sports Science and Medicine*, 2002; 1: 1-14.
- Atalay, M.; Laaksonen, D.E.; Khanna, S; Kaliste-Korhonen, E.; Hanninen, O., and Sen, C.K. Vitamin E regulates changes in tissue antioxidants induced by fish oil and acute exercise. *Medicine and science in sports and Exercise*, 2000; 32:601-607.
- Atalay, M., and Sen, C.K. Physical exercise and antioxidant defenses in the heart. *Annals New York Academy of Sciences*, 1999; 874:169-177.
- Bagchi, K.; and Puri, S. Free Radicals and Antioxidants in Healthy and Disease. *Estran Mediterrean Health Journal*, 1998; 4(2): 350-360.
- Banerjee, D.; Kumar, P.A.; Kumar, B.; Madhusoodanan, U.K.; Nayak, S., and Jacob, J. Determination of Absolute Hydrogen Peroxide Concentration by Spectrophotometric Method. *Current Science*. 2002; 83(10): 1193-1194.
- Baynes, J.W. Role of Oxidative Stress in Development of Complication in Diabetes. *Diabetes*, 1991; 40: 400-412.

- Becker, A.; Smnlders, Y.M.; Guldener, C.V., and Stehouwer, C.D.A. Epidemiology of Homocysteine as a Risk Factor in Diabetes. Metabolic Syndrome and Related Disorders, 2003; 1: 100-120.
- Beckg, M.A. The Influence of Antioxidant Nutrient in Non-Viral Infection. Nutr. Rev., 1998; 56: 0140-0146.
- Bedwal, R.S.; Nair, N.; Sharma, M.P., and Mathur, R.S. Selenium and its Biological Perspective. Med. Hypotheses, 1993; 41: 100-109.
- Belinda, S.O., and Connell, M.S. Select Vitamins and Minerals in the Management of Diabetes. Diabetes Spectrum., 2001; 14: 133-148.
- Berg, J.M.; Tymoczko, J.L.; and Stryer, L. "Biochemistry" 3rd ed. New York, Freeman W.H. & Company, 2002: 223-228.
- Bishop, M.L.; Engelkirk, J.L.D.; and Fody, E.P. "Clinical Chemistry" 4th ed. Philadelphia. Lippincott Williams & Wilkins Company, 2000: 220-230.
- Blom, H.J. Consequences of Homocysteine Export and Oxidation in the Vascular System Semin. Thromb. Hemost., 2002; 26: 227-232.
- Boers, G.H. Mild Hyperhomocysteinemia is an Independent Risk Factor of Arterial Vascular Disease. Semin. Thromb. Hemost., 2000; 26: 29.
- Borders, C.L.J.R., and Fridovich, I. A Comparison of the Effects of Cyanide Hydrogen Peroxide and Phenylglyoxal on Eukaryotic and Prokaryotic Cu/Zn SOD. Arch. Biochem. Biophys. 1980; 241: 472-476.
- Bork, C. "antioxidant and Cancer" SCI. Med. 1997; 112: 02-71.

- Brownlee, M. "The Role of Non-Enzymatic Glycosylation in the Pathogenesis of Diabetic Angiopathy In: Draznin, B.; Melmed, S.; LcRoith, D. eds. "Molecular and Cellular Biology of Diabetes Mellitus." Vol.III, New York, Alan R Liss, pp.: 9-17.
- Buettner, G.R.; Oberley, L.W. Buthionine Sulfoximine: Glutathione Depletor : Free Radicals in Biology and Medicine. Iowa University. Iowa, 2001; 1-10.
- Bursell, S.E.; Clermont, A.C.; Aiello, L.P.; Aiello, L.M.; Schlossman, D.K.; Feener, E.P.; Laffe, L., and King, G.L. High-Dose Vitamin E Supplementation Normalizes Retinal Blood Flow and Creatinine Clearance in Patients with Type 1 Diabetes. *Diabetes Care*, 1999; 22(8): 1240-1251.
- Burtis, C.A., and Ashwood, E.R. "Tietz Textbook of Clinical Chemistry," 3rd ed., W.B. Saunders Company, Tokyo, 1999, pp.: 1034-1054.
- Cameron, N.E.; Cotter, M.A. "Neurovascular Dysfunction in Diabetic Rats: Potential Contribution of Autoxidation and Free Radicals Examined Using Transition Metal Chelating Agents. *J. Clin. Invest.* 1990; 96: 1109-1113.
- Cedeberg, J. "Oxidative Stress, Antioxidative Defense and Outcome of Gestation in Experimental Diabetic Pregnancy," (Thesis), Ph.D., Sweden, UpPsala University, 2001.
- Ceriello, A. Hyperglycemia: The Bridge between Non-Enzymatic Glycation and Oxidative Stress in the Pathogenesis of Diabetic Complications. *Diabetes. Nutr. Metab.*, 1999; 12(1): 42-6.
- Cerutti, P.A. "Oxy-Radicals and Cancer." *Lancet*, 1994; 344: 872-873.

- Champe, P.C., and Harvey, R.A. "Lippincott's Illustrated Reviews: Biochemistry." 2nd. Ed. Philadelphia, Lippincott Williams & Wilkins Company, 1994: 290-302.
- Chase, H.P. Cigarette Smoking Increases the Risk of Albuminuria among Subjects with type 1 Diabetes. *JAMA*. 1991; 266(5): 714-717.
- Chelchowska, M.; Laskowska-Klita, T., and Szybork, J. Level of Retinol and Beta-Carotene in Plasma of Smoking and Non-Smoking Women. *Wiad-Lek.*, 2001; 54(5-6): 248-54.
- Chow, C.K. Cigarette Smoking and Oxidative Damage in the Lung. *Ann. N.Y. Acad. Sci.* 1993; 787: 289-98.
- Chow, F.I., and Omaye, S.I. "Lipids," 1983; 18: 837-841. In: Salman A.M.H. "Clinical Biochemical Study of Oxidation and Antioxidants in Patients with Non-Insulin-Dependent Diabetes Mellitus" (Thesis), Ph.D., Iraq, Baghdad University, 2001.
- Church, D.F., and Pryor, W.A. Free Radical Chemistry of Cigarette Smoke and its Toxicology Implication. *Environ. Health Perspect.*, 1980; 74: 111-126.
- Collier, A.; Rumley, A.; Rumely, A.G.; Paterson, J.R.; Leach, J.P.; Lowe, G.D.O, and. Small, M. Free Radical Activity and Homostatic Factors in NIDDM Patients with and without Microalbuminuria. *Diabetes*, 1992; 41: 909-913.
- Colman, P.G.; Wang, L.I., and Lafferty, K.J. Molecular Biology and Autoimmunity of Type 1 Diabetes Mellitus, 1989; In: Drazini, B.; Melmed, S.; Lepoith, D., eds. *Molecular and Cellular Biology of Diabetes Mellitus. Insulin Secretion*. New York, Alan R. Liss Inc., pp.: 120-137.

- Corbett, J.A.. and McDaniel, M.L. Intraislet Release of Interleukin 1 Inhibits B-Cell Expression of Inducible Nitric Oxide Synthase. *J. Exp. Med.*, 1990; 181: 509-518.
- Cordoba, P.A.; Sanches, J.L.Q.; Gonzalez, F.S; Ordone, J.L., and Blanco, F.V. Susceptibility of Plasma Low- and High-Density Lipoproteins to Oxidation in Patients with Severe Hyperhomocysteinemia. *J. Mol. Med.*, 1996; 24: 771-776.
- Cunningham-Rundles, S. Zinc Modulation Immune Function: Specificity and Mechanism of Interaction. *J. Lab. Clin. Med.*, 1996; 128: 9-11.
- Delmas-Beanvieux, M.C.; Peuchant, E.; Couchouron, A.; Constans, J.; Sergeant, C.; Simonoff, M.; Pellegrin, J.L.; Leng, B.; Corni, C., and Clerc, M. The Enzymatic Antioxidant System in Blood and Glutathione Status in Human Immunodeficiency Virus (HIV)-Infected Patients: Effects of Supplementation with Selenium or Beta-Carotene. *Am. J. Clin. Nutr.*, 1996; 64: 101-107.
- Domingues, C.; Ruiz, E.; Gussinye, M., and Carrascosa, A. Oxidative Stress at Onset and Early Stages of Type 1 Diabetes in Children and Adolescents. *Diabetes Care*, 1998; 21(10): 1736-1742.
- Draper, H.H.; Squires, E.J.; Mahmoodi, H.; Wu, J.; Agarwal, S., and Hadley, M. A Comparative Evaluation of Thiobarbituric Acid Methods for the Determination of Malondialdehyde in Biological Materials. *Free Radical Biology and Medicine*. 1993; 10: 353-363.

- Dzeja, P.P., and Terizc, A. Phosphotransfer Networks and Cellular Energetics. *Journal of Experimental Biology.*, 2003; 206: 2039-2047.
- Edwards, C.R.W., and Bouchier, J.A.D. "Disease of Liver and Biliary System: Principles and Practice of Medicine" Eds. Churchill Press. Livingstone. 1991, pp. 491-492.
- Elgawish, A.; Glomb, M.; Friendlander, M., and Monnier, V.M. Involvement of Hydrogen Peroxide in Collagen Cross-Linking by Glucose In Vitro and In Vivo. *J. Bio. Chem.* 1990; 261: 12964-12971.
- Ewadh, M.J., and Jabir, F.A. Homocystine Induce Endothelial Cells Damage Due to Glutathione Level Depletion. *Journal of Al-Qadisiya, Pure Sciences*, 2002; 6(4):
- Faure, P.; Benhamou, P.Y.; Perard, A.; Halimi, S., and Roussel, A.M. Lipid Peroxidation in Insulin-Dependant Diabetic Patients with Early Retina Degenerative Lesions: Effects of an Oral Zinc Supplementation. *Eur. J. Clin. Nutr.*, 1990; 44(4): 282-8.
- Fernandez-Real, J.M.; Lapez-Bermejo, A., and Ricart, W. Cross-Talk between Iron Metabolism and Diabetes. *Diabetes*, 2002; 51: 2348-2354.
- Fiskerstrand, T.; Refsum, H.; Kvalheim, G., and Ueland, P.M. Homocysteine and other Thiol in Plasma and Urine: Automated Determination and Sample Stability. *Clin. Chem.*, 1993; 39: 263-71.
- Fodinger, M.; Mannhalter, C.; Wolf, G.; Pabinger, I.; Muller, E.; Schmid, R.; Horl, W.H., and Sunder-Plassman, G. Mutation (C to T) in the Methylene tetrahydrofolate Reductase gene Aggravates

Hyperhomocysteinemia in Hemodialysis Patients. *Kidney Int.*,
1997; 52: 517-523.

Frank, S.; Kämffer, H.; Podda, M.; Kaufmann, R., and Pfeils-Chifter, P.
Identification of Copper/Zinc Superoxide Dismutase as a Nitric
Oxide-Regulated Gene in Human (Ha CaT) Keratinocytes:
Implication for Keratinocyte Proliferation. *Biochem. J.*, 2000;
346: 719-728.

Franz, M.J., and Bantle, J.P. "American Diabetes Association Guide to
Medical Nutrition Therapy for Diabetes" Eds., Alexandria Va.
Press, American Diabetes Association, 1999.

Franz, M.J., and Bantle, J.P.; Beebe, C.A.; Brunzell, J.D.; Chiasson, J.L.;
Garg, A.; Holzmeister, L.A.; Hoogwerf, B.; Mayer-Davis, E.;
Moordian, A.D.; Purnell, J.Q., and Wheeler, M. Evidence Based
Nutrition Principles and Recommendations for the Treatment
and Prevention of Diabetes and Related Complications.
Diabetes Care, 2002; 25: 148-198.

Fujimoto, S.; Kawakami, N., and Ohara, A. Non-Enzymatic Glycation of
Transferrin: Decrease of Iron-Binding Capacity and Increase of
Oxygen Radical Production. *Biol. Pharm. Bull.*, 1990; 18: 396-
400.

Fuller, C.J.; Chandalia, M.; Gary, A.; Grundy, S., and Jialal, I. RRR-alpha-
tocopherol acetate supplementation at pharmacologic doses
decreases low-density-lipoprotein oxidative susceptibility but
not protein glycation in proteins with diabetes mellitus. *A. J.*
Clin. Nutr. 1996; 63(5): 703-9.

Ganong, W.F. "Review of Medical Physiology" 14th ed. Hall International Com. USA., 1997, pp. 313-317.

Gazzaruso, C.; Garzaniti, A.; Giordanetti, S.; Falcone, C., and Fratino, P. Silent Coronary Artery Disease in Type 2 Diabetes Mellitus: The Role of Lipoprotein (a), Homocysteine and apo(a) Polymorphism. *Cardiovascular Diabetology*, 2002; 1: 5.

Gerbitz, K.D. Does the Mitochondrial DNA Play a Role in the Pathogenesis of Diabetes?, *Diabetologia*, 1992; 35: 1181-1186.

Gillham, B.; Papachristodoulou, D.K., and Thomas, J.H. "Free Radical in Health and Disease In: Will's Biochemistry Basis of Medicine" 3rd ed., Butterworth Heinemann Press. 2000; pp. 346-347.

Glugliano, D.; Ceriello, A., and Paolisso, G. Diabetes Mellitus, Hypertension, and Cardiovascular Disease: Which Role for Oxidative Stress. *Metabolism*, 1990; 44: 363-368.

Glugliano, D.; Eriello, A., and Paolisso, G. Oxidative Stress and Diabetic Vascular Complication. *Diabetes Care*, 1996; 19: 207-217.

Goughlin, S.S., and Hall, I.J. Genetics in Medicine: Glutathione S-transferase Polymorphisms and Risk of Ovarian Cancer. Atlanta. 2002; 4(4): 200-07.

Gunst, J.J.; Langlois, M.R., and Delanghe, J.R. Serum Creatin Kinase Activity is not a Reliable Marker for Muscle Damage in Conditions Associated with Low Extracellular Glutathione Concentration. *Clinical Chemistry*, 1998; 44(5): 939-943.

- Habig, W.H.; Pabst, M.J., and Jakoby, W.B. Glutathione S-transferase, the First Enzymatic Step in Mercapturic Acid Formation. *J. Biol. Chem.* 1974; 249: 7130-7139.
- Hadwan, M.H. "Diabetes Correlation between Creatine Kinase Activity and Antioxidants in Diabetes Mellitus Type 1 and Type 2" (Thesis), M.Sc., Iraq, Babylon University, 2000.
- Halliwell, B., and Gutteridge, J.M.C. "Free Radicals in Biology and Medicine" 3rd ed., Oxford University Press. UK., 1999.
- Halliwell, B., and Aruoma. O.I. DNA Damage by Oxygen-Derived Species. Its Mechanism and Measurement in Mammalian System. *FEBS Lett.*, 1991; 28: 9-11.
- Handelman, G.J. The Evolving Role of Carotenoid in Human Biochemistry. *Nutrition.* 2001; 17(10): 818-22.
- Harris, E. The Iron-Copper Connection: The Risk of Ceruloplasmin Grows Stronger. *Nutr. Rev.*, 1990; 53: 170-173.
- Hayden, M.R., and Tyagi, S.C. Homocysteine and Reactive Oxygen Species in Metabolic Syndrome, Type 2 Diabetes Mellitus, and Atheroscleropathy: The Pleiotropic Effect of Folate Supplementation. *Nutr. J.*, 2004; 3: 4.
- Hayden, M.R., and Tyagi, S.C. Myocardial Redox Stress and Remodeling in Metabolic Syndrome, Type 2 Diabetes Mellitus and Congestive Heart Failure. *Med. Sci. Monit.*, 2003; 9: SR 30-02.
- Hayden, M.R., and Tyagi, S.C. Islet Redox Stress: The Manifold Toxicities of Insulin Resistance, Metabolic Syndrome and Amylin Derived Islet Amyloid in Type 2 Diabetes Mellitus. *JOP.* 2002; 3: 87-108.

- Hayden, M.R., and Tyagi, S.C. Intimal Redox Stress: Accelerated Atherosclerosis in Metabolic Syndrome and Type 2 Diabetes Mellitus. *Atheroscleropathy. Cardiovasc. Diabetol.* 2002; 1: 3.
- Hayden, M.R., and Tyagi, S.C. Is Type 2 Diabetes Mellitus a Vascular Disease (Atheroscleropathy) with Hyperglycemia a Late Manifestation? The Role of NOS, NO and Redox Stress. *Cardiovasc. Diabetol.*, 2003; 2: 2.
- Hayes, A.W. "Metals In: Principles and Methods of Toxicology" ed. Tylor and Francis. 2001; pp. 661-663.
- Hermes-Lima, M.; Willmore, W.G., and Story, K.B. Quantification of Lipid Peroxidation in Tissue Extracts Based on Fe(III) Xylenol Orange Complex Formation. *Free Radical Biology and Medicine.* 1990; 19: 271-280.
- Heury, R.J. "Clinical Chemistry Principles and Techniques" Ed. New York, Harper & Row Press, 1968; p. 386.
- Higgs, P.J., and Bunn, H.F. Kinetic Analysis of the Non-Enzymatic Glycosylation of Hemoglobin. *J. Biol. Chem.*, 1981; 256: 5204-5208.
- Hoogeveen, E.K.; Kostense, P.J., and Jakobs, C. Hyperhomocysteinemia Increase Risk of Death, Especially in Type 2 Diabetes: 0 Years Follow-Up of the Hoorn Study. *Circulation*, 2000; 101: 1006-1011.
- Hoogeveen, E.K.; Kostense, P.J., and Eysink, P.E. Hyperhomocysteinemia is Associated with the Presence of Retinopathy in Type 2 Diabetes Mellitus: The Hoorn Study. *Arch. Intern. Med.*, 2000; 160: 2984-2990.

Howard, J.A. "Advances in Free Radical Chemistry." 1st ed., Academic Press. New York, 1972.

Hristozova, T.; Rasher, T.; Nedeva, T., and Kujumdzieva, A. Superoxide Dismutase During Glucose Repression of Hansenula Polymorpha. CBS 4732. Z. Naturforsch., 2000; 57: 313-318.

Imley, J.A., and Linn, S. DNA Damage and Oxygen Radical Toxicity. Science, 1988; 240: 1302-1309.

Inal, M., and Kanbak, G. Antioxidant Status and Lipid Peroxidation in Red Blood Cells of P-Aminophenol-Treated Rats. Med. Sci. Res., 1997; 25: 323-325.

Ioannides, C.; Barnett, C.R.; Irizar, A., and Flatt, P.R. Drug Metabolism and Chemical Toxicity in Diabetes In: "Drugs, Diet and Disease" Eds., Vol. 2. Ioannides, C.; Flatt, P.R.; Hemel Hempstead Press, UK. Ellis Horwood, 1990; pp. 330-353.

Jacobs, R.L.; House, J.D.; Brosnan, M.E., and Brosnan, J.T. Effects of Streptozotocin-Induced Diabetes and of Insulin Treatment on Homocysteine Metabolism in the Rat. Diabetes, 1998; 47: 1967-1970.

Jain, S.K., and McVie, R. Effect of Glycemic Control, Race (White versus Black) and Duration of Diabetes on Reduced Glutathione Content in Erythrocytes of Diabetic Patients. Metabolism, 1998; 47(1): 20-23.

James, R.W.; Levier, I., and Righetti, A. Smoking is Associated with Reduced Serum Paraoxonase Activity and Concentration in

Patients with Coronary Artery Disease. *Circulation*, 2000; 101: 2202-9.

Javanovic, L.; Gutierrez, M., and Peterson, C.M. Chromium Supplementation for Women with Gestational Diabetes Mellitus. *J. Trace Elem. Exp. Med.*, 1999; 12: 91-97.

Jennings, P.E.; McLaren, M.; Scott, N.A.; Saniabadi, A.R., and Blech, J.J. The Relationship of Oxidative Stress to Thrombotic Tendency in Type 1 Diabetic Patients with Retinopathy. *Diabetic Medicine*, 1991; 8: 870-875.

Juckett, M.R.; Balla, J.; Balla, G.; Jessurun, J. Jacob, H.S., and Vercellotti, G.M. Ferritin Protects Endothelial Cells from Oxidized Low Density Lipoprotein In Vitro. *Am. J. Pathol.*, 1990; 137: 782-789.

Kanbak, G.; Inal, M., and Baycu, C. The Role of Free Radicals in P-Aminophenol-Induced Nephrotoxicity Does Reduced Glutathione Have a Protective Effect. *Clinical Chimica Acta.*, 1997; 252: 71-71.

Kaneto, H.; Fujji, J.; Myint, T.; Miyazawa, N.; Islam, K.N.; Kawasaki, Y.; Suzuki, K.; Nakamura, M.; Tatsumi, H.; Yamasaki, Y., and Taniguchi, N. Reducing Sugars Trigger Oxidative Modification and Apoptosis in Pancreatic Beta-Cells by Provoking Oxidative Stress through the Glycation Reaction. *Biochemical Journal*, 1997; 320: 800-813.

Kannel, W.B. Cigarettes Coronary Occlusion and Myocardial Infraction. *J. AMA*. 1981; 246: 871-2.

Kasai, H., and Nishimura, S. Hydroxylation of Guanine in Nucleosides and DNA at the C-8 Position by Heated Glucose and Oxygen

Radical Forming Agents. Environmental Health Perspective.
1987; 67: 111-116.

Kashiwagi, A.; Asahina, T., and Ikebuchi, M. Abnormal Glutathione Metabolism and Increased Cytotoxicity Caused by H₂O₂ in Human Umbilical Vein Endothelial Cells Cultured in High Glucose Medium. Diabetologia, 1994; 37: 264-269.

Keith, R.E. Antioxidant and Health. Nutrition and Food Science, 1999; 1: 1-5.

Kelley, D.E.; He, J.; Menshikova, E.V., and Ritov, V.B. Dysfunction of Mitochondria in Human Skeletal Muscle in Type 2 Diabetes. Diabetes, 2002; 51: 2944-2950.

Kelly, S.A.; Havrilla, C.H.M.; Brady, T.C.; Abramo, K.H., and Levin, E.D. Oxidative Stress in Toxicology: Established Mammalian and Emerging Piscine Model Systems Review. Environmental Health Perspective, 2005; 113(7).

Khanna, S.; Atalay, M.; Laaksonen, E.E.; Roy, S., and Sen, C.K. Alpha-lipoic acid supplementation: tissue glutathione homeostasis at rest and after exercise. Journal of Applied Physiology, 1999; 87:1191-1196.

Kim, H.S., and Miller, D.D.: Proline-Rich Proteins Moderate the Inhibitory Effect of Tea on Iron Absorption in Rats. J. Nutr., 2005; 135: 532-537.

Kinlaw, W.B.; Levine, A.S., and Morley, J.E. Abnormal Zinc Metabolism in Type II Diabetes Mellitus. Am. J. Med., 1983; 75: 273-7.

- Knight, G.A. "Oxidative Stress and Free Radical Antioxidants Aging and Disease" ed. American Association for Clinically Chemistry. 1999; pp. 30, 310.
- Langseth, L. Oxidants, Antioxidants and Disease Prevention. Belgium, International Life Science Institute, 1996.
- Leahy, J.L., and Weir, G.C. Non-Insulin-Dependant Diabetes Mellitus: Current Concepts of Pathogenesis In: Draznin, B.; Melmed, S. , and LeRoith, D. eds. Molecular and Cellular Biology of Diabetes Mellitus. Insulin Secretion. New York, Alan, R. Liss Inc., 1989; pp.: 149-108.
- Lehninger, A.L. "Biochemistry: The Molecular Basis of Cell Structure and Function" 2nd ed. Worth Press. New York, 1970.
- Lim, P.S.; Chan, E.C.; Lu, T.C.; Yu, Y.C.; Kuo, S.Y.; Wang, T.H., and Wei, Y.H. Lipophilic Antioxidants and Iron Status in ESRD Patients on Hemodialysis. Nephron, 2000; 87: 428-430.
- Lokitch, G.; Godophin, W., and Pendray, M. R. Serum Zinc, Copper, Retinol-binding, Prealbumin, and Ceruloplasmin Concentrations in infant Receiving intravenous Zinc and Copper supplementation. J. Pediat., 1998; 102: 304.
- Lunec, J.; Halloran, S.P.; White, A.C., and Domrmandy, T.L. Free Radical Oxidation (Peroxidation) Products in Serum and Synovial Fluid in Rheumatoid Arthritis. J. Rheumatol., 1981; 8: 233-240.
- Lunec, J.: Review Article. Ann. Clin. Biochem., 1990; 27: 173-182.
- Luo, M.; Kannar, K.; Wahlqvist, M.L., and O'Brien, R.C.: Inhibition of LDL Oxidation by Green Tea Extract. Lancet, 1997; 349:370-1.

Luxton, R. "Clinical Biochemistry" 1st ed. Butterworth-Heinemann Press. Oxford, 1999.

MacRury, S.M.; Gordon, D.; Wilson, R.; Bradley, H.; Gemmell, C.G.; Paterson, J.R.; Rumley, A.G., and MacCuish, A.C. A Comparison of Different Methods of Assessing Free Radical Activity in Type 2 Diabetes and Peripheral Vascular Disease. *Diabetic Medicine*, 1993; 10: 231-235.

Malchoff, C.D. Diagnosis and Classification of Diabetes Mellitus. *Conn. Med.*, 1991; 55(11): 625.

Mannervik, B. , and Banielson, V.H. Glutathione Transferase S- Structure and Catalytic Activity. *Crit. Rev. Biochem.*, 1988; 23(3): 283-337.

Marangon, K.; Herbeth, B.; Lecomte, E.; Paul-Dauphin, A.; Grolier, P.; Chancerle, Y., and Artur, Y. Diet-Antioxidant Status and Smoking Habits in French men. *Am. J. Clin. Nutr.*, 1998; 67: 231-239.

Mari, M., and Cederbaum, A.I. Induction of Catalase, Alpha and Microsomal Glutathione S-Transferase in CYP2E1 Overexpressing HepG2 Cells and Protection against Short-Term Oxidative Stress. *Hepatology.*, 2001; 33: 652-661.

Marra, G.; Cotroneo, P.; Pitocco, D.; Manto, A.; Dileo, M.A.S.; Rnotolo, V.; Caputo, S.; Giardino, B.; Ghirlanda, G., and Santini, S.A. Early Increase of Oxidative Stress and Reduced Antioxidant Defense in Patients with Uncomplicated Type 1 D.M. *Diabetes Care*, 2002; 25: 370-375.

- Mayesca, J.B., and Holden, H.E. Genetic Effects of P-Aminophenol in Chinese Hamster and Mouse Lymphoma Cells: Results of a Multiple Endpoint Test. *Environ. Mol. Mutagen.*, 1990; 26: 163-170.
- Mawim-Mateo, M.C.; Molpeceres, L.M., and Gamos, G. Assay for Erythrocyte Superoxide Dismutase Activity in Patients with Lung Cancer and Effects on Population and Smoke Trace Elements. *Biological Trace Element Research*, 1997; 60: 210-226.
- McCord, J.M. Is Iron Sufficiently a Risk Factor in Ischemic Heart Disease. *Circulation*, 1991; 83: 1112-1114.
- Meister, A. Glutathione Metabolism. *Methods in Enzymology*, 1990; 201: 3-7.
- Mekhfi, H.; Veksler, V.; Mateo, P.; Maupoil, V.; Rochette, L., and Ventura-Clapier, R. Creatine Kinase is the Main Target of Reactive Oxygen Species in Cardiac Myofibrils. *Circulation Research*, 1996; 78: 1016-1027.
- Meneghini, R. Iron Homeostasis, Oxidative Stress, and DNA Damage. *Free Radic. Biol. Med.*, 1997; 22(5): 783-792.
- Mezzetti, A.; Lappenna, D., and Pierdomenico, S.D. Vitamin E, C, and Lipid Peroxidation in Plasma and Arterial Tissue of Smokers and Non-Smokers. *Atherosclerosis*, 1990; 112: 91-99.
- Michiels, C.; Raes, M.; Toussan, O., and Remacie, J. Importance of Se- Glutathione, Peroxidase, Catalase, and Cu-Zn-SOD for Cell Survival against Oxidative Stress. *Free Radical Biological Medicine*, 1994; 17: 230-248.

- Miro, O.; Alonso, J.R., and Jarreta, D. Smoking Disturbs Mitochondrial Respiratory Chain Function on Human Circulating Lymphocytes. *Carcinogenesis*, 1999; 20(7): 133-6.
- Morrow, J.; Frei, B., and Longmire, A. Increase in Circulating Products to Lipid Peroxidation (F₂-Isoprostanes) in Smokers. *N. Engl. J. Med.*, 1990; 332: 1198-203.
- Mudd, S.H.; Finkelstein, J.D.; Refsum, H.; Ueland, P.M.; Malinow, M.R.; Lentz, S.R.; Jacobsen, D.W.; Brattström, L.; Wilecken, B.; Wilckon, D.E.; Blom, H.J.; Stabler, S.P.; Allen, R.H.; Selhub, J., and Rosenberg, I.H. Homocysteine and its Disulfide Derivatives: A Suggested Consensus Terminology. *Arterioscler. Thromb. Vase. Biol.*, 2000; 20: 1704-1706.
- Mueller, S.; Riedel, H.D., and Stremmel, W. Determination of Catalase Activity at Physiological Hydrogen Peroxide Concentrations. *Analytical Biochemistry*, 1997; 240: 50-60.
- Mulhauser, I. Cigarette Smoking and Progression of Retinopathy and Nephropathy in Type 1 Diabetes Mellitus. *Diabetes Med.*, 1996; 13: 536-543.
- Murray, R.K.; Granner, D.K.; Mayes, P.A., and Rodwell, V.W. "Harper's Biochemistry" 20th ed. Appleton & Lange Press, Lebanon, 2000; 640-641.
- National Diabetes Data Group. Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Tolerance. *Diabetes*, 1979; 28: 1039-1057.
- Neumann, D.; Schlattner, V., and Walliamann, T. A Molecular Approach to the Concerted Action of Kinase Involved in Energy Homoestasis. *Biochem. Soc. Trans.*, 2003; 31: 169-174.

- Noto, R.; Alicata, R.; Sfogliano, L.; Neri, S., and Bifarella, M. A Study of Cupremia in a Group of Elderly Diabetics. *Acta. Diabet. Lat.*, 1983; 20: 81-5.
- Nourooz-Zadeh, J.; Rahimi, A.; Jajaddini,-Sarmadi, J.; Tritschler, H.; Rosen, P.; Halliwell, B., and Betteridge, D.J. Relationship between Plasma Measures of Oxidative Stress and Metabolic Control in NIDDM. *Diabetologia*, 1997; 40: 747-753.
- Oberley, L.W. Free Radical and Diabetes. *Free Radical Bio. Med.*, 1988; 5: 113-124.
- Okada, E.; Oida, K., and Tada, H. Hyperhomocysteinemia is a Risk Factor for Coronary Arteriosclerosis in Japanese Patients with Type 2 Diabetes. *Diabetes Care*, 1999; 22: 484-490.
- Ou, P., and Wolff, S.P. Erythrocyte Catalase Inactivation (H₂O₂ Production) by Ascorbic Acid and Glucose in the Presence of Aminotriazol: Role of Transition Metals and Relevance to Diabetes. *Biochemical Journal*, 1994; 303: 935-939.
- Palmer, H.J., and Paulson, E.K. Reactive Oxygen Species and Antioxidants in Single Transduction and Gene Expression. *Nutr. Rev.*, 1997; 55: 535-71.
- Paolisso, G.; Balbi, V.; Volpa, C. Varricchio, G.; Gambardella, A. Saccomanno, F.; Ammendola, S.; Varricchio, M., and D'Onofrio, F. Metabolic Benefits Deriving from Chronic Vitamin C Supplementation in Aged Non-Insulin-Dependant Diabetics. *J. Am. Coll. Nutr.*, 1995; 14(4): 387-92.
- Paolisso, G.; Tagliamonte, M.R.; Barbieri, M.; Zito, G.A.; Gambardella, A.; Varricchio, G.; Ragno, M., and Varricchio, M. Chronic

Vitamin E Administration Improves brachial Reactivity and Increases Intracellular Magnesium Concentration in Type II Diabetic Patients. *Journal of Clinical Endocrinology and Metabolism*, 2000; 80(1): 1-17.

Pastore, A.; Massoud, R.; Motti, C.; LoRusso, A.; Fucci, G.; Cortese, C., and Federici, G. Fully Automated Assay for Total Homocysteine, Cysteine, Cysteinglycine, Glutathione, Cysteamine, and γ -Mercaptopropionylglycine in Plasma and Urine. *Clinical Chemistry*, 1998; 44(4): 820-832.

Percival, S. Neutropenia Caused by Copper Deficiency Possible Mechanisms of Action. *Nutr. Rev.*, 1990; 48(3): 59-77.

Peuchant, E.; Delmas-Beauvieux, M.C.; Couchouron, A.; Dubourg, L.; Thomas, M.J.; Perromet, A.; Clerc, M., and Gin, H. Short-Term Insulin Therapy and Normoglycemia. Effects on Erythrocyte Lipid Peroxidation in NIDDM Patients. *Diabetes Care*, 1997; 20: 202-207.

Popovich, B.K.; Sayen, M.R., and Dillmann, W.H. Insulin Responsiveness of Ck-M and Ck-BmRNA in the Diabetic Rat Heart. *Am. J. Physiol. Endocrinol. Metab.*, 1991; 261(3): 377-381.

Popovich, B.K.; Boheler, K.R., and Dillmann, W.H. Diabetes Decreases Creatine Kinase Enzyme Activity and mRNA Level in the Rat Heart. *Am. J. Physiol. Endocrinol. Metab.*, 1989; 207(4): 573-577.

Pryor, W.A. , and Ston, K. Oxidant in Cigarette Smoke. Radicals, Hydrogen Peroxide, Peroxynitrate and Peroxynitrite. *Ann NY Acad. Sci.*, 1993; 686: 12-27.

- Rabini, R.A.; Fumelli, P.; Galassi, R.; Dousset, N.; Tans, M.; Ferretti, G.; Mazzanti, L.; Curatola, G.; Solera, M.L., and Valdiguie, P. Increased Susceptibility to Lipid Oxidation of Low-Density Lipoproteins and Erythrocyte Membranes from Diabetic Patients. *Metabolism*, 1994; 43: 1470-1474.
- Rahbani-Nobar, M.E.; Rahimi-Pour, A.; Rahbani-Nobar, M.; Adi-Beig, F., and Mirhashemi, S.M. Total Antioxidant Capacity Superoxide Dismutase and Glutathione Peroxidase in Diabetic Patients. *Medical Journal of Islamic Academy of Sciences*, 1999; 12(4): 1-7.
- Rajpathak, S.; Rimm, E.B.; Tricia, L.; Morris, J.S.; Stampfer, M.J.; Willett, W.C., and Hu, F.B. Lower Toenail Chromium in Men with Diabetes and Cardiovascular Disease Compared with Healthy Men. *Diabetes Care*, 2004; 27: 2211-2216.
- Rasmussen, K. , and Moller, J. Total Homocysteine Measurement in Clinical Practice. *Ann Clin. Biochem.*, 2000; 37: 627-648.
- Ravina, A.; Slezak, L.; Mirsky, N.; Bryden, N.P., and Anderson, R.A. Reversal of Corticosteroid-Induced Diabetes with Supplementation Chromium. *Diabet. Med.*, 1999; 16: 164-167.
- Raza, H.; Robin, M.A.; Fang, J.K., and Avadhani, N.G. Multiple Isoforms of Mitochondrial Glutathione S-Transferases and their Differential Induction under Oxidative Stress. *Biochem. J.*, 2002; 366: 40-50.
- Raza, H.; Prabu, S.K.; Robin, M.A., and Avadhani, N.G. Elevated Mitochondrial Cytochrome P450 2E1 and Glutathione S-Transferase A4:4 in Streptozotocin-Induced Diabetic Rats. *Diabetes*, 2004; 53: 180-194.

- Reddy, S.; Jones, A.D.; Cross, C.E.; Wong, P.S-X., and Van der Vliet, A. Inactivation of Creatine Kinase by S-Glutathionylation of the Active-Site Cysteine Residue. *Biochem. J.*, 2000; 347: 821-827.
- Reif, D.W. Ferritin as a Source of Iron for Oxidative Damage. *Free Rad. Biol. Med.*, 1992; 2: 417-427.
- Rice, J. "Principles of Pharmacology for Medical Assisting" 3rd ed. Canada, International Thomson Publishing Company Ltd., 1999; 338-342.
- Ritz, E.; Keller, C., and Bergis, K. Nephropathy of Type II Diabetes Mellitus. *Nephrol. Dial. Transplant*, 1996; 11(9): 38-44.
- Ros, R.C., and Nahrwold, D.L. *Anal. Biochem.*, 1981; 114: 140-140. In: Salman, A.M.H. "Clinical Biochemical Study of Oxidation and Antioxidants in Patients with Non-Insulin-Dependant Diabetes Mellitus" (Thesis), Ph.D., Iraq, Baghdad University, 2001.
- Sahin, U.; Unlu, M.; Ozguner, F.; Stucu, R.; Akkaga, A., and Delibas, N. Lipid Peroxidation and Glutathione Peroxidase Activity in Chronic Obstructive Pulmonary Disease Exacerbation: Prognostic Value of Malondialdehyde. *J. Basic Clin. Physiol. Pharmacol.*, 2001; 12(1): 59-68.
- Salman, A.M.H. "Clinical Biochemical Study of Oxidation and Antioxidants in Patients with Non-Insulin-Dependant Diabetes Mellitus" (Thesis), Ph.D., Iraq, Baghdad University, 2001.
- Samman, S.; Sandström. B.; Toft, M.J.; Bukhave, K.; Jensen, M.; Sorensen, S.S., and Hansen, M. Green Tea or Rosemary Extract Added to Foods Reduces Nonheme Iron Absorption. *Clinical Nutrition*, 2001; 20(3): 67-72.

- Sasagawa, S.; Suzuki, K.; Sakatani, T., and Fujikura, T. Effects of Nicotine on the Function of Human Polymorphonuclear Leukocyte In Vitro. *Journal of Leukocyte Biology*, 1980; 37: 493-502.
- Sedlak, J., and Lindsay, R.H. *Annal. Biochem.*, 1968; 20:192.
- Sen, C.K. Glutathione homeostasis in response to exercise training and nutritional supplements. *Mol. Cell Biochem.*, 1999; 196:31-42.
- Sen, C.K., and Hanninen, O. *Physiological Antioxidants In: Exercise and Oxygen Toxicity*. Ed. Sen, C.K.; Packer, L.; Hanninen, O. Amsterdam. Elsevier, 1994; pp. 89-126.
- Sen, C.K.; Packer, L., and Hanninen, O. "Handbook of oxidants and antioxidants in exercise" 1st ed., Elsevier Press. Amsterdam, 2000.
- Shanshel, A.A.; Hamash, M.H.; Hamid, A.W.R., and Abid, F.M. Determination of Homocysteine and Other Amino Thiols in Plasma from Healthy Subjects and Patients with Ischemic Stroke. *National Journal of Chemistry*, 2003; 9: 182-190.
- Sharma, R.N.; Deva, D.; Dehera, D., and Khandja, K.L. Reactive Oxygen Species Formation in Peripheral Blood Neutrophils in Different Types of Smokers. *Indian, J. Med. Res.*, 1997; 106: 470-80.
- Sinclair, A.J.; Barnett, A.H., and Lunec, J. Free Radicals and Antioxidant System in Health and Disease. *Br. J. Hosp. Med.*, 1990; 43: 334-343.
- Singh, R., and Pathak, D.N. Lipid Peroxidation and Glutathione Peroxidase, Glutathione Reductase, Superoxide Dismutase, Catalase, and Glucose-6-Phosphate Dehydrogenase Activities in FeCl₂-Induced

Epileptogenic Foci in the Rat. *Epilepsia*, 1990; 31(1):
10-20.

Smulders, Y.M.; Rakic, M., and Slaats, E.H. Fasting and Postmethionine Homocysteine Levels in NIDDM. Determinants and Correlations with Retinopathy, Albuminuria, and Cardiovascular Disease. *Diabetes Care*, 1999; 22: 120-132.

Soinio, M.; Marniemi, J.; Laakso, M.; Lehto, S., and Ronnema, T. Elevated Plasma Homocysteine Level is an Independent Predictor of Coronary Patients with Type 2 Diabetes Mellitus. *Ann. Intern. Med.*, 2004; 140: 94-100.

Stadtman, E.R., and Berlett, B.S. Reactive Oxygen-Mediated Protein Oxidation in Aging and Disease. *Chem. Res. Toxicol.*, 1997; 10: 480-494.

Starkebaum, G, and Harlan, J.M. Endothelial Cell Injury Due to Copper-Catalyzed Hydrogen Peroxide Generation from Homocysteine. *J. Clin. Invest.*, 1987; 77: 1370-1376.

Suarez, L., and Barrett-Connor, E. Interaction between Cigarette Smoking and Diabetes Mellitus in the Prediction of Death Attributed to Cardiovascular Disease. *Am. J. Epidemiol.*, 1984; 120: 670-670.

Szaleezky, E.; Prechl, J.; Feher, J., and Somogyi, A. Alterations in Enzymatic Antioxidant Defense in Diabetes Mellitus – A Rational Approach. *Postgrad Med. J.*, 1999; 70: 13-17.

Targher, G. Cigarette Smoking and Insulin Resistance in Patients with Non-Insulin-Dependent Diabetes Mellitus. *J. Clin. Endocrinol. Metab.*, 1997; 82: 3619-3624.

- Terpilowsks, S., and Zaporowska, H. The Role of Chromium in Cell Biology and Medicine. *Przegl. Lek.*, 2004; 61(3): 51-4.
- Tesfamarian, B. Free Radicals in Diabetic Endothelial Cell Dysfunction. *Free Radic. Bio. Med.*, 1993; 16: 383-391.
- Tesfamarian, B. Free Radicals in Diabetic Endothelial Cell Dysfunction. *Free Radical Biology and Medicine*, 1994; 16: 383-391.
- The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, 2003; 26: 50-70.
- Thornalley, P.J.; McLellan, A.C.; Lo, T.W.; Benn, J., and Sonksen, P.H. Negative Association between Erythrocyte Reduced Glutathione Concentration and Diabetic Complication. *Clinical Science*, 1996; 91: 575-582.
- Tietz, N.W.; Caraway, W.T.; Freier, E.F.; Kachmar, J.F. , and Rawnsley, H.M. "Fundamentals of Clinical Chemistry" 1st ed. W.B. Saunders Company, Canada, 1979; pp. 543-544.
- Tihant, T.; Ghiba, P., and Eher, R. Influence of Cell Cycle on Selenium Dependant Glutathione Peroxidase Carcinogeneses, 1989; 10(9): 1709-12.
- Tousoulis, D.; Antoniadis, C.; Tountas, C.; Bosinakou, E.; Kotsopoulou, M.; Toutouzas, P., and Stefanadis, S. Vitamin C Effects Thrombosis/Fibrinolysis System and Reactive Hyperemia in Patients with Type 2 Diabetes and Coronary Artery Disease. *Diabetes Care*, 2003; 26: 2749-2753.

- Tripathi, K.D. "Essentials of Medical pharmacology" 2nd ed., Jaypee Brothers Press, 1988, pp: 237-243.
- Trow, L.G.; Lewis, J.; Greenwood, R.H.; Sampson, M.J.; Self, K.A.; Grews, H.M., and Fairweather-Tait, S.J. Lack of Effect of Dietary Chromium Supplementation on Glucose Tolerance, Plasma Insulin and Lipoprotein Levels in patients with Type 2 Diabetes. *Int. J. Vitam. Nutr. Res.*, 2000; 70: 14-18.
- Tutuncu, N.B.; Bayraktar, M., and Varli, K. Reversal of Defective Nerve Conduction with Vitamin E Supplementation in Type 2 Diabetes: A Preliminary Study. *Diabetes Care*, 1998; 21(11): 1910-11.
- Uchiama, M. , and Mihara, M. Determination of Malondialdehyde Precursors in Tissues by Thiobarbituric Acid Test. *Anal. Biochem.*, 1987; 161: 271-278.
- Ulusu, N.N., and Turan, B. Beneficial Effects of Selenium on Some Enzymes of Diabetic Rat Hearts. *Biol. Trace Elem. Res.*, 2000; 103(3): 207-116.
- Valk Marx, J.J. Iron, Atherosclerosis, and Ischemic Heart Disease. *Arch. Intern. Med.*, 1999; 159: 1042-1048.
- Van-Antwerpan, V.L.; Theron, A.J. , and Richard, G.A. Vitamin E, Pulmonary Function and Phagocyte-Mediated Oxidative Stress in Smokers and Non-Smokers. *Free Radic. Biol. Med.*, 1990; 18(5): 930-41.
- Van-Guldener, C.; Stom, F., and Stehouwer, C.D. Homocysteine Metabolism in Renal Failure. *Kidney Int.*, 2001; 59(78): S234-S237.

- Vasankari, T.; Ku, U., and Heinonen, O. Measurement of Serum Lipid Peroxidation During Exercise Using Three Different Methods: Diene Conjugation, Thiobarbutric Acid Reactive Material and Fluorescent Chromolipids. *Clin Chim Acta.*, 1990; 234: 63-69.
- Vatassery, G.T.; Johnson, G.T., and Krezcwski, A.M. *Am. Cou. Nutr.* 1983; 4: 369. In: Salman, A.M.H. "Clinical Biochemical Study of Oxidation and Antioxidants in Patients with Non-Insulin-Dependant Diabetes Mellitus" (Thesis), Ph.D., Iraq, Baghdad University, 2001.
- Vijayalingam, S.; Parthibam, A.; Shanmugasundaram, K.R., and Mohan, V. Abnormal Antioxidant Status in Impaired Glucose Tolerance and Non-Insulin-Dependant Diabetes Mellitus. *Diabetic Medicine*, 1996; 13: 710-719.
- Vincent, J.B. Recent Advances in the Nutritional Biochemistry of Trivalent Chromium. *Proc. Nutr., Soc.*, 2004; 63: 41-7.
- Walter, R.M.; Uriu Hare, J.Y.; Olin, K.L.; Oster, M.H.; Anawalt, B.D.; Critchfield, J.W., and Keen, C.L. Copper, Zinc, Manganese, and Magnesium Status and Complications of Diabetes Mellitus. *Diabetes Care*, 1991; 14: 100-106.
- Wang, H.; Zhang, Z.B., and Wen, R.R. Reduction of Erythrocyte Sorbitol by Ascorbic Acid in Patients with Diabetes Mellitus. *Chung Hua I Hsueh Isa Chih.*, 1994; 74(9): 048-01, 083.

- Will, J.C., and Byers, T. Does Diabetes Mellitus Increase the Requirement for Vitamin C? *Nutr. Rev.*, 1996; 54: 193-202.
- Winterboun, C.C.; Hawking, R.E.; Brain, M., and Carrel, R.W. Determination of Superoxide Dismutase. *J. Lab. Clin. Med.*, 1970; 2: 337-341.
- Wolff, H.P. Cigarette Smoking Increases the Risk of Albuminuria among Subjects with Type 1 Diabetes. *JAMA*, 1991; 266(5): 614-617.
- Wolff, S.P., and Dean, R.T. Glucose Autoxidation and Protein Modification. The Potential Role of Autoxidative Glycosylation in Diabetes. *Biochem. J.*, 1987; 240: 243-50.
- World Health Organization. Diabetes Mellitus Report of a WHO Study Group. Geneva: WHO. (Technical Report Series 727), 1985.
- Yildiz, D., and Kurman, C.I. Recovery of 1-chloro-2, 4-dinitrobenzene Detoxification by N-acetyl-L-cysteine in Glutathione Predepleted Human Erythrocytes. *Turk. J. Med. Sci.*, 2004; 34: 233-238.
- Young, D.S. , and Hicks, J.M. Method for Automatic Determination of Serum Iron. *J. Clin. Pathol.*, 1960; 18: 98-102.
- Zappacosta, B.; Persichilli, S.; Mordente, A.; Minucci, A.; Lazzaro, D.; Meucci, E., and Giardina, B. Inhibition of Salivary Enzymes by Cigarette Smoke and the Protective Role of Glutathione. *Hum. Exp. Toxicol.*, 2002; 21(1): 7-11.
- Zargar, A.H.; Shah, N.A., and Massodi, S.R. Copper, Zinc, and Magnesium Levels in Non-Insulin-Dependant Diabetes Mellitus. *Postgrad Med. J.*, 1998; 74: 660-8.

Zhao, Y.X., and Yu, R.J. Effect of Smoking on the Lipid Peroxidase Antioxidation and Alpha 1-Antitrypsin. *Zhongha Jie He Hc Hu Xi Za Zhi*, 1998; 21(4): 218-220.

Zhao, L. Effects of Free Radicals in Diabetes: Offered by the Free Radicals and Radiation Biology Graduate Program, Iowa University, Iowa, 2001; 77: 222.

Zinneman, H.H.; Nuttall, F.Q., and Goetz, F.C. Effect of Endogenous Insulin on Human Amino Acid Metabolism. *Diabetes*, 1966; 15: 5-8.